"";"Ref ID";"Outcome Data?";"First Author";"Year";"Country";"Journal Name";"Title";"Number of Studies";"Number of Treatments";"Number of Nodes";"Control intervention";"Intervention comparison type";"Includes Complex Interventions";"Includes different treatment doses";"Did the model account for different treatment doses?";"Primary Outcome(s)";"Description of the outcome(s)";"Safety/
Effectiveness";"Harmful/
Beneficial Outcome";"Type of outcome";"Objective outcome?";"Effect measure";"Outcome measured as";"Indirect Method";"level
";"Number of 2-arm trials";"Number of 3-arm trials";"Number of 4-arm trials";"Number of 5-arm trials";"Number of 6+ -arm trials";"Shape of network";"Total loops";"Assessment of consistency assumption";"NMA includes both direct and indirect evidence";"Models used to adjust for inconsistency";"Assessment of Transitivity";"Fixed effect or Random effects model";"Rationale for FE or RE provided";"Assumption for heterogeneity in Random Effects model";"Heterogeneity estimator/prior";"Mantel Haenszel / Peto / Inverse Variance Method";"Analysis for heterogeneity
";"Was publication bias assessed?";"Method used to assess publication bias";"Ranking";"Reporting of effect sizes";"Use of individual patient data?";"Was missing participant data reported?";"How was missing data handled?";"Funding Source";"Funding Type";"I squared of heterogeneity";"I squared of inconsistency";"I  squared both";"Bayesian / Frequentist Approach";"format";"verified";"checked";"error";"label";"X__1";"X__2";"X__3";"X__4";"X__5";"X__6";"X__7";"X__8";"X__9";"X__10";"X__11";"X__12";"X__13"
"2";"473269";"YES";"Lin";2014;"Singapore";"Annals of Pharmacotherapy";"Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension";14;"5";5;"timolol";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"treatment success";"proportion of patients achieving at least 30% reduction in intraoccular pressure";"Effectiveness";"Beneficial";"Binary";"Objective";"risk ratio";"proportion of patients achieving a target of at least 30% IOP reduction";"Multivariate meta-analysis model";"Arm";"13";"1";"0";"0";"0";"Full Network";"Unclear";"Design by treatment";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"not reported";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"3";"473552";"YES";"Valentin";2011;"Hungary";"Orv Hetil";"Efficacy of the biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model";32;"42";9;"placebo";"2 (pharmacological vs placebo)";"Yes";"Yes";"No - lump doses";"ACR70 improvement";"Efficacy of biologic therapies in rheumatoid arthritis";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"proportion of patients achieving ACR70 response";"Bayesian Hierarchical Model";"Arm";"11";"14";"5";"2";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"common within-network";"NR";"NA";"Yes";"No";"NA";"NA";"All";"No";"No";"not reported";"TÁMOP-4.2.1.B-09/1 / KMR-2010-0005";"Funding source not reported";NA;NA;NA;NA;"long";0;1;"""Identical treatments for the following studies:\n  '7' - 'NA' - 'NA' - 'NA' - 'NA' - 'NA' - 'NA'";NA;NA;NA;NA;NA;NA;NA;NA;NA;"(some studies contain multiple arms with the same intervention)";NA;NA;NA;NA
"4";"474842";"YES";"Castellucci";2014;"Canada";"Journal of the American Medical Association";"Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism A Systematic Review and Meta-analysis";45;"8";8;"LMWH + vitamin K antagonist";"1 (pharmacological vs pharmacological)";"Yes";"Unclear";"NA";"recurrent venous thromboembolism";"Efficacy associated with 8 anticoagulation options for treatment of venous thromboembolism";"Effectiveness";"Harmful";"Binary";"Objective";"hazard ratio";"proportion of patients experiencing recurrent venous thromboembolism (over 3 and 6 months)";"Bayesian Hierarchical Model";"Arm";"41";"4";"0";"0";"0";"Full Network";"2";"Comparison of model fit and parsimony (DIC)";"Yes";"Yes";"NR";"Both FE and RE";"Assessment of model fit was based on comparison of residual deviance to the num- ber of unconstrained data points, assessment of the devi- ance information criterion, and between-study standard deviation";"Unclear";"vague priors";"NA";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"not reported";"CGV 121171, the Canadian Institutes of Health Research, Canadian Network and Centre for Trials Internationally (CANNeCTIN), grant, Heart and Stroke foundation
(116573) through the CIHR Drug Safety and
Effectiveness Network.";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"5";"476033";"YES";"Jansen";2009;"USA";"Current Medical Research and Opinion";"Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies";7;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"vertebral fractures (morphometric)";"Efficacy of bisphosphonates in postmenopausal osteoporotic women";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"proportion of patients with vertebral fractures";"Bayesian Hierarchical Model";"Arm";"7";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"The average age of women across trials was comparable";"Both FE and RE";"Assessment of residual deviance showed no appreciable difference between random and fixed effects assumptions, and a fixed effects model can be considered appropriate. Because residual deviance analyses are not commonly accepted, to be definitive we reported results under the conser- vative random effects assumptions as well";"common within-network";"non-informative priors";"NA";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"not reported";"Novartis Pharma AG";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"6";"476343";"YES";"Edwards";2015;"UK";"Health Technology Assessment";"Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
hydrochloride, paclitaxel, trabectedin and gemcitabine
for advanced recurrent or refractory ovarian cancer:
a systematic review and economic evaluation";6;"13";4;"PLDH+carboplatin";"1 (pharmacological vs pharmacological)";"Yes";"Yes";"No - lump doses";"overall survival";"Effectiveness of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of advanced, recurrent ovarian cancer";"Effectiveness";"Beneficial";"Survival";"Objective";"hazard ratio";"# of deaths in pts with platinum sensitive ovarian cancer";"Bayesian Hierarchical Model";"Study";"10";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"sufficient comparable data accross studies";"Fixed-effect";"the sparse number of trials available necessitated the use of a fixed effects model fixed-effects model";"NA";"uninformed prior for the between trial heterogeneity";"NA";"NA";"No";"NA";"NA";"All";"No";"Yes";"missing completely at random (MCAR)";"National Institute for Health Research (NIHR)";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"7";"479531";"YES";"Patel";2014;"USA";"PLoS One";"48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1– Infected Patients: A Systematic Review and Network Meta-Analysis";26;"33";12;"dolutegravir";"1 (pharmacological vs pharmacological)";"Yes";"No";"NA";"virologic supression";"Efficacy of Dolutegravir Relative to Commonly Used Third Agents";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"HIV-RNA suppression <50 copies/mL";"Bayesian Hierarchical Model";"Arm";"23";"1";"2";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"Studies were found to be generally similar with respect to age and baseline clinical characteristics";"Both FE and RE";"Based on DIC and only one study for most comparisons. Limited data to estimate random-effects model parameters have been noted to lead to poor estimation of the width of the distribution of intervention effects";"Unclear";"NR";"NA";"Yes";"No";"NA";"NA";"Subset";"No";"Yes";"Studies with missing data excluded";"ViiV Healthcare";"Industry-sponsored";NA;NA;NA;NA;"long";0;1;"Network consists of 2 separate sub-networks.\n  Use R function 'netconnection' to identify sub-networks.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"8";"479574";"YES";"Biondi-Zocca";2005;"Italy";"International Journal of Cardiology";"Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials";18;"7";7;"drug-eluting stents (DES)";"1 (pharmacological vs pharmacological)";"Yes";"No";"NA";"target lesion revascularization";"Intracoronary drug-eluting stents (DES) in comparison to bare-metal stents (BMS) in target lesion revascularization (TLR) after percutaneous
coronary intervention";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"the rate of target lesion revascularization (TLR) at <=12 months";"Adjusted indirect comparison (Bucher)";"Arm";"17";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"Inverse Variance Method";"Unclear";"Yes";"Funnel plot; Egger's test";"NA";"Subset";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"9";"479585";"YES";"Singh";2013;"USA";"Cochrane Database of Systematic Reviews";"Adverse effects of biologics: a network meta-analysis and Cochrane overview";49;"13";10;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"Yes - Subgroup analyses";"total adverse events";"To compare the potential adverse effects of tumor necrosis factor inhibitor (adalimumab, certolizumab, etanercept, golimumab, infliximab),
interleukin (IL)-1 antagonist (anakinra), IL-6 antagonist (tocilizumab), anti-CD28 (abatacept), and anti-B cell (rituximab)
therapy in patients with any disease condition except human immunodeficiency disease";"Safety";"Harmful";"Binary";"Semi-objective";"odds ratio";"number of total adverse events (= # events or # people with events?)";"Bayesian Hierarchical Model";"Arm";"49";"0";"0";"0";"0";"Tree Network";"Unclear";"Back-calculation; Node-splitting";"Yes";"Yes";"NR";"Both FE and RE";"model selection was based on the deviance information criterion (DIC) and residual deviance";"Unclear";"Basic parameters were assigned non- informative or vague prior distributions; more informative pri- ors were considered after evaluation of the information base and clinical expert advice";"NR";"Yes";"No";"NA";"NA";"All";"No";"Yes";"NR";"Canadian Institutes of Health Research; National Institutes of Health Research, Cochrane Review Incentive Scheme 2009, UK.";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"11";"479600";"YES";"Donahue";2012;"USA";"Agency for Healthcare Research and Quality";"Drug Therapy for Rheumatoid Arthritis in Adults: An Update";30;"9";9;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - Other (recommended dosing ranges/ doses that that could be considered equivalent to the recommended doses, but were not identical to recommended doses are included in the report)";"response to treatment (defined as achieving ACR50 response)";"comparative efficacy of biologic disease modifying
antirheumatic drugs (DMARDs) in improving RA symptoms";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"proportion of patients with ACR50 response";"Bayesian Hierarchical Model";"Arm";"29";"1";"0";"0";"0";"Full Network";"1";"Informal comparison of NMA results with previously published results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"uniform prior distribution centered at zero with sufficiently large variance";"NA";"Yes";"Yes";"Funnel plot";"Probability of being the best";"All";"No";"No";"NA";"Agency for Healthcare Research and Quality";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"12";"479603";"YES";"Shamliyan";2013;"USA";"Agency for Healthcare Research and Quality";"Migraine in Adults: Preventive Pharmacologic Treatments
Preventive
Pharmacologic
Treatments";83;"45";14;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"Reduction of migraine attacks by >50 percent from baseline";"Effectiveness of preventive pharmacologic treatments for community-dwelling adults with episodic or chronic migraine";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"≥50 percent reduction in monthly migraine frequency";"Bayesian Hierarchical Model; Bucher method";"Arm";"77";"6";"0";"0";"0";"Full Network";"Unclear";"Inconsistency model";"Yes";"Yes";"Patient age and baseline migraine
characteristics were similar in most trials";"Both FE and RE";"We used multiple models to test robustness of inferential statistics. Models included random and fixed effects inverse variance methods, maximum
likelihood methods, Peto odds ratio,57 double arcsine transformation for comparing two
proportions, and odds ratios from random-effects generalized nonlinear mixed-effect models";"common within-network";"non-informative prior";"NA";"Yes";"Yes";"We assess publication bias by analyses of the publication rates of the registered studies and the NIH funded studies";"NA";"Subset";"No";"No";"NA";"Agency for Healthcare Research and Quality";"Publicly-sponsored";NA;NA;NA;NA;"long";0;1;"After removing comparisons with missing treatment effects or standard errors,\n  study '16' has a wrong number of comparisons. Please check data and\n  consider to remove study from network meta-analysis.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"14";"479622";"YES";"Thakkinstian";2012;"Thailand";"British Journal of Urology International";"α -blockers, antibiotics and anti-infl ammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome";13;"15";5;"placebo";"2 (pharmacological vs placebo)";"Yes";"No";"NA";"Total symptom scores";"Treatments effects in chronic prostatitis/chronic pelvic pain syndrome";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"NIH-CPSI measure (total symptoms)
total symptoms score, ranged from 0 to 43,
was a summation of pain, voiding and
quality of life scores)";"Meta regression";"Arm";"11";"1";"1";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NR";"Inverse Variance Method";"Unclear";"No";"NA";"NA";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;1;"""Problem in multi-arm studies!\n  - Study with negative treatment arm variance: '10'\n";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"15";"479629";"YES";"Reinecke";2015;"Germany";"British Journal of Pharmacology";"Analgesic efficacy of opioids in chronic pain: recent meta-analyses";46;"44";8;"placebo";"3 (non-pharmacological vs any)";"Yes";"Unclear";"NA";"pain intensity";"Efficacy of opioids in chronic pain";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"weighted mean difference";"single scales linearly transformable to a 0- to 100-
point scale such as the numerical rating scale or the visual
analogue scale";"Adjusted indirect comparison (Bucher)";"Study";"33";"13";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"Yes";"Egger’s regression intercept";"NA";"Subset";"No";"Yes";"missing values were computed by addition or
subtraction of data presented in the same study";"German Society for the Study of Pain, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung
Studium des Schmerzes, Deutsche Forschungsgemeinschaft
and Bundesministerium für
Bildung und Forschung";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"17";"479650";"YES";"Coleman";2008;"USA";"Journal of Hypertension";"Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials";27;"NR";7;"placebo/untreated control";"2 (pharmacological vs placebo)";"No";"Unclear";"NR";"incidence of cancer";"Association between antihypertensive agents and the incidence of cancer";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"proportion of patients with incidence of cancer";"Bayesian Hierarchical Model";"Arm";"25";"2";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"common within-network";"NR";"NA";"Unclear";"No";"NA";"NR";"Subset";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;1;"Non-numeric value for argument 'event'.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"18";"479652";"YES";"Leibovici-Weissman";2014;"Israel";"Cochrane Database of Systematic Reviews";"Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials";39;"12";10;"placebo or no treatment";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Diarrhoea duration";"To quantify the benefit of antimicrobial treatment for patients with cholera";"Safety";"Beneficial";"Continuous";"Semi-objective";"mean difference";"the period from the time of initiation of study drug until the end of diarrhoea
study drug until the end of diarrhoea as defined in the study";"Adjusted indirect comparison (Bucher)";"Arm";"23";"0";"14";"2";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"Yes";"Funnel plot";"NR";"All";"No";"Yes";"complete case analysis for all outcomes and recorded the number
of dropouts";"NA";"Non-sponsored";NA;NA;NA;NA;"long";0;1;"Identical treatments for the following studies:\n  '13' - '18'";NA;NA;NA;NA;NA;"- 'NA' - 'NA'";NA;NA;NA;NA;NA;NA;NA;NA
"20";"479661";"YES";"Owen";2010;"UK";"International Journal of Cardiology";"Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: A reappraisal of the evidence and network meta analysis";14;"4";4;"control intervention";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split doses";"all strokes";"Efficacy of treatments for stroke";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"patients with atrial fibrillation";"Bayesian Hierarchical Model";"Arm";"12";"2";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"low information prior";"NA";"Yes";"No";"NR";"NR";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"22";"479664";"YES";"Wilhelmus";2015;"USA";"Cochrane Database of Systematic Reviews";"Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis
herpes simplex virus epithelial keratitis";95;"NR";13;"Control intervention";"3 (non-pharmacological vs any)";"Yes";"Unclear";"NR";"the proportion of eyes healed at 14 days
";"To compare the relative effectiveness of antiviral agents, interferon, and corneal debridement in the treatment ofHSV epithelial keratitis";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk ratio";"proportion of patients with healed eyes at 14 days";"Adjusted indirect comparison (Bucher)";"Arm";"105";"3";"3";"0";"0";"Full Network";"Unclear";"Inconsistency model: random-effects meta-regression (White 2012)";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"Yes";"Funnel plot";"NR";"Subset";"No";"Yes";"all participants were extracted from studies that reported sufficient information for an intention-to-treat analysis
studies that reported sufficient information for an intention-totreat
analysis";"Grant 1 U01 EY020522 National Eye Institute, National Institutes of Health, USA. Methodological support provided by the Cochrane Eyes and Vision Group, US Project Research to Prevent Blindness, Inc, US• Sid W Richardson Foundation, USA.
• National Institute for Health Research, UK.
• Richard Wormald, Co-ordinating Editor for the Cochrane Eyes and Vision Group (CEVG) acknowledges financial support for
his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre
for Ophthalmology.
• The NIHR also funds the CEVG Editorial Base in London.";"Publicly-sponsored";NA;NA;NA;NA;"long";0;1;"""After removing comparisons with missing treatment effects or standard errors,\n  study '88' has a wrong number of comparisons";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"23";"479688";"YES";"Zhou";2005;"Canada";"American Heart Journal";"Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention";8;"6";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Major coronary events";"The relative efficacy of different statins for long-term cardiovascular prevention";"Safety";"Harmful";"Binary";"Objective";"risk ratio";"patients with fatal coronary heart disease and nonfatal myocardial infarctions";"Adjusted indirect comparison (Bucher)";"Study";"8";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NR";"NR";"All";"No";"No";"NA";"Natural Science and Engineering Research Council of Canada (NSERC) , Canadian Cardiovascular Outcome Research Team (CCORT), Arthritis Society";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"24";"479719";"YES";"Zintzaras";2014;"USA";"Clinical Therapeutics";"Assessment of the Relative Effectiveness and Tolerability of Treatments of Type 2 Diabetes Mellitus: A Network Meta-analysis";199;"68";18;"metformin";"1 (pharmacological vs pharmacological)";"Yes";"Yes";"No - lump doses";"target HbA1c for glycemic control";"The relative effectiveness of the treatments of type 2 diabetes mellitus";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"patients achieving the HbA1c goal";"Indirect comparison meta-analysis";"Study";"168";"26";"4";"1";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"NA";"No";"NR";"Random effects";"No";"NR";"NR";"Inverse Variance Method";"Unclear";"No";"NA";"NR";"Subset";"No";"Yes";"Studies with missing data excluded";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"25";"479757";"YES";"Chan";2014;"Canada";"PLoS One";"A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer";16;"9";9;"gemcitabine";"1 (pharmacological vs pharmacological)";"Yes";"Unclear";"NR";"overall survival";"Efficacy of treatments for advanced pancreatic cancer";"Effectiveness";"Beneficial";"Survival";"Objective";"hazard ratio";"Median overall survival in months";"Bayesian Hierarchical Model";"Arm";"16";"0";"0";"0";"0";"Full Network";"1";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"all studies in included in
the meta-analysis were comparable in terms of patient characteristics and outcomes";"Both FE and RE";"residual deviance was less than the number of unconstrained data points and the deviance information criterion for each of these outcome measures favoured this model over the fixed effects model";"common within-network";"τ = 0.0001";"ΝΑ";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"ΝΑ";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"26";"479767";"YES";"Katsanos";2014;"UK";"Journal of Vascular Surgery";"Bayesian network meta-analysis of nitinolstents, covered stents, drug-eluting stents, anddrug-coated balloons in the femoropopliteal artery";16;"6";6;"balloon angioplasty";"3 (non-pharmacological vs any)";"No";"No";"NA";"technical success";"Technical success was defined as successful recanalization of the target vessel withno significant residual stenosis on completion angiogram(30-50% threshold, depending on the trial design) and without any bail-out stenting in the case of BA trials. Cross-overs to the other treatment arm were considered as technical failures.";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"number of patients achieving technical success with intervention";"Bayesian Hierarchical Model";"Arm";"16";"0";"0";"0";"0";"Full Network";"1";"Back-calculation; Loop-specific";"Yes";"Yes";"uncertainty was accounted for by incorporating a meta-regression model on trial-specific baseline risk of the control arms";"Random effects";"A random-effects model was chosen to allow for heterogeneity among trials on the assumption that various treatment effects originated from a normal distribution";"Unclear";"Minimally informative priors";"NA";"Yes";"Yes";"Funnel plot; Egger's test";"SUCRA";"All";"No";"Unclear";"NA";"NR";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"27";"479770";"YES";"Greco";2015;"Italy";"British Journal of Anaesthesia";"A Bayesian network meta-analysis on the effect of inodilatory agents on mortality";46;"NR";5;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"mortality";"Effects of inodilators on survival in adult cardiac surgery patients";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"proportion of deaths";"Bayesian Hierarchical Model";"Arm";"46";"0";"0";"0";"0";"Full Network";"Unclear";"Comparison of model fit and parsimony";"Yes";"Yes";"NR";"Both FE and RE";"fixed effect model in case of low statistical heterogeneity (I2≤25%)";"Unclear";"Inverse-Gamma distribution";"NA";"Yes";"Yes";"Funnel plot";"SUCRA";"All";"No";"Yes";"When a study had missing or incomplete data on survival we contacted all authors by e-mail, letter or both";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"28";"479773";"YES";"Ellis";2014;"USA";"Value in Health";"Bazedoxifene versus Oral Bisphosphonates for the Prevention of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis at Higher Risk of Fracture : A Network Meta-Analysis";11;"7";5;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Incidence of nonvertebral fractures";"Efficacy of bazedoxifeneandoral
bisphosphonates for the prevention of nonvertebral fractures(NVFs)
in women with higher risk of postmenopausal osteoporosis";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"proportion of patients with nonvertebral fractures
";"Bayesian Hierarchical Model";"Arm";"11";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"Model fit";"Unclear";"vague ~Uniform(0,2)";"NA";"Yes";"No";"NA";"Probability of being the best, P (Better)";"Subset";"No";"No";"NA";"Pfizer, Inc.A.G.E.and Mapi";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"30";"479806";"YES";"Messori";2014;"Italy";"Therapeutic Advances in Musculoskeletal Disease";"Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence";7;"5";5;"MTX monotherapy";"1 (pharmacological vs pharmacological)";"Yes";"No";"NA";"ACR50 achievement at 12 months";"Efficacy of biologics in rheumatoid arthritis";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"patients achieving ACR50 at 12 months";"Bayesian Hierarchical Model";"Arm";"7";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"using a randomeffects model, the possible between-study variance was accounted for";"Unclear";"NR";"NA";"Unclear";"No";"NA";"Rankograms (histogram of rankings)";"All";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"31";"479807";"YES";"Galvan-Banqueri";2013;"Spain";"The Journal of Clinical Pharmacy and Therapeutics";"Biological treatments for moderate-to-severe psoriasis: indirect comparison";14;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"Psoriasis Area Severity Index reduction by 75%";"Efficacy of the biological agents in patients with psoriasis";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk difference";"The primary end point (PASI 75) was determined taking into account the estimated response time for each of the drugs, so that PASI 75 was determined at week 12, 16, 10 and 24 for ustekinumab, adalimumab, infliximab and etanercept respec- tively. First, we calculated the absolute risk reduction (ARR) in the primary end point compared with placebo for each of the biological agents";"Adjusted indirect comparison (Bucher)";"Arm";"14";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"trials with similar characteristics";"Both FE and RE";"sensitivity analysis";"Unclear";"NR";"Inverse Variance Method";"Unclear";"No";"NA";"NR";"Subset";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"32";"479808";"YES";"Singh";2009;"USA";"Cochrane Database of Systematic Reviews";"Biologics for rheumatoid arthritis: an overview of Cochrane reviews";31;"7";7;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"50% improvement in patient- and
physician-reported criteria of the American College of Rheumatology (ACR 50)";"Efficacy of currently available biologic disease-modifying anti-rheumatic drugs in adults with rheumatoid arthritis";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"patients achieving more than 50% symptomatic improvement";"Meta regression";"Arm";"31";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"trials with similar patients characteristics";"Both FE and RE";"Model fit";"common within-network";"NR";"NR";"Yes";"No";"NA";"NR";"All";"No";"Yes";"for missing values we contacted the authors of the review and requested
data and/or an update to the review";"NIH CTSA Award, The Oak Foundation";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"33";"479816";"YES";"Musini";2014;"Canada";"Cochrane Database of Systematic Reviews";"Blood pressure-lowering efficacy of monotherapy with
thiazide diuretics for primary hypertension";55;"7";27;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"Unclear";"systolic blood pressure reduction";"To determine the dose-related decrease in systolic and/or diastolic
blood pressure due to thiazide diuretics compared with placebo
control in the treatment of patients with primary hypertension";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"blood pressure within 12 hours of the dose and secondary
 between 12 and 24 hours";"Adjusted indirect comparison (Bucher)";"Arm";"29";"13";"11";"2";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"fixed effect
model in case with low heterogeneity";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot";"NR";"Subset";"No";"Yes";"missing values from information in the same trial or from other
trials using the same dose";"Canadian Institutes of Health Research";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"35";"479887";"YES";"Zhang";2014;"China";"World Journal of Gastroenterology";"Chemotherapy for patients with gastric cancer after complete resection: A network meta-analysis";13;"5";5;"surgery";"3 (non-pharmacological vs any)";"Yes";"Unclear";"NR";"overall mortality";"Efficacy of different chemotherapy regimens for patients with gastric cancer";"Effectiveness";"Harmful";"Survival";"Objective";"hazard ratio";"number of patients for the time from randomization to death from any cause, or to the last follow-up, which was used as the date of censoring";"Indirect comparison meta-analysis";"Arm";"31";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"NR";"All";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"36";"479888";"YES";"Gresham";2014;"Canada";"BioMed Central Cancer";"Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis";23;"20";20;"gemcitabine";"1 (pharmacological vs pharmacological)";"Yes";"Unclear";"NR";"overall survival";"Efficacy of chemotherapy regimens for the treatment of advanced pancreatic cancer";"Effectiveness";"Beneficial";"Survival";"Objective";"hazard ratio";"number of patients from the date of randomization until the date of death";"Bayesian Hierarchical Model";"Study";"23";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"use of fixed effects models for comparisons in which only a single study was included for that particular treatment comparison";"Unclear";"vague/flat priors";"NR";"Yes";"Yes";"Funnel plot";"Probability of being the best; mean rank";"All";"No";"No";"NR";"CIHR; Canadian Network and Centre for Trials Internationally (CANNeCTIN)";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"37";"479907";"YES";"Cost";2011;"Portugal";"Epilepsia";"Clinical comparability of the new antiepileptic drugs
in refractory partial epilepsy: A systematic review and meta-analysis";70;"NR";11;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"responder (>=50% seizure reduction)";"Evaluate the clinical comparability of new
antiepileptic drugs (AEDs) in partial refractory epilepsy";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio (pooled)";"proportion of patients experiencing a
50% or greater reduction in seizure frequency in the treatment
period compared to the prerandomization baseline period";"Adjusted indirect comparison (Bucher)";"Arm";"69";"1";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"all trials enrolled patients with similar clinical characteristics and study
designs";"Random effects";"No";"NR";"NR";"Inverse Variance Method";"Yes";"No";"NA";"NR";"Subset";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;1;"Non-numeric value for argument 'n'.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"38";"479911";"YES";"Brown";2013;"UK";"Health Technology Assessment";"Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation";18;"NR";4;"Unclear";"1 (pharmacological vs pharmacological)";"Yes";"Yes";"No - lump doses";"overall survival";"Effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).";"Effectiveness";"Beneficial";"Survival";"Objective";"hazard ratio";"# of deaths in Non-small cell lung cancer population with squamous disease";"Bayesian Hierarchical Model";"Arm";"14";"3";"1";"0";"0";"Full Network";"2";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Both FE and RE";"Model fit was assessed based on residual deviance and deviance information criteria";"Unclear";"non-informative (flat prior)";"NA";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"The National Institute for Health Research Health Technology Assessment";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"39";"479914";"YES";"Loveman";2015;"UK";"Health Technology Assessment";"The clinical effectiveness and cost-effectiveness of
treatments for idiopathic pulmonary fibrosis: a systematic
review and economic evaluation";10;"7";7;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"Forced vital capacity";"Clinical effectiveness of
treatments for idiopathic pulmonary fibrosis";"Effectiveness";"Beneficial";"Continuous";"Objective";"standardized mean difference";"FVC per cent predicted; and absolute change from baseline";"Bayesian Hierarchical Model";"Arm";"10";"0";"0";"0";"0";"Full Network";"1";"Loop-specific";"Yes";"Yes";"NR";"Both FE and RE";"There were insufficient data to allow random-effects variances to vary between treatments (page 92)";"Unclear";"NR";"NA";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"The National Institute for Health Research Health Technology Assessment programme";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"40";"479918";"YES";"Gao";2013;"Australia";"Epilepsy Research";"Clinical efficacy and safety of the newer antiepileptic
drugs as adjunctive treatment in adults with
refractory partial-onset epilepsy: A meta-analysis of
randomized placebo-controlled trials";15;"24";7;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"Yes - Subgroup analyses";"Response Rate";"To evaluate the clinical efficacy of the newer antiepileptic drugs (AEDs)  as adjunctive therapy for adults with partialonset
seizures (POS)";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"50% reduction in seizure frequency comparing to baseline";"Adjusted indirect comparison (Bucher)";"Arm";"15";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"Mantel Haenszel";"Yes";"No";"NA";"NA";"Subset";"No";"Yes";"last observation carried forward
(LOCF) analysis";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"43";"479969";"YES";"Lewis";2015;"UK";"The Spine Journal";"Comparative clinical effectiveness of management strategies for sciatica:
systematic review and network meta-analyses";64;"NR";21;"no treatment, sham treatment or placebo";"3 (non-pharmacological vs any)";"No";"Unclear";"NA";"Overall response or global effect";"Effectiveness of different treatment strategies for sciatica";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"response in terms of overall improvement";"Bayesian Hierarchical Model";"Arm";"94";"1";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"relative treatment effect of one treatment versus another is the same across the entire set of studies";"Random effects";"We used a random-effects model to pool the data, which is based on the assumption that different studies assessed different, yet related, treatment effects";"comparison-specific";"NR";"NA";"Unclear";"Yes";"Funnel plot";"Probability of being the best";"All";"No";"Yes";"missing data were estimated from the published data, using standard methods, such as standard deviations (SDs) derived from
standard errors (SEs). Where mean values were unavailable but the medians were reported, these were used
instead. If SDs for baseline values were available, these were substituted for missing SDs. For studies that did not
report sufficient data to derive the SDs, they were imputed
using the weighted mean, which was calculated separately
for each intervention category";"UK National Institute for Health Research
Health Technology Assessment";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"44";"479971";"YES";"Loke";2014;"UK";"British Journal of Clinical Pharmacology";"Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison";27;"NR";4;"placebo, heparin or vitamin K antagonist";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"adverse coronary events";"Compare treatment options such as rivaroxaban or apixaban with dabigatran for the risk of acute coronary syndrome";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"proportion of patients with acute coronary syndrome";"Adjusted indirect comparison (Bucher)";"Arm";"27";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"If there was substantial heterogeneity (I2 >60%), we planned to use random effects metaanalysis and to explore potential sources of heterogeneity.";"Unclear";"NR";"Inverse Variance Method";"Yes";"No";"NA";"NA";"Subset";"No";"Yes";"Authors were contacted to obtain any missing data,  but we did not receive any response.";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"45";"479974";"YES";"Wen-Huey Lee";2014;"Malaysia";"BJU International";"Comparative effectiveness and safety of various
treatment procedures for lower pole renal calculi:
a systematic review and network meta-analysis";13;"4";4;"SWL – Shockwave lithotripsy alone";"3 (non-pharmacological vs any)";"No";"No";"NA";"stone-free rate";"Compare the effectiveness of various treatments used for
lower pole renal calculi";"Effectiveness";"Beneficial";"Binary";"Objective";"risk ratio";"proportion of patients
who were stone-free at 3 months";"Multivariate meta-analysis model";"Arm";"13";"0";"0";"0";"0";"Full Network";"1";"Inconsistency factors";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"Yes";"Funnel plot; Egger's test";"SUCRA; Probability of being the best";"All";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"47";"479993";"YES";"Craddy";2013;"Switzerland";"Diabetes Therapy";"Comparative Effectiveness of Dipeptidylpeptidase-4
Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison";83;"120";6;"placebo, or standard of care for diabetes";"2 (pharmacological vs placebo)";"Yes";"Yes";"No - lump doses";"glycemic control : mean change in HbA1c from baseline to endpoint; proportion
of patients achieving target HbA1c ( smaller than 7%)
";"Safety of the dipeptidylpeptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes and inadequate
glycemic control";"Effectiveness";"Beneficial";"Continuous";"Objective";"mean difference";"mean changes from baseline in HbA1c";"Bayesian Hierarchical Model";"Study";"44";"18";"10";"2";"3";"Full Network";"Unclear";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"Random-effects models were utilized to account for heterogeneity from varying study populations.";"Unclear";"NR";"NA";"Yes";"No";"NA";"NA";"Subset";"No";"Yes";"missing standard
errors  derived from available
published information. If possible, standard
errors were obtained from confidence intervals
(CIs) and standard deviations (SDs); if these data
were unavailable, they were derived from the
p value referring to the change from baseline. If
none of the above was available, standard errors
were imputed using data from other wellreported
studies, using methods outlined by the Cochrane Collaboration.Alternatively,
as a final option, if there was no other wellreported
study, p values for the difference
between treatments were used and the pooled
SD applied to both arms.";"Takeda Pharmaceuticals International GmbH";"Industry-sponsored";NA;NA;NA;NA;"long";0;1;"""Identical treatments for the following studies:\n  'NA' - 'NA' - 'NA'";NA;NA;NA;NA;NA;NA;"(some studies contain multiple arms with the same intervention)";NA;NA;NA;NA;NA;NA;NA
"48";"479996";"YES";"Hazlewood";2015;"Canada";"Gastroenterology";"Comparative Effectiveness of Immunosuppressants and
Biologics for Inducing and Maintaining Remission in Crohn’s
Disease: A Network Meta-analysis";21;"9";9;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"induction of remission";"Efficacy of therapies for induction of remission in adult patients with Crohn’s disease";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"patients with Crohn’s Disease Activity Index (CDAI) less than 150";"Bayesian Hierarchical Model";"Arm";"19";"1";"1";"0";"0";"Full Network";"3";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"effect modifiers are balanced across trials";"Both FE and RE";"RE model was preferred based on the clinical heterogeneity across trials. Additional sensitivity analyses included FE model";"Unclear";"NR";"Mantel Haenszel";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"Alberta IBD Consortium, funded by an AHFMR Interdisciplinary Team Grant (AHFMR is now Alberta Innovates–Health Solutions).";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"49";"479999";"YES";"Loymans";2014;"Netherlands";"British Medical Journal";"Comparative effectiveness of long term drug treatment
strategies to prevent asthma exacerbations: network
meta-analysis";66;"23";16;"placebo";"2 (pharmacological vs placebo)";"Yes";"No";"NA";"rate of severe exacerbations";"Comparative effectiveness of current maintenance strategies in preventing exacerbations of asthma";"Effectiveness";"Harmful";"Rate";"Semi-objective";"rate ratio";"the proportion of patients
with at least one exacerbation, or exacerbation rates (numbers
per person time of follow-up)";"Bayesian Hierarchical Model";"Arm";"54";"9";"3";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"modifiers of relative treatment effect were similar across studies";"Random effects";"No";"comparison-specific";"median of
the posterior distribution of the between trial variance τ^2";"NA";"Unclear";"Yes";"Funnel plot";"Rankograms";"All";"No";"Yes";"emailed the corresponding authors for missing data on outcomes";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"50";"480001";"YES";"Nagayama";2014;"Japan";"JNCI: Journal of National Cancer Institute";"Comparative Effectiveness of Neoadjuvant Therapy for HER2–
Positive Breast Cancer: A Network Meta-Analysis";10;"7";7;"unclear";"1 (pharmacological vs pharmacological)";"Yes";"No";"NA";"pathologically complete response (PCR)";"Efficacy of neoadjuvant therapy for HER2-positive breast cancer";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"the number of patients who achieved pathologically complete response (PCR) with the number of patients treated";"Bayesian Hierarchical Model";"Arm";"7";"2";"1";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR";"Random effects";"No";"common within-network";"NR";"NA";"Unclear";"No";"NA";"SUCRA; Probability of being the best";"All";"No";"Yes";"Authors were contacted to obtain missing data. If no response was received, analysis was performed without these data";"Ministry of Education, Culture, Sports, Science
and Technology of Japan Grants-in-Aid for Scientific Research";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"56";"480029";"YES";"Xiong";2014;"UK";"BMJ open";"Comparative efficacy and safety of
treatments for localised prostate cancer:
an application of network meta-analysis";17;"8";8;"unclear";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split doses";"all-cause mortality";"Εfficacy of different treatments for patients with localised
prostate cancer";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"proportion of patients with death";"Bayesian Hierarchical Model";"Arm";"17";"0";"0";"0";"0";"Full Network";"2";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"to allow for heterogeneity even when only a single study was available";"comparison-specific";"log-normal (−3.93, 1.51^2)";"NA";"Unclear";"No";"NA";"SUCRA; median ranks";"All";"No";"No";"NA";"National Institute for Health Research Health
Technology Assessment programme, Medical Research, the National Institute for
Health Research";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"57";"480037";"YES";"Singh";2014;"USA";"Mayo Clinic Proceedings";"Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis";11;"15";7;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Induction of clinical remission (Crohn's Disease Activity Index (CDAI)<150)";"Efficacy of biologics agents of biologic-naïve patients with Crohn disease";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk ratio";"patients with Crohn's Disease Activity Index (CDAI)<150";"Bayesian Hierarchical Model";"Arm";"17";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"NA";"Unclear";"Yes";"Funnel plot; Egger's test";"Probability of being the best";"All";"No";"Yes";"Studies with missing data excluded";"Center for the Science of Healthcare Delivery, National Center for Advancing Translational Sciences, National Institutes of Health and NIH";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"58";"480038";"YES";"Signorovitch";2014;"USA";"British Journal of Dermatology";"Comparative efficacy of biological treatments for moderateto-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response";15;"7";7;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"50% reduction in the Psoriasis Area and Severity Index (PASI)";"Efficacy of biological treatments for moderate to-severe psoriasis";"Effectiveness";"Beneficial";"Rate";"Semi-objective";"rate ratio";"patients with 50% reduction from baseline in the Psoriasis Area and Severity Index (PASI)";"Bayesian Hierarchical Model";"Arm";"10";"5";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"similarity of patient
populations";"Random effects";"The variance of the random effect, which provides a measure of between trial heterogeneity";"Unclear";"vague normal prior";"NA";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"AbbVie";"Industry-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"59";"480039";"YES";"Jansen";2014;"USA";"Health and Quality of Life Outcomes";"Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis";13;"8";8;"placebo";"2 (pharmacological vs placebo)";"Yes";"No";"NA";"improvement in pain";"Compare biologics as monotherapy or in combination with methotrexate in rheumatoid arthritis patients";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"patients who are intolerant or show an inadequate
response (IR) to traditional disease-modifying antirheumatic
drugs (DMARDs)";"Bayesian Hierarchical Model";"Arm";"13";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"Model fit - The random effects model resulted in the lowest DIC, and was considered appropriate for the synthesis of the available evidence.";"Unclear";"uniform distribution with range of 0–20";"NA";"Unclear";"No";"NR";"Probability of being the best";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"63";"480052";"YES";"Singh";2015;"USA";"Gastroenterology";"Comparative Efficacy of Pharmacologic Interventions
in Preventing Relapse of Crohn’s Disease After Surgery:
A Systematic Review and Network Meta-analysis";20;"24";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"clinical relapse with at
least 6 months of follow-up evaluation after surgery";"Efficacy of different pharmacologic
interventions for postoperative prophylaxis of Crohn’s disease";"Safety";"Harmful";"Binary";"Semi-objective";"risk ratio";"patients with Crohn’s Disease Activity Index (CDAI) value of greater than 150";"Bayesian Hierarchical Model";"Arm";"19";"2";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NA";"Unclear";"Yes";"Funnel plot; Egger's test";"NA";"All";"No";"No";"NA";"Science of Healthcare Delivery, Mayo Clinic,
and Center for Clinical and Translational Science grant UL1 TR000135 from
the National Center for Advancing Translational Sciences and
the National Institutes of Health";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"64";"480060";"YES";"Tadrous";2014;"Canada";"Osteoporosis International";"Comparative gastrointestinal safety of bisphosphonates
in primary osteoporosis: a network meta-analysis";46;"NR";5;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"Yes";"any gastrointestinal related to adverse events";"Comparative  gastrointestinal safety of bisphosphonates";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"number of any gastrointestinal adverse events";"Bayesian Hierarchical Model";"Arm";"45";"1";"0";"0";"0";"Full Network";"3";"Informal comparison of NMA results with previously published results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"noninformative flat prior";"NA";"Yes";"Yes";"NR- from previous completed reviews";"Probability of being the best";"All";"No";"Yes";"However, given that we leveraged and updated prior
completed systematic reviews and reported Cochrane reviews,
we are confident that little evidence was missed.";"Ontario Ministry of Research and Innovation Early
Researcher Award";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"65";"480074";"YES";"Phan";2014;"Australia";"European Journal of Cardio-Thoracic Surgery";"Comparing energy sources for surgical ablation of atrial fibrillation: a Bayesian network meta-analysis of randomized, controlled trials";16;"5";5;"no ablation";"3 (non-pharmacological vs any)";"No";"No";"NA";"incidence of sinus rhythm";"Safety of different energy sources for surgical ablation for atrial fibrillation";"Safety";"Beneficial";"Binary";"Objective";"odds ratio";"beyond the 12-month follow-up";"Bayesian Hierarchical Model";"Arm";"16";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"NA";"Unclear";"No";"NR";"Probability of being the best";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"67";"480215";"YES";"Mavranezouli";2013;"UK";"PharmacoEconomics";"The Cost Effectiveness of Pharmacological Treatments
for Generalized Anxiety Disorder";26;"11";11;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"response to treatment";"To assess the cost effectiveness of pharmacological interventions for patients with generalized anxiety disorder (GAD)";"Effectiveness";"Beneficial";"Survival";"Semi-objective";"hazard ratio";"conditional response, defined as at least a 50 % reduction in the Hamilton Rating Scale for Anxiety (HAM-A) score in patients not discontinuing
treatment due to side effects";"Bayesian Hierarchical Model";"Arm";"25";"14";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"Uninformative prior";"NA";"Unclear";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"NICE";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"69";"480430";"YES";"Gómez-Outes";2012;"Spain";"British Medical Journal";"Dabigatran, rivaroxaban, or apixaban versus
enoxaparin for thromboprophylaxis after total hip or
knee replacement: systematic review, meta-analysis,
and indirect treatment comparisons";16;"22";4;"enoxaparin";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - lump doses";"symptomatic venous thromboembolism";"Clinical outcomes with new oral anticoagulants
for prophylaxis against venous thromboembolism after total hip or knee
replacement";"Safety";"Harmful";"Binary";"Objective";"risk ratio";"number of patients with symptomatic venous thromboembolism";"Adjusted indirect comparison (Bucher)";"Arm";"16";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"fixed effects model led to closer confidence intervals than those obtained using random effects";"Unclear";"NR";"Mantel-Haenszel";"Unclear";"Yes";"Funnel plot";"NA";"Subset";"No";"Yes";"contact sponsors or the main investigators for missing
outcome data";"All studies were sponsored by pharmaceutical companies. The
sponsor was responsible for the collection and statistical analysis
of the data. In all cases the sponsor was involved in the design
and oversight of the study with or without the collaboration of
a scientific committee, and at least one of the authors of the
publications were employees of the sponsor.";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"70";"480486";"YES";"Dai";2014;"China";"The American Journal of the Medical Sciences";"Different b-Blockers and Initiation Time in Patients
Undergoing Noncardiac Surgery: A Meta-analysis";8;"9";5;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"all-cause mortality";"Effects of various b-blockers and timing of treatment
on postoperative outcomes";"Safety";"Harmful";"Binary";"Objective";"risk ratio";"patients in b-blocker";"Adjusted indirect comparison (Bucher)";"Study";"8";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"patient characteristics are common between trials";"Both FE and RE";"fixed effect was chosen in the absense of heterogeneity";"Unclear";"NR";"Mantel-Haenszel";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"None";"Funding source not reported";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"71";"480492";"YES";"Meissner";2013;"Germany";"JAMA
The Journal of the American Medical Association";"Differential Effectiveness of Placebo Treatments
A Systematic Review of Migraine Prophylaxis";40;"NR";7;"placebo";"3 (non-pharmacological vs any)";"No";"No";"NA";"the proportion of responders";"To investigate whether different types of placebo treatments are associated with
different responses using the studies of migraine prophylaxis";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"patients with a reduction in attack frequency of at least 50%.";"Meta regression";"Arm";"37";"3";"0";"0";"0";"Full Network";"3";"NR";"Unclear";"Unclear";"NR";"Fixed-effect";"No";"NA";"NR";"Inverse Variance Method";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"German Ministry of Education and Research";"Publicly-sponsored";NA;NA;NA;NA;"long";0;1;"""Non-numeric value for argument 'event'.""";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"75";"480563";"YES";"Caldeira";2014;"Portugal";"American Journal of Cardiovascular Drugs";"Dyspnea and Reversibility Profile of P2Y12 Antagonists: Systematic Review of New Antiplatelet Drugs";8;"16";5;"clopidogrel";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - lump doses";"Incidence of dyspnea";"Compare new antiplatelet drugs";"Safety";"Harmful";"Binary";"Semi-objective";"risk ratio";"an adverse event in accordance with each study definition";"Adjusted indirect comparison (Bucher)";"Arm";"8";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"By default, we used the random-effects model because adjusted indirect comparisons that use the fixedeffects model tend to underestimate the standard errors of pooled estimates";"Unclear";"NR";"Mantel–Haenszel method";"Yes";"No";"NA";"NR";"Subset";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"77";"480611";"YES";"Graudal";2014;"Denmark";"PLOS ONE";"Effect of Combination Therapy on Joint Destruction in
Rheumatoid Arthritis: A Network Meta-Analysis of
Randomized Controlled Trials";38;"NR";7;"single DMARD/GS";"1 (pharmacological vs pharmacological)";"Yes";"No";"NA";"difference between follow-up radiographic erosion score and baseline radiographic";"Effect of combination treatments of disease modifying
anti-rheumatic drugs (DMARDs) with and without biologic agents";"Safety";"Harmful";"Continuous";"Semi-objective";"standardized mean difference";"change scores from baseline
to follow-up";"Adjusted indirect comparison (Bucher)";"Study";"33";"3";"1";"1";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"NA";"Yes";"NR";"Both FE and RE";"Both fixed and random effect models were used, but the existence of statistically significant heterogeneity would determine whether a fixed effect model (nonsignificant heterogeneity test) or a random effect model (significant heterogeneity test) would be used in the primary or secondary analysis";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot";"NA";"Subset";"No";"Yes";"If SD was not given, it could often be calculated from a 95%
confidence interval, a standard error or a p-value [The Nordic Cochrane Centre].";"A.P. Møller Foundation";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"78";"480612";"YES";"Kunitomi";2015;"Japan";"PLOS ONE";"Effect of Common Comparators in Indirect
Comparison Analysis of the Effectiveness of
Different Inhaled Corticosteroids in the
Treatment of Asthma";23;"28";5;"placebo";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - lump doses";"change from baseline in forced expiratory
volume in 1 s (FEV1(L))";"Comparisons of interventions
for mild-to-moderate asthma patients";"Effectiveness";"Beneficial";"Continuous";"Objective";"mean difference";"change from baseline in forced expiratory volume in
1 s (FEV1(L))";"Adjusted indirect comparison (Bucher)";"Arm";"10";"6";"7";"0";"0";"Full Network";"1";"Loop-specific";"Yes";"Yes";"patients with similar demographic
characteristics, such as age, duration of disease, and baseline FEV1(L) values";"Random effects";"We applied the random effect model in this study because some I2 values in metaanalysis suggested the existence of heterogeneity";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"81";"480617";"YES";"Skoetz";2013;"Germany";"The Lancet Oncology";"Effect of initial treatment strategy on survival of patients
with advanced-stage Hodgkin’s lymphoma: a systematic
review and network meta-analysis";14;"11";11;"doxorubicin, bleomycin, vinblastine,
dacarbazine, dacarbazine (ABVD)";"1 (pharmacological vs pharmacological)";"Yes";"No";"NA";"overall survival";"Compare treatments strategies for adults with advanced-stage Hodgkin’s lymphoma";"Effectiveness";"Harmful";"Survival";"Objective";"hazard ratio";"# of deaths";"Bayesian Hierarchical Model";"Study";"10";"4";"0";"0";"0";"Full Network";"Unclear";"Back-calculation";"Yes";"Yes";"NR";"Random effects";"No";"common within-network";"NR";"NA";"Yes";"No";"NA";"Probability of being the best";"Subset";"Yes";"Yes";"If outcome data were missing, we asked the contact author of the individual study for additional information";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"84";"480629";"YES";"Devine";2011;"USA";"Pharmacotherapy";"Effectiveness of Biologic Therapies for Rheumatoid Arthritis:
An Indirect Comparisons Approach";23;"43";10;"Placebo ± methotrexate";"2 (pharmacological vs placebo)";"Yes";"Yes";"No - lump doses";"American College of Rheumatology
50% improvement criteria ACR50";"Efficacy of biologic disease-modifying
antirheumatic drugs (DMARDs) versus placebo with or without
methotrexate, in treating rheumatoid arthritis";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"proportion of patients with American College of Rheumatology
50% improvement criteria ACR50 at 6 months";"Bayesian Hierarchical Model";"Arm";"23";"0";"0";"2";"1";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"vague";"NA";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;1;"""Identical treatments for the following studies:\n  'NA' - 'NA' - 'NA'";NA;NA;NA;NA;NA;NA;"(some studies contain multiple arms with the same intervention)";NA;NA;NA;NA;NA;NA;NA
"86";"480655";"YES";"Vestergaard";2007;"Denmark";"Osteoporosis International";"Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk – a meta-analysis";12;"9";9;"placebo";"2 (pharmacological vs placebo)";"Yes";"Yes";"Unclear";"change in BMD in spine (abstracted)/fracture risk reduction";"Effects of parathyroid hormone (PTH) alone or in
combination with antiresorptive therapy on changes in fracture risk";"Effectiveness";"Harmful";"Binary";"Objective";"risk ratio";"number of patients with one or more vertebral fractures during follow-up";"Adjusted indirect comparison (Bucher)";"Arm";"13";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"We chose a random effects model for heterogeneous outcomes, and a fixed effects model for homogeneous outcomes";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot";"NA";"Subset";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"87";"480666";"YES";"Kriston";2014;"Germany";"Depression and Anxiety";"Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis";45;"10";10;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"50% improvement
on a symptom severity rating scale";"Efficacy of specific treatments for persistent depressive disorder";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"proportion of patients who responded to the allocated treatment";"Bayesian Hierarchical Model";"Arm";"37";"8";"0";"0";"0";"Full Network";"Unclear";"Comparison of model fit and parsimony";"Yes";"Yes";"trials were similar due to strict inclusion criteria";"Both FE and RE";"based on model fit and parsimony";"Unclear";"vague, uninformative";"NA";"Yes";"Yes";"""calculated the percent effect overestimation needed in available studies in contrast to all existing studies for an effect against placebo to become nonsignificant""";"NA";"Subset";"No";"Yes";"For trials including participants with missing data, intention-to-treat (ITT) estimates were used as reported by the trial authors. If ITT estimates were unavailable, participants with missing data were considered non- responders.";"German Ministry of Education and Research";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"88";"480667";"YES";"Linde";2015;"Germany";"The Annals of Family Medicine";"Efficacy and Acceptability of Pharmacological Treatments
for Depressive Disorders in Primary Care:
Systematic Review and Network Meta-Analysis";59;"25";9;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - Lump doses and meta-regressions";"response to treatment";"Efficacy of antidepressants in the primary care setting";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"50% score reduction on a depression scale";"Bayesian Hierarchical Model";"Arm";"52";"7";"0";"0";"0";"Full Network";"Unclear";"Comparison of model fit and parsimony";"Yes";"Yes";"NR";"Both FE and RE";"sensitivity analysis";"Unclear";"NR";"NA";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"Yes";"missing values were imputed from available score
data";"German Ministry of Education and Research";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"95";"480679";"YES";"Hansen";2008;"USA";"Journal of Clinical Interventions in Aging";"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis";14;"12";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"cognition";"Efficacy of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease";"Effectiveness";"Beneficial";"Continuous";"Subjective";"weighted mean difference";"Alzheaimer's disease assessment scale-cognition (ADAS-cog) change from baseline to endpoint";"Adjusted indirect comparison (Bucher)";"Study";"14";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"Inverse Variance Method";"Unclear";"Yes";"Funnel plot";"NA";"Subset";"No";"No";"NA";"Cecil G Sheps Center for Health Services Research through the Center for Evidence-Based Policy; Oregon Health and Science University; one author was supported by grant K12RR023248.";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"97";"480693";"YES";"Schmitt";2014;"Germany";"British Journal of Dermatology";"Efficacy and safety of systemic treatments for moderate-tosevere
psoriasis: meta-analysis of randomized controlled
trials";43;"20";10;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split and lump doses";"75% reduction in Psoriasis Area and Severity Index";"NR";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"risk difference";"% pts with 75% reduction in Psoriasis Area and Severity Index";"Adjusted indirect comparison (Bucher)";"Arm";"33";"10";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Random effects";"The populations included in trials 20 years ago and today may differ in important characteristics such as body weight and previous exposures to systemic anti-inflammatory agents, which may add some heterogeneity and is one reason why we generally used random effects meta-analysis";"Unclear";"NR";"NA";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"98";"480695";"YES";"Yang";2014;"China";"PLOS ONE";"Efficacy and Safety of Therapies for Acute Ischemic
Stroke in China: A Network Meta-Analysis of 13289
Patients from 145 Randomized Controlled Trials";145;"NR";5;"placebo";"2 (pharmacological vs placebo)";"Yes";"Unclear";"Unclear";"acute ischemic
stroke";"Efficacy of several commonly used drugs for acute ischemic stroke";"Effectiveness";"Harmful";"Binary";"Objective";"risk ratio";"National Institutes of Health Stroke Scale (NIHSS)
scores";"Bayesian Hierarchical Model";"Arm";"145";"0";"0";"0";"0";"Full Network";"2";"Loop-specific";"Yes";"Yes";"comparability of effect modifiers";"Both FE and RE";"for fixed, we assumed that the true treatment effect of a given
therapy is the same across all trials included in the comparison
network";"common within-network";"vague";"Mantel Haenszel";"Unclear";"No";"NA";"NA";"Subset";"No";"Yes";"When unreported, missing mean differ- ences and s.d.’s were estimated based on reported CIs, and the authors of the study were contacted if necessary.";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"102";"480706";"YES";"Regnier";2014;"Switzerland";"PLoS One";"Efficacy of Anti-VEGF and Laser Photocoagulation in the Treatment of Visual Impairment due to Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis";8;"5";5;"ranibizumab 0.5 mg";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"gaining >=10 letters best-corrected visual acuity (BCVA)";"Efficacy of ranibizumab, aflibercept, laser, and sham in the first-line treatment of diabetic macular edema";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"the percentage of patients experiencing an improvement in (best-corrected visual acuity) BCVA of at least 10 letters (2 lines) on the ETDRS scale";"Bayesian Hierarchical Model";"Arm";"5";"3";"0";"0";"0";"Full Network";"1";"Node-splitting";"Yes";"Yes";"NR";"Both FE and RE";"RE justified because of the heterogeneity among trials (with a between-study standard deviation of 0.40).";"Unclear";"between-study standard deviation is 0.40";"NA";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"Novartis Pharma AG";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"103";"480720";"YES";"Myers";2014;"USA";"BMC Musculoskeletal Disorders";"The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis";34;"12";9;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"function";"Efficacy of duloxetine, non-steroidal anti-inflammatory drugs and opioids in osteoarthritis";"Effectiveness";"Beneficial";"Continuous";"Subjective";"standardized mean difference";"change from baseline total  (the Western Ontario
MacMaster Universities Osteoarthritis Index) WOMAC score as reported
at 12 or more weeks.";"Bayesian Hierarchical Model; Bucher method";"Arm";"24";"9";"1";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR";"Random effects";"No";"NR";"uniform distribution";"NR";"Yes";"Yes";"Funnel plot; Trim and fill method";"Probability of being the best";"Subset";"No";"Yes";"Authors were contacted to obtain any missing data";"Eli Lilly and Co";"Industry-sponsored";NA;NA;NA;NA;"long";0;1;"""Identical treatments for the following studies:\n  'NA' - 'NA' - 'NA'";NA;NA;NA;NA;NA;NA;"(some studies contain multiple arms with the same intervention)";NA;NA;NA;NA;NA;NA;NA
"104";"480721";"YES";"Stam";2012;"The Netherlands";"The Open Rheumatology Journal";"Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective NSAIDs,
and Acetaminophen in Osteoarthritis: A Mixed Treatment Comparison";29;"14";14;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"pain";"Efficacy of acetaminophen, nsNSAIDs, and COX-2 selective NSAIDs in patients with osteoarthritis";"Effectiveness";"Beneficial";"Continuous";"Subjective";"mean difference";"Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scales";"Bayesian Hierarchical Model";"Arm";"12";"11";"3";"3";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"baseline characteristics of the patients in the
different trials were comparable";"Random effects";"To capture heterogeneity a random effects model was used";"Unclear";"uniform distribution with range of 0-5 was used for the
prior distribution of heterogeneity";"NA";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"Merck & Co";"Industry-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"105";"480737";"YES";"Pichenot";2011;"France";"HIV Medicine";"Efficacy of new antiretroviral drugs in treatmentexperienced
HIV-infected patients: a systematic review and
meta-analysis of recent randomized controlled trials";10;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"CD4 cell count
changes";"Immunological efficacy of new antiretroviral drugs
compared with placebo";"Effectiveness";"Beneficial";"Continuous";"Objective";"weighted mean difference";"change in CD4 cell count at week 48 from baseline";"Adjusted indirect comparison (Bucher)";"Study";"10";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"Yes";"Missing values
were imputed as no increase in CD4
cell count from baseline";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"108";"480804";"YES";"Palmer";2014;"New Zealand";"Cochrane Database of Systematic Reviews";"Erythropoiesis-stimulating agents for anaemia in adults with
chronic kidney disease: a network meta-analysis";19;"100";6;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"preventing blood transfusion";"Efficacy of ESAs (epoetin alfa, epoetin beta, darbepoetin alfa, or methoxy polyethylene glycol-epoetin beta, and biosimilar ESAs, against each other, placebo, or no treatment) to treat anaemia in adults with chronic kidney disease";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"responses to treatment at any time during
study follow-up";"Bayesian Hierarchical Model";"Arm";"19";"0";"0";"0";"0";"Full Network";"Unclear";"Loop-specific; Design by treatment";"Yes";"Yes";"Studies grouped by comparison were deemed
comparable for the effect modifiers of stage of CKD, haemoglobin
target with ESA treatment, age of participants and duration of
follow-up";"Random effects";"No";"common within-network";"with empirical distribution of heterogeneity";"NA";"Yes";"No";"NA";"SUCRA";"All";"No";"No";"NA";"European Research Council Starting Grant";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"110";"480851";"YES";"Stowe";2010;"UK";"Cochrane Database of
Systematic Reviews";"Evaluation of the efficacy and safety of adjuvant treatment to
levodopa therapy in Parkinson´ s disease patients with motor
complications";29;"4";4;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"off-time reduction";"Benefits of the three classes of drugs (dopamine agonists, COMTIs and
MAOBIs) in Parkinson’s disease patients suffering from motor complications";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"mean off-time reduction";"Adjusted indirect comparison (Bucher)";"Arm";"29";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Fixed-effect";"No";"NA";"NR";"Peto";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"Parkinson’s Disease Society, UK";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"111";"480926";"YES";"Messori";2015;"Italy";"Annals of Hematology";"First-line treatments for chronic lymphocytic leukaemia:
interpreting efficacy data by network meta-analysis";9;"NR";8;"Unclear";"1 (pharmacological vs pharmacological)";"Yes";"Unclear";"Unclear";"progression-free
rates at 3 years";"Effectiveness of treatments for chronic lymphocytic leukaemia";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"patients without progression at 3 years";"Bayesian Hierarchical Model";"Arm";"8";"1";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"To carry out our analysis, firstly, we separately ran the fixed-effect and the random-effect models. According to the deviance information criterion, the fixed-effect model showed a better fit than the random-effect one. Therefore, our study was based on the results generated by the former.";"Unclear";"NR";"NA";"Unclear";"No";"NA";"Rankograms";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"112";"480931";"YES";"Rochwerg";2014;"Canada";"Annals of Internal Medicine";"Fluid Resuscitation in Sepsis: A Systematic Review and Network Meta-analysis";13;"13";4;"crystalloids";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - lump doses";"90-day mortality";"The effect of different resuscitative fluids on
mortality in patients with sepsis";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"proportion of ill patients with severe sepsis or septic shock";"Bayesian Hierarchical Model";"Arm";"12";"1";"0";"0";"0";"Full Network";"1";"Loop-specific";"Yes";"Yes";"indirect estimates were potentially
rated down for intransitivity";"Fixed-effect";"No";"NA";"NR";"NA";"Unclear";"No";"NA";"NA";"Subset";"No";"Yes";"Authors were contacted to obtain any missing data";"Hamilton Chapter of the Canadian
Intensive Care Foundation, the Critical Care Medicine Residency
Program and Critical Care Division Alternate Funding Plan";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"113";"480935";"YES";"Dal Molin";2014;"Italy";"The Journal of Vascular Access";"Flushing the central venous catheter: is heparin necessary?";8;"14";5;"herapin";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - lump doses";"occlusion of catheter";"Efficacy of heparin flushing in the lock of central venous
catheters";"Effectiveness";"Harmful";"Binary";"Semi-objective";"odds ratio";"adult patients with central venous catheter";"Bayesian Hierarchical Model";"Arm";"7";"1";"0";"0";"0";"Full Network";"1";"Design by treatment";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NA";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"114";"480967";"YES";"Sun";2015;"China";"Diabetes Technology & Therapeutics";"Gastrointestinal Adverse Events
of Glucagon-Like Peptide-1 Receptor
Agonists in Patients with Type 2 Diabetes:
A Systematic Review and Network Meta-Analysis";60;"26";26;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"incidence of nausea";"Frequency of GI-related events with glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus";"Safety";"Harmful";"Binary";"Subjective";"odds ratio";"patients with nausea";"Bayesian Hierarchical Model";"Arm";"47";"13";"8";"2";"1";"Full Network";"Unclear";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NA";"Unclear";"No";"NA";"SUCRA; rankograms";"Subset";"No";"No";"NA";"the National Natural
Science Foundation of China, the Beijing Natural Science Foundation, the Research Fund for the Doctoral Program
of Higher Education, and the
Doctoral Fund of Corps";"Publicly-sponsored";NA;NA;NA;NA;"long";0;1;"""After removing comparisons with missing treatment effects or standard errors,\n  the following studies have a wrong number of comparisons: '41', '42'\n";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"115";"481009";"YES";"Ziakas";2014;"USA";"PLOS ONE";"Graft-Versus-Host Disease Prophylaxis after Transplantation: A Network
Meta-Analysis";33;"13";13;"CsA/MTX";"1 (pharmacological vs pharmacological)";"Yes";"No";"NA";"grade II-IV acute GvHD";"Comparative efficacy of immunospressant protocols for GvHD prophylaxis after hematopoietic stem cell transplantation";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"reduction in grade II-IV acute GvHD";"NR";"Arm";"33";"0";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with previously published results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"Yes";"Harbord-Egger test";"NA";"Subset";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"117";"481107";"YES";"Wang";2015;"USA";"Supportive Care in Cancer";"The impact of primary prophylaxis with granulocyte
colony-stimulating factors on febrile neutropenia
during chemotherapy: a systematic review and meta-analysis
of randomized controlled trials";30;"NR";5;"no primary G-CSF / placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - Lump doses and meta-regressions";"febrile
neutropenia risk for all chemotherapy
cycles without adjustment for
relative dose intensity";"Efficacy of granulocyte colony-stimulating factor (G-CSF) products administered
as primary prophylaxis (PP) to patients with cancer
receiving myelosuppressive chemotherapy";"Effectiveness";"Harmful";"Binary";"Semi-objective";"odds ratio";"patients with febrile
neutropenia";"Bayesian Hierarchical Model";"Arm";"30";"0";"0";"0";"0";"Full Network";"2";"Inconsistency model";"Yes";"Yes";"NR";"Random effects";"No";"common within-network";"priors were predefined and then up- dated by using the data from the literature review";"NA";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"Amgen Inc";"Funding source not reported";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"119";"481109";"YES";"Trinquart";2012;"France";"PLOS ONE";"Impact of Reporting Bias in Network Meta-Analysis of
Antidepressant Placebo-Controlled Trials";74;"13";13;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"depression severity score";"Impact of antidepressant drugs";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"standardized mean difference";"change from baseline to follow-up in
depression score";"Bayesian Hierarchical Model";"Study";"74";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"trial similarity";"Random effects";"No";"NR";"NR";"NA";"Unclear";"Yes";"contour enhanced funnel plots";"SUCRA; Probability of being the best";"Subset";"No";"No";"NA";"French Ministry of Health Programme Hospitalier de Recherche Clinique National and European Union Seventh Framework Programme";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"120";"481118";"YES";"Mealing";2014;"UK";"Systematic Reviews";"The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis";13;"8";8;"Entecavir 0.5 mg";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"Undetectable hepatitis B virus (HBV)
DNA at 1 year";"Efficacy of interventions for chronic hepatitis B (CHB)";"Effectiveness";"Harmful";"Binary";"Objective";"risk ratio";"number of hepatitis B e
antigen (HBeAg)-positive patients";"Bayesian Hierarchical Model";"Arm";"14";"0";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with previously published results";"Yes";"Yes";"trials are sufficiently similar on study and patient characteristics";"Both FE and RE";"""Fixed effect models were used in the unadjusted analysis. For the adjusted analyses we used both fixed and random effects models, and final model choice in all analyses was based on deviance information criteria (DIC)""";"Unclear";"NR";"NA";"Yes";"No";"NA";"Probability of being the best";"Subset";"Yes";"No";"NA";"Bristol-Myers Squibb";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"121";"481140";"YES";"Kunitomi";2013;"Japan";"British Journal of Clinical
Pharmacology";"Indirect comparison analysis
of efficacy and safety
between olanzapine
and aripiprazole for schizophrenia";20;"4";4;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"symptoms of schizophrenia";"Efficacy between
aripiprazole and olanzapine for schizophrenia";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"change from baseline in the Positive and Negative Syndrome Scale (PANSS)";"Adjusted indirect comparison (Bucher)";"Arm";"19";"1";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"NA";"Yes";"NR";"Random effects";"No";"NR";"NR";"NA";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"None";"Funding source not reported";NA;NA;NA;NA;"long";0;1;"""Non-numeric value for argument 'sd'.""";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"122";"481147";"YES";"Galvan-Banqueri";2015;"Spain";"Farmacia Hospitalaria";"Indirect comparison for Anti-TNF drugs in moderate to
severe ulcerative colitis";5;"4";4;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"clinical remission";"Comparative efficacy of anti-TNG agents in ulcerative colitis";"Effectiveness";"Beneficial";"Binary";"Objective";"risk ratio";"clinical remission in induction period (week 6-8)";"Adjusted indirect comparison (Bucher)";"Arm";"6";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"patients had similar baseline
characteristics";"Both FE and RE";"fixed-effect model, in the absence of heterogeneity";"in the absence of heterogeneity";"NR";"Inverse Variance Method";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"123";"481150";"YES";"Laporte";2014;"France";"Thrombosis and Haemostasis";"Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs.";44;"11";11;"enoxaparin 3000 anti-Xa IU/enoxaparin 4000 anti-Xa IU";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split doses";"incidence of venous thomboembolism definition 1   (""the composite of asymptomatic, systematically detected proximal DVT, symptomatic DVT (whether distal or proximal), symptomatic PE and death related to VTE "")";"Efficacy of treatments for venous
thromboembolism prophylaxis";"Effectiveness";"Harmful";"Binary";"Objective";"relative risk";"proportion of patients
undergoing hip (THR) or knee (TKR) replacement or hip fracture
surgery (HFS)";"Adjusted indirect comparison (Bucher)";"Arm";"40";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"In the absence of any clear explanation for heterogeneity, a random-effects model for the RR was planned instead of a fixed-effect model.";"Unclear";"NR";"Inverse Variance Method";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"Programme Hospitalier de Recherche Clinique 2008";"Publicly-sponsored";NA;NA;NA;NA;"long";0;1;"Non-numeric value for argument 'event'.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"125";"481159";"YES";"Ellis";2014;"USA";"Current Medical Research & Opinion";"Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women";8;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"incidence vertebral fractures";"Efficacy of bazedoxifene with oral bisphosphonates for 
postmenopausal osteoporotic (PMO) women and in higher-risk patients";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"proportion of patients with vertebral fractures";"Bayesian Hierarchical Model";"Arm";"8";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"Extending NMA models with treatment-by-covariate
interactions allows  the
impact of bias due to any differences in the distribution
of relative treatment-effect modifiers to be reduced";"Both FE and RE";"""For each analysis, fixed and random effects models were compared regarding the goodness-of-fit to the data, using the deviance information criterion (DIC). The fixed effects model resulted in a lower DIC, and hence was considered appropriate for the synthesis of the available evidence""";"Unclear";"uniform distribution with
a (non-informative) range of 0–2";"NA";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"Pfizer Inc";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"126";"481163";"YES";"Gallego-Galisteo";2012;"Spain";"Journal of Clinical Pharmacy and Therapeutics";"Indirect comparison of biological treatments in refractory rheumatoid arthritis";10;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"response to treatment (ACR50)";"Efficacy of biological drugs used in rheumatoid arthritis";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk difference";"number of patients achieving ACR50 (50% reduction in painful/swollen joints) at 24 week follow-up";"Adjusted indirect comparison (Bucher)";"Arm";"10";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"studies were basically
similar in terms of methodology and the type of patients
included";"Fixed-effect";"No";"NA";"NR";"Inverse Variance Method";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"127";"481174";"YES";"Mantha";2015;"USA";"Journal of Thrombosis and Thrombolysis";"Indirect comparison of dabigatran, rivaroxaban, apixaban
and edoxaban for the treatment of acute venous thromboembolism";6;"5";5;"warfarin/VKA";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"recurrent venous thromboembolism";"Efficacy to prevent recurrent VTE (including
death from VTE) between dabigatran, rivaroxaban, apixaban
or edoxaban";"Effectiveness";"Harmful";"Survival";"Objective";"risk ratio";"patients with recurrent venous thromboembolism";"Adjusted indirect comparison (Bucher)";"Study";"6";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"patient characteristics
were similar across all studies";"Fixed-effect";"No";"NA";"null (Fixed effect)";"Inverse Variance Method";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"128";"481193";"YES";"Moore";2005;"UK";"BMC Urology";"Indirect comparison of interventions using published randomised
trials: systematic review of PDE-5 inhibitors for erectile dysfunction";45;"10";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses and sensitivity analyses";"Improved erection dysfunction";"Efficacy between phosphodiesterase-5 inhibitors";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"patients with erection dysfunction";"NR";"Arm";"36";"0";"0";"1";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Fixed-effect";"No";"NA";"null (Fixed effect)";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"Pfizer Ltd";"Industry-sponsored";NA;NA;NA;NA;"long";0;1;"Non-numeric value for argument 'event'.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"129";"481195";"YES";"Fournier";2014;"France";"German Medical Science";"Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus";7;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"weight change";"Efficacy of treatment outcomes with lixisenatide versus neutral protamine Hagedorn (NPH)-insulin in type 2 diabetes mellitus (T2DM) patients with suboptimal glycaemic control with oral antidiabetic drugs (OADs)";"Effectiveness";"Beneficial";"Continuous";"Objective";"mean change";"difference in weight from baseline to follow-up";"Adjusted indirect comparison (Bucher)";"Arm";"7";"0";"0";"0";"0";"Full Network";"1";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"As heterogeneity tests were sometimes statistically significant, exclusively random effects results were systematically used as inputs for indirect comparisons.";"Unclear";"NR";"Inverse Variance Method";"Unclear";"No";"NA";"NA";"Subset";"No";"Yes";"missing standard deviations
(SDs) or SEs were requested from the corresponding
author";"Sanofi-Aventis";"Industry-sponsored";NA;NA;NA;NA;"long";0;1;"Non-numeric value for argument 'sd'.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"130";"481200";"YES";"Wu";2013;"Taiwan";"Alimentary Pharmacology & Therapeutics";"Indirect comparison of randomised controlled trials:
comparative efficacy of dexlansoprazole vs. esomeprazole in
the treatment of gastro-oesophageal reflux disease";5;"4";4;"Lansoprazole 30 mg";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split doses";"healing erosive
oesophagitis (EO)";"Efficacy for erosive
oesophagitis healing";"Effectiveness";"Beneficial";"Binary";"Objective";"risk ratio";"the complete healing rate of patients with baseline EO at Los Angeles (LA) grade A, B, C and D at 8 weeks";"Adjusted indirect comparison (Bucher)";"Arm";"3";"2";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"Mantel Haenszel";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"Takeda Pharmaceutical Company Limited";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"131";"481216";"YES";"Bergman";2010;"The Netherlands";"Seminars in Arthritis and Rheumatism";"Indirect Comparison of Tocilizumab and Other
Biologic Agents in Patients with Rheumatoid Arthritis and
Inadequate Response to Disease-Modifying Antirheumatic Drugs";18;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"ACR criteria for 50% clinical improvement (ACR20) were 20% improvement";"Efficacy of American College of Rheumatology (ACR) response to
tocilizumab with those of other biologic agents in patients
with rheumatoid arthritis who have inadequate response to disease-modifying antirheumatic drugs";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk ratio";"ACR 50%  response criteria from baseline to month 6";"Bayesian Hierarchical Model";"Arm";"17";"1";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"the trial populations included
in this analysis were comparable";"Both FE and RE";"Assessment of residual deviance for the ACR70 response showed no appreciable difference between random- and fixed-effects assumptions; hence, a fixed-effects model was chosen. Because residual deviance analyses are not commonly accepted, to be definitive we also report results under the random-effects assumptions. For the other (overlapping and nonoverlapping) response ACR categories, a conservative random-effects model was more appropriate.";"Unclear";"noninformative prior";"NA";"Unclear";"No";"NA";"NA";"All";"No";"Yes";"last observation carried
forward";"Hoffmann La-Roche";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"132";"481236";"YES";"Zagmutt";2012;"USA";"International Journal of Neuroscience";"Indirect Comparisons of Adverse Events and Dropout
Rates in Early Parkinson’s Disease Trials of Pramipexole,
Ropinirole, and Rasagiline";6;"7";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Total Adverse Events";"Comparison of adverse events
among clinical trials reporting
the safety profiles of pramipexole, ropinirole, and rasagiline
";"Safety";"Harmful";"Binary";"Semi-objective";"odds ratio";"patients with adverse events";"Bayesian Hierarchical Model; Bucher method";"Arm";"6";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"only the results from the fixed-effects Bayesian model are reported as they are appropriate in a small study setting";"Unclear";"NR";"NA";"Unclear";"No";"NA";"NA";"All";"No";"No";"NA";"Teva Neuroscience, Inc";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"133";"481263";"YES";"GUYOT";2012;"UK";"The Journal of Rheumatology";"Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United Kingdom";11;"7";7;"placebo in combination with methotrexate
";"2 (pharmacological vs placebo)";"Yes";"No";"NA";"Health Assessment Questionnaire (HAQ) change from baseline";"Efficacy of abatacept and alternative biologic disease-modifying
antirheumatic drugs in patients with rheumatoid arthritis";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"mean Health Assessment Questionnaire (HAQ) change from baseline at 6 months";"Bayesian Hierarchical Model";"Arm";"10";"1";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"The clinical trials were similar in trial
design, baseline patient characteristics, and background therapy";"Both FE and RE";"either a fixed effect or a random effects model was chosen, depending on the heterogeneity as assessed by the deviance informa- tion criteria";"Unclear";"non informative
prior distribution";"NA";"Unclear";"No";"NA";"NA";"Subset";"No";"Yes";"When no information about the uncertainty was
available, the average of all the other SD explicitly reported was imputed to the missing SD";"Bristol-Myers Squibb";"Industry-sponsored";NA;NA;NA;NA;"long";0;1;"object 'n' not found";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"137";"481323";"YES";"Mills";2014;"USA";"Lancet HIV";"Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis";13;"10";10;"standard of care (SOC)";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"Adherence to treatment";"Effectiveness of different interventions for improving Adherence in HIV-infected people living in Africa";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"proportion of patients had at least 3 months to follow-up";"Bayesian Hierarchical Model";"Arm";"11";"2";"1";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"priors were normally distributed centred at zero with wide variance";"NA";"Yes";"No";"NA";"NA";"All";"No";"Yes";"Authors were contacted to obtain any missing data";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"138";"481354";"YES";"Haspinger";2015;"Italy";"Critical Reviews in Oncology/Hematology";"Is there evidence for different effects among EGFR-TKIs? Systematicreview and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs)versus chemotherapy as first-line treatment for patients harboring EGFR mutations";9;"NR";4;"chemotherapy alone";"1 (pharmacological vs pharmacological)";"No";"Unclear";"Unclear";"PFS";"Effectiveness of 3 EGFR tyrosine kinase inhibitors to standard chemotherapy as up-front treatment in patients with advanced EGFR-positive NSCLC";"Effectiveness";"Beneficial";"Survival";"Objective";"hazard ratio";"NR";"Adjusted indirect comparison (Bucher)";"Arm";"9";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"139";"481378";"YES";"Alfirevic";2014;"UK";"British Medical Journal";"Labour induction with prostaglandins: a systematic review and network meta-analysis";94;"13";13;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split and lump doses in ranges";"vaginal delivery not achieved within 24-hours";"Effectiveness of prostaglandins used for labour induction";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"womens with Vaginal delivery not achieved within 24-hours";"Bayesian Hierarchical Model";"Arm";"89";"5";"0";"0";"0";"Full Network";"Unclear";"Comparison of model fit and parsimony (DIC)";"Yes";"Yes";"similar distribution of characteristics was
observed for failure to achieve vaginal delivery within
24 hours";"Both FE and RE";"model fit";"Unclear";"Vague prior distributions";"ΝΑ";"Yes";"No";"ΝΑ";"Probability of being the best, second best, etc.";"Subset";"No";"No";"ΝΑ";"National Institute for Health Research";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"140";"481384";"YES";"Schoenberg";2013;"Germany";"Annals of Surgery";"Laparoscopic Heller myotomy versus endoscopic balloon dilatation for the treatment of achalasia: a network meta-analysis.";16;"4";4;"EBD";"3 (non-pharmacological vs any)";"No";"No";"NA";"Success Rates at 12 months";"Effects after laparoscopic Heller myotomy (LHM)";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"Success Rates at 12 months";"Meta regression";"Arm";"16";"0";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Fixed-effect";"No";"NA";"null (Fixed effect)";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"141";"481412";"YES";"Kew";2014;"UK";"Cochrane Database of Systematic Reviews";"Long-acting inhaled therapy (beta-agonists, anticholinergics
and steroids) for COPD: a network meta-analysis (Review)";25;"20";5;"placebo";"2 (pharmacological vs placebo)";"Yes";"Yes";"No - lump doses";"quality of life";"Efficacy of treatment options for patients whose chronic obstructive pulmonary disease cannot be controlled by shortacting
therapies alone";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"St George’s Respiratory Questionnaire (SGRQ) total score at 6 months";"Bayesian Hierarchical Model";"Arm";"14";"4";"4";"3";"0";"Full Network";"Unclear";"Inconsistency model; Node-splitting";"Yes";"Yes";"trials were similar with
regards to methodology, inclusion and exclusion criteria and key baseline characteristics";"Both FE and RE";"based on model fit statistics and deviance information criteria";"Unclear";"Uniform (0,5) prior for between heterogeneity";"NA";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"Yes";"When data or study characteristics were not reported in the primary
publication, we searched clinical trial reports, trial registries
and drug company websites to look for additional data. When
possible, we used data fromintention-to-treat (ITT) analyses from
all randomly assigned participants";"The National Institute for
Health Research (NIHR)";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"142";"481418";"YES";"Chen";2014;"China";"Current Medical Research & Opinion";"Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons";12;"4";4;"dual antiplatelet therapy (DAL)";"1 (pharmacological vs pharmacological)";"Yes";"No";"NA";"composite incidence of major adverse cardiovascular events (MACE)";"clinical efficacy of adding cilostazol to aspirin plus clopidogrel (triple antiplatelet therapy, TAT) in patients undergoing percutaneous coronary intervention (PCI)";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"events of cardiovascular death";"Adjusted indirect comparison (Bucher)";"Arm";"10";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"variations of clinical factors may do harm to the similarity assumption";"Both FE and RE";"according to the value of heterogeneity";"Unclear";"NR";"Mantel Haenszel for fixed effect model, Inverse Variance Method for random effects model";"Yes";"Yes";"Funnel plot; Egger's test; Fail-safe number (Nfs)";"ΝΑ";"Subset";"No";"No";"ΝΑ";"National Natural Science
Foundation of China, the Science
and Technology Commission of Shanghai Municipality and the Doctor Innovation
Fund of Shanghai Jiaotong University School of Medicine";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"145";"481470";"YES";"Carter";2014;"UK";"Journal of Human Nutrition and Dietetics";"A Mediterranean diet improves HbA1c but not fasting blood glucose compared to alternative dietary strategies: a network meta-analysis";6;"5";5;"Mediterranean diet + education";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"fasting blood glucose";"the effects of a Mediterranean diet compared to other dietary interventions on glycaemic control irrespective of weight loss";"Effectiveness";"Beneficial";"Continuous";"Objective";"weighted mean difference";"prespecified follow-up point";"Bayesian Hierarchical Model";"Arm";"6";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"As a result of difficulty in conducting random effects analysis with a small number of studies, an arbitrary cut-off was used to fit a fixed effect model when there were less than five studies and a random effects model if there were five or more studies in the analysis.";"common within-network";"NR";"NA";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"Cardiovascular Research Department";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"146";"481511";"YES";"Piccolo";2014;"Italy";"American Journal of Cardiology";"Meta-Analysis of Randomized Trials Comparing the Effectiveness of Different Strategies for the Treatment of Drug-Eluting Stent Restenosis";8;"5";5;"balloon angioplasty (BA)";"3 (non-pharmacological vs any)";"No";"No";"NA";"diameter stenosis at follow-up angiography";"effectiveness of currently available strategies for the treatment of drug-eluting stent (DES) restenosis";"Effectiveness";"Beneficial";"Continuous";"Objective";"mean difference";"Angiographic follow-up  after 6 to 12 months";"Bayesian Hierarchical Model";"Arm";"7";"0";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NA";"Unclear";"No";"NA";"SUCRA";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;1;"Non-numeric value for argument 'n'.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"149";"481551";"YES";"Gurusamy";2011;"UK";"Cochrane Database of Systematic Reviews";"Methods to decrease blood loss and transfusion requirements
for liver transplantation (Review)";14;"7";7;"Control intervention";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split and lump doses in ranges";"mortality at 60 days";"To compare the benefits and harms of different interventionmethods
aimed at decreasing blood loss and/or allogeneic blood transfusion
requirements during liver transplantation";"Effectiveness";"Harmful";"Binary";"Objective";"risk ratio";"number of deaths";"Meta regression";"Arm";"13";"1";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"Yes";"Egger's test";"NA";"Subset";"No";"Yes";"best-case, worst-case, best-worst and worse-best
scenarios";"National Insititute of Health Research or NIHR";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"150";"481571";"YES";"Dakin";2010;"UK";"Value in Health";"Mixed Treatment Comparison Meta-Analysis Evaluating the
Relative Efficacy of Nucleos(t)ides for Treatment of
Nucleos(t)ide-Naive Patients with Chronic Hepatitis B";10;"8";8;"placebo";"2 (pharmacological vs placebo)";"Yes";"No";"NA";"HBeAg-Positive Treatment-Naive Patients";"Efficacy of adefovir, entecavir, lamivudine, telbivudine, tenofovir
disoproxil fumarate, and nucleos(t)ide combinations in the treatment
of chronic hepatitis B";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"proportion of patients achieving HBV DNA < 300 copies/ml at 1 year";"Bayesian Hierarchical Model";"Arm";"9";"1";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Both FE and RE";"We used random-effects models when there was evidence of heterogeneity or when fixed-effects models fitted the data poorly. Model fit was assessed based on residual deviance and deviance information criteria (DIC)";"Unclear";"Informative half-normal priors";"NA";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"Gilead Sciences Ltd";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"151";"481583";"YES";"Sun";2014;"Belgium";"Current Medical Research & Opinion";"A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome";14;"22";5;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Change in IRLS score at the end of maintenance";"Efficacy of licensed pharmaceuticals for moderate-to-severe restless legs syndrome";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"change in International RLS Study Group Rating
Scale (IRLS) at week 12";"Bayesian Hierarchical Model";"Arm";"12";"0";"2";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"set of trials in which effect modifiers were  balanced
across treatment comparisons";"Both FE and RE";"model fit";"Unclear";"NR";"ΝΑ";"Unclear";"No";"ΝΑ";"Probability of being the best";"Subset";"Yes";"No";"ΝΑ";"UCB Pharma";"Industry-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"152";"481588";"YES";"Turkstra";2011;"Australia";"Current Medical Research & Opinion";"A mixed treatment comparison of the
short-term efficacy of biologic disease
modifying anti-rheumatic drugs in established
rheumatoid arthritis";27;"20";10;"placebo";"2 (pharmacological vs placebo)";"Yes";"No";"NA";"ACR20";"Εfficacy of biological disease modifying anti-rheumatic drugs for the treatment of
established moderate to severe rheumatoid arthritis (RA)";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"number of patients achieving a response ACR20 at
approximately six months";"Bayesian Hierarchical Model";"Arm";"22";"5";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"no important differences in baseline characteristics
were reported in the trials";"Random effects";"As these trials may have been performed amongst different patient groups and with different methodologies, heterogeneity between trials is anticipated where the true effects in each trial are not identical. With mixed treatment analysis, a randomeffects normal distribution is placed on these effect sizes, and the mean used as the estimate of the overall mean.";"Unclear";"NR";"NA";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"The Pharmaceutical Benefits Advisory Committee";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"153";"481589";"YES";"Desai";2012;"USA";"The Annals of Pharmacotherapy";"Mixed Treatment Comparison of the Treatment Discontinuations
of Biologic Disease-Modifying Antirheumatic Drugs in Adults with
Rheumatoid Arthritis";41;"22";10;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"overall withdrawal";"Efficacy of treatment discontinuations of 9 biologics
with placebo in patients with rheumatoid arthritis";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"overall withdrawals, withdrawals resulting from lack of efficacy, and withdrawals
resulting from adverse events";"Bayesian Hierarchical Model";"Arm";"41";"0";"0";"1";"0";"Tree Network";"NA";"NA";"NA";"NA";"trials were of similar design and
believed to be reflective of similar settings with comparable
patient populations";"Random effects";"No";"NR";"heterogeneity prior: uniform distribution centered at zero with
sufficiently large variance";"NA";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"No";"NA";"Agency for Healthcare Research and Quality";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"156";"481659";"YES";"Biondi-Zoccai";2014;"Italy";"International Journal of Cardiology";"Nephropathy after administration of iso-osmolar and low-osmolar contrast media: Evidence from a network meta-analysis";33;"NR";7;"iodixanol";"1 (pharmacological vs pharmacological)";"No";"Unclear";"Unclear";"short-term (≤30 days) rate of contrast-induced nephropathy";"NR";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"proportion of patients with absolute increase ≥0.5 mg/dL in serum creatinine";"Bayesian Hierarchical Model";"Arm";"42";"0";"0";"0";"0";"Full Network";"1";"I2 statistic";"Yes";"Yes";"NR";"Both FE and RE";"model fit (DIC)";"Unclear";"non-informative priors";"NA";"Unclear";"Yes";"Funnel plot";"Probability of being the best";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"157";"481695";"YES";"Liang";2014;"China";"PLoS One";"Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations";12;"NR";6;"control intervention";"1 (pharmacological vs pharmacological)";"No";"Unclear";"Unclear";"objective response rate";"Efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs)for patients with advanced non-small-cell lung cancer (NSCLC)";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"number of events with response";"Bayesian Hierarchical Model";"Arm";"12";"0";"0";"0";"0";"Full Network";"1";"Node-splitting";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NA";"Unclear";"No";"NA";"SUCRA; Probability of being the best";"All";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"163";"481731";"YES";"Peruzzi";2014;"Italy";"BioMed Research International";"A Network Meta-Analysis on Randomized Trials Focusing on the
Preventive Effect of Statins on Contrast-Induced Nephropathy";14;"6";6;"placebo or no statin";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"occurrence of odinated contrast-induced nephropathy";"Effectiveness of treatments based on statins for the prevention of
contrast-induced nephropathy";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"relative increase in serum creatinine ≥25% or an absolute increase in serum creatinine ≥0.5 mg/dL (44 𝜇mol/L), typically 48–72 hours after the index procedure.";"Bayesian Hierarchical Model";"Arm";"14";"0";"0";"0";"0";"Full Network";"1";"Inconsistency model";"Yes";"Yes";"NR";"Both FE and RE";"model fit - DIC";"Unclear";"NR";"NA";"Unclear";"Yes";"Funnel plot";"Probability of being the best";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"164";"481733";"YES";"Yang";2014;"China";"International Journal of Surgery";"A network meta-analysis on the efficacy of 5-aminosalicylates,immunomodulators and biologics for the prevention of postoperative recurrence in Crohn’s disease";15;"12";4;"placebo";"2 (pharmacological vs placebo)";"No";"No";"No - lump doses";"endoscopic recurrence";"Efficacy of 5-aminosalicylates, immunomodulators and biologics for postoperative prophylaxis of Crohn’s disease recurrence";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"proportion of patients with recurrence epithelial lesions at short term followup
after surgery";"Bayesian Hierarchical Model";"Arm";"13";"2";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"NR";"NA";"Unclear";"Yes";"Egger's test";"Probability of being the best";"All";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"165";"481734";"YES";"Zhang";2013;"China";"Chinese Pharmaceutical Journal";"A Network Meta-Analysis on the Influence of Antihypertensive Agents on New-onset Diabetes";28;"6";6;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"new-onset diabetes";"development of diabetes in patients treated with antihypertensive drugs";"Safety";"Harmful";"Binary";"Semi-objective";"odds ratio";"# pts developed diabetes during treatment";"Bayesian Hierarchical Model";"Arm";"25";"3";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR";"Both FE and RE";"The models in WinBUGS were similarly divided into the fixed effects model and the random effects model. The variance of the random effects model included the intra-study variance and inter-study variance. Therefore, when there was heterogeneity, the random effects model was more robust than the fixed effects model; thus the authors adopted the random effects model";"Unclear";"NR";"NA";"Unclear";"No";"NA";"NA";"All";"No";"No";"NR";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"166";"481736";"YES";"Nelson";2014;"UK";"The Journal of Allergy and Clinical Immunology: In Practice";"Network Meta-analysis Shows Commercialized
Subcutaneous and Sublingual Grass Products Have
Comparable Efficacy";37;"4";4;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"allergic rhinoconjunctivitis symptom score";"Efficacy of subcutaneous immunotherapy (SCIT) and
sublingual immunotherapy (SLIT) for pollen allergies";"Safety";"Beneficial";"Continuous";"Semi-objective";"standardized mean difference";"mean symptom scores";"Bayesian Hierarchical Model";"Arm";"37";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"Similarity of trial populations was  assessed only qualitatively through the comparison of reported trial characteristics";"Both FE and RE";"model fit - DIC";"Unclear";"the sources of heterogeneity were explored by removing
possible study outliers, conducting subgroup and sensitivity
analysis.";"NA";"Yes";"Yes";"Egger's test";"NA";"All";"No";"Yes";"Data were requested from authors and study sponsors";"Merck & Co, Inc.";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"167";"481766";"YES";"Zaccara";2013;"Italy";"Seizure";"Neurological adverse events of new generation sodium blocker
antiepileptic drugs. Meta-analysis of randomized, double-blinded
studies with eslicarbazepine acetate, lacosamide and oxcarbazepine";8;"10";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"overall neurological adverse effects (dizziness)";"Neurological adverse events of new generation sodium blocker antiepileptic drugs";"Safety";"Harmful";"Binary";"Semi-objective";"risk difference";"proportion of patients experiencing neurological adverse effects";"Adjusted indirect comparison (Bucher)";"Arm";"8";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"Heterogeneity (I2 > 70%) was found with ESL at all doses and with LCM at 200 mg/d dose and in these cases a random model was adopted. In all other cases a fixed-effect model was used.";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"All";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"168";"481781";"YES";"Chatterjee";2013;"USA";"American Medical Association";"New Oral Anticoagulants and the Risk
of Intracranial Hemorrhage
Traditional and Bayesian Meta-analysis
and Mixed Treatment Comparison of Randomized Trials
of New Oral Anticoagulants in Atrial Fibrillation";6;"9";5;"warfarin
or aspirin";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - lump doses";"Intracranial Hemorrhage";"Assess the rates of intracranial hemorrhage
(ICH) with use of novel oral anticoagulants";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"intracranial hemorrhage events";"Bayesian Hierarchical Model";"Arm";"6";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"Bayesian random-effects models (as appropriate for conservative assessment of varied clinical moieties using data from published sources) using vague priors (to account for a wide variation among the baseline variables in the study subjects)";"Unclear";"vague or noninformative
priors";"NA";"Yes";"Yes";"Funnel plot";"NA";"Subset";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"171";"481836";"YES";"Roskell";2014;"UK";"International Journal of Chronic Obstructive Pulmonary Disease";"Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol";16;"6";6;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"trough forced expiratory volume in 1 second (FEV1)";"Efficacy of treatments in patients of chronic obstructive pulmonary disease";"Effectiveness";"Beneficial";"Continuous";"Objective";"mean difference";"change from baseline in FEV1";"Meta regression";"Arm";"5";"4";"7";"0";"0";"Full Network";"3";"NR";"Unclear";"Unclear";"comparable trials/similar trial conditions";"Random effects";"These models included fixed treatment effects, fixed study effects, and random effects for the interaction between treatment and study. The random effects were included to allow the treatment effects to vary from study to study";"Unclear";"NR";"NR";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"Yes";"Studies with missing data excluded";"Boehringer Ingelheim GmbH. RTI Health Solutions";"Industry-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"172";"481856";"YES";"Cleach";2014;"France";"The Cochrane Library";"Oral antiviral therapy for prevention of genital herpes
outbreaks in immunocompetent and nonpregnant patients
(Review)";22;"20";4;"Placebo/no treatment/control";"2 (pharmacological vs placebo)";"No";"Yes";"Yes";"at least one clinical recurrence";"Effectiveness of three oral antiviral drugs (acyclovir, famciclovir and valacyclovir) prescribed to suppress
genital herpes outbreaks in non-pregnant patients";"Safety";"Harmful";"Binary";"Objective";"risk ratio";"proportion of paticipants with at least one genital herpes recurrence";"Bayesian Hierarchical Model";"Arm";"21";"1";"0";"0";"0";"Full Network";"2";"Lu and Ades";"Yes";"Yes";"NR";"Both FE and RE";"""the choice between the two models was based on the
number of studies, the distribution of effect sizes,measures of heterogeneity,
and clinical and methodological diversity""";"Unclear";"NR";"NA";"Yes";"Yes";"Funnel plot";"Probability of being the best";"All";"No";"Yes";"""we assumed that any participants with missing outcome data experienced at least one recurrent episode, whatever the group""";"Association Recommandations en Dermatologie (aRED), a group of the French Society of Dermatology (SFD), France.
French Ministry of Health, France.
Grant support was from the Programme Hospitalier de Recherche Clinique (AOM 11151)";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"175";"481908";"YES";"Chou";2008;"USA";"Journal of Viral Hepatitis";"Pegylated interferons for chronic hepatitis C virus infection:
an indirect analysis of randomized trials";16;"4";4;"dual therapy with non-pegylated interferon";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"Sustained virologic response rate 6 months after treatment";"Compare benefits of dual therapy
with pegylated interferon-alfa 2a vs dual therapy with
pegylated interferon-alfa 2b";"Effectiveness";"Beneficial";"Binary";"Objective";"risk ratio";"the absence of detectable HCV RNA in the serum 6 months after the end of a course of therapy";"Adjusted indirect comparison (Bucher)";"Arm";"16";"0";"0";"0";"0";"Tree Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Random effects";"We chose the random effects model because trials differed in patient demographics, markers of severity of baseline disease, dosing of drugs and other factors.";"Unclear";"NR";"NR";"Yes";"Yes";"Egger's test; Trim and fill method";"NA";"Subset";"No";"No";"NA";"Drug Effectiveness Review Project";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"177";"481941";"YES";"Dong";2014;"China";"PLoS One";"Pharmacological Interventions for Acceleration of the Onset Time of Rocuronium: A Meta-Analysis";20;"4";4;"control";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"onset time of rocuronium";"Efficacy of pharmacological interventions in reducing the onset time of rocuronium";"Safety";"Beneficial";"Continuous";"Objective";"mean difference";"mean onset time of rocuronium";"Bayesian Hierarchical Model";"Arm";"43";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"similar results";"Unclear";"NR";"NA";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"178";"481942";"YES";"Kwak";2013;"Korea";"Journal of Anesthesia";"Pharmacological prevention of rocuronium-induced injection pain
or withdrawal movements: a meta-analysis";44;"6";6;"control";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"Response rate of injection pain or withdrawal movement (IPWM)";"NR";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk ratio";"number of patients with injection pain or withdrawal movement (IPWM)";"Meta regression";"Arm";"34";"7";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"common within-network";"τ^2/ restricted maximum likelihood estimator";"Mantel Haenszel";"Yes";"Yes";"Funnel plot; Begg–Mazumdar test";"NA";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"180";"481974";"YES";"Chambers";2014;"USA";"American Journal of Managed Care";"Potential Role of Network Meta-Analysis in Value-Based Insurance Design";32;"6";6;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"vertebral fracture";"Efficacy of various treatments in preventing fracture";"Safety";"Harmful";"Binary";"Objective";"risk ratio";"proportion of patients had at least 6 months to follow-up";"Bayesian Hierarchical Model";"Study";"32";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"model fit - DIC";"Unclear";"NR";"NA";"Unclear";"No";"NA";"Probability of being the best";"All";"Yes";"No";"NA";"California Health Care Foundation";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"181";"481988";"YES";"Dumville";2013;"UK";"The Cochrane Library";"Preoperative skin antiseptics for preventing surgical wound
infections after clean surgery (Review)";10;"6";6;"control";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"Occurance of postoperative surgical site infections (SSI)";"NR";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"rates of infection";"Bayesian Hierarchical Model";"Arm";"10";"2";"1";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Both FE and RE";"(where there was no clinical or statistical heterogeneity) with model fit - DIC";"Unclear";"NR";"NA";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"Yes";"contact authors to obtain the required missing data";"Internal sources: • Welsh Risk Pool, UK.• University of Glamorgan, UK.
External sources:• 3M Clinical Fellowship Award/NATN, UK.• NIHR/Department of Health (England), (Cochrane Wounds Group), UK.• NIHR Programme Grants for Applied esearch, UK.";"Industry and Publicly sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"183";"482001";"YES";"Jalota";2011;"USA";"British Medical Journal";"Prevention of pain on injection of propofol: systematic review and meta-analysis";126;"9";9;"placebo or control group";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"pain response rate";"Effectiveness of interventions for reducing pain from propofol injection";"Safety";"Harmful";"Binary";"Subjective";"risk ratio";"number of patients reporting any pain";"Meta regression";"Arm";"138";"2";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"common within-network";"τ^2/restricted maximum likelihood
estimator";"Mantel Haenszel";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"No";"NA";"Perioperative Clinical Research
Core";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"184";"482003";"YES";"Maratea";2011;"Italy";"Journal of Thrombosis and Haemostasis";"Prevention of venous thromboembolism after major orthopedic
surgery: indirect comparison of three new oral anticoagulants";8;"5";5;"Enoxaparin 40 mg per daily";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split doses";"venous thromboembolism";"Effectiveness of new oral anticoagulants in patients at risk for venous thromboembolism";"Safety";"Harmful";"Binary";"Objective";"risk ratio";"""The clinical endpoint was a composite of symptomatic or asymptomatic deep vein thrombosis, non-fatal pulmonary embolism and/or all-cause mortality""";"Adjusted indirect comparison (Bucher)";"Arm";"6";"2";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Fixed-effect";"No";"NA";"NR";"NR";"Unclear";"No";"NA";"NA";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"185";"482004";"YES";"Shamliyan";2013;"USA";"Journal of General Internal Medicine";"Preventive Pharmacologic Treatments for EpisodicMigraine in Adults";27;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"prevention of epidsodic migraine";"Efficacy for Prevention of Episodic Migraine";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"≥50 % reduction in frequency of migraine attack";"Bayesian Hierarchical Model";"Arm";"25";"2";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"No";"comparison-specific";"dk ~ N(0, 10000)
µiB ~ N(0, 10000)
";"NA";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"AHRQ";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"186";"482006";"YES";"Lin";2014;"Taiwan";"Journal of Dentistry";"Primary molar pulpotomy: A systematic review and network meta-analysis";22;"5";5;"unclear";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"clinical success of primary molar pulpotomy";"Comparing the clinical outcomes in primary molar pulpotomy amongst different dressing materials";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"proportion of patients with 9-12 month follow-up";"Bayesian Hierarchical Model";"Arm";"17";"2";"3";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results; Informal comparison of NMA results with previously published results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NA";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"Yes";"Authors were contacted to obtain any missing data";"National Science Council";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"187";"482016";"YES";"Cope";2013;"USA";"Value in Health";"Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network meta-Analysis with Parametric Survival Models";11;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"progression free survival";"To estimate the expected progression-free survi-
val (PFS) for fulvestrant 500mg versus alternative hormonal therapies
for postmenopausal women with advanced breastcancer";"Effectiveness";"Beneficial";"Survival";"Objective";"risk difference";"Patient population: Postmenopausal ER+ advanced breast cancer (stageIIIorIV) who relapsed on prior endocrine therapy";"Bayesian Hierarchical Model";"Arm";"5";"6";"0";"0";"0";"Full Network";"Unclear";"Comparison of model fit and parsimony (DIC)";"Yes";"Yes";"NR";"Both FE and RE";"""The DIC was comparable for the fixed and random effects model. Hence, on statistical grounds, there was no reason to reject the fixed effects model in favor of a more complicated random effects model.""";"NA";"non informative prior";"NA";"NA";"No";"NA";"NA";"Subset";"Yes";"No";"NA";"AstraZeneca";"Industry-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"190";"482104";"YES";"Walsem";2015;"Netherlands";"Arthritis Research & Therapy";"Relative benefit-risk comparing diclofenac to
other traditional non-steroidal anti-inflammatory
drugs and cyclooxygenase-2 inhibitors in patients
with osteoarthritis or rheumatoid arthritis: a
network meta-analysis";59;"7";7;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"pain relief";"Efficacy of commonly used tNSAIDs
(diclofenac, ibuprofen, and naproxen) and COXIBs (celecoxib
and etoricoxib) in patients with pain caused by osteoarthritis";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"standardized mean difference";"visual analogue scale (VAS); Western Ontario McMaster Universities
Arthritis Index (WOMAC) VAS or WOMAC Likert scale";"Bayesian Hierarchical Model";"Arm";"149";"24";"3";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with previously published results";"Yes";"Yes";"NR";"Both FE and RE";"model fit - DIC";"Unclear";"a uniform distribution with range zero to five was used as the prior of the between study
standard deviation";"NA";"Unclear";"Yes";"To further reduce the potential of a publication bias, our literature review results were cross-checked with the results of the CNT Collaboration study";"Probability of being the best";"Subset";"No";"Yes";"studies often use different
methods for handling missing data due to dropouts,
including last observation carried forward, baseline observation
carried forward, multiple imputation, available data,
and others";"Novartis Pharma AG";"Industry-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"191";"482109";"YES";"Kwok";2013;"UK";"Chest";"Relative Effects of Two Different Enoxaparin
Regimens as Comparators Against Newer
Oral Anticoagulants: Meta-analysis and Adjusted Indirect Comparison";14;"12";6;"enoxaparin (40 mg once daily or 30 mg bid)";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - lump doses";"venous thromboembolism";"Efficacy between bid and once-daily enoxaparin by conducting
a systematic review of randomized trials of new
oral anticoagulants against either of the enoxaparin
regimens";"Safety";"Harmful";"Binary";"Objective";"risk ratio";"patients with venous thromboembolism events";"Adjusted indirect comparison (Bucher)";"Study";"14";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Fixed-effect";"No";"NA";"NR";"Inverse Variance Method";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"193";"482117";"YES";"Llorca";2014;"USA";"Current Medical Research and Opinion";"Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies";57;"9";9;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"response of antidepressant drugs";"Efficacy of drugs in major depressive disorder (MDD) patients";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"standardized mean difference";"change from baseline to 2 months";"Meta regression";"Study";"57";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"similar patient populations and primary objectives in included studies";"Random effects";"A randomeffects model was used, as it can handle a certain amount of between-study heterogeneity and, in the presence of significant heterogeneity, gives more conservative results than does a fixed-effect model";"comparison-specific";"residual maximum likelihood method";"Inverse Variance Method";"Yes";"No";"NA";"NA";"Subset";"Yes";"Yes";"observed case (OC) imputation";"H. Lundbeck";"Industry-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"194";"482120";"YES";"Hopkins";2011;"Canada";"BMC Musculoskeletal Disorders";"The relative efficacy of nine osteoporosis
medications for reducing the rate of fractures in
post-menopausal women";17;"10";9;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"hip fractures";"Efficacy of reduction of fractures in post-menopausal women";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"rates of hip fractures";"Bayesian Hierarchical Model";"Arm";"17";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Unclear";"No";"Unclear";"NR";"NA";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"195";"482129";"YES";"Pandor";2013;"UK";"Heart";"Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review
and network meta-analysis";21;"5";5;"Usual care";"3 (non-pharmacological vs any)";"No";"No";"NA";"All Cause Mortality";"Efficacy of homemonitoring post hospital discharge after heart failure";"Safety";"Harmful";"Survival";"Objective";"hazard ratio";"number of deaths";"Bayesian Hierarchical Model";"Arm";"20";"1";"0";"0";"0";"Full Network";"1";"Comparison of model fit and parsimony (residual deviance)";"Yes";"Yes";"NR";"Random effects";"A random treatment effects model was fitted to the data to allow for the possibility of between-study statistical heterogeneity in treatment effects";"common within-network";"estimator: The between-study SD was estimated to be 0.34
(95% CrI: 0.03, 0.75)";"NA";"Yes";"No";"NA";"NA";"Subset";"No";"Yes";"contact authors to obtain the required missing data";"UK NIHR Health Technology Assessment
programme";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"196";"482156";"YES";"Windecker";2014;"Switzerland";"British Medical Journal";"Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis";95;"9";9;"medical treatment";"3 (non-pharmacological vs any)";"No";"No";"NA";"all-cause mortality";"Efficacy of revascularization versus standard treament in stable coronary artery disease";"Safety";"Harmful";"Survival";"Objective";"rate ratio";"number of deaths";"Bayesian Hierarchical Model";"Study";"90";"5";"0";"0";"0";"Full Network";"Unclear";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"No";"NR";"estimator: median between trial variance τ^2 observed in the posterior distribution(range of τ^2
across outcomes: 0.003 to 0.047)";"NA";"Unclear";"Yes";"‘comparison-adjusted’ funnel plot";"Probability of being the best";"All";"No";"No";"NA";"Department of Cardiology, Bern University Hospital, and the Institute
of Social and Preventive Medicine, University of Bern, Switzerland";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"197";"482159";"YES";"Klemp";2011;"Norway";"Journal of Clinical Psychopharmacology";"A Review and Bayesian Meta-Analysis of Clinical Efficacy
and Adverse Effects of 4 Atypical Neuroleptic Drugs
Compared With Haloperidol and Placebo";30;"43";6;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"number of responders";"Efficacy of atypical neuroleptic drugs and
haloperidol";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk ratio";"number of patients experiencing >=20% -30% reduction from baseline
score on the Positive and Negative Syndrome Scale/Brief
Psychiatric Rating Scale or a Clinical Global Impression of
much improved; usually at least 20%Y30% Positive and Negative
Syndrome Scale/Brief Psychiatric Rating Scale reduction";"Bayesian Hierarchical Model";"Arm";"22";"8";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NR";"NA";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"Research Council of Norway project
‘‘Modern Application Driven Statistical Challenges (186951/I30).’’";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"200";"482231";"YES";"Bulluck";2014;"UK";"International Journal of Cardiology";"Safety of short-term dual antiplatelet therapy after drug-eluting stents:An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials";7;"4";4;"common control dual antiplatelet therapy duration";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"Death or myocardial infarction";"comparative safety of different durations of dual anti-platelet therapy following percutaneous coronary intervention (PCI)";"Safety";"Harmful";"Binary";"Objective";"risk ratio";"duration of dual antiplatelet therapy";"Adjusted indirect comparison (Bucher)";"Arm";"8";"0";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"NR";"NA";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"202";"482258";"YES";"Price";2014;"UK";"BMJ";"Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis";29;"NR";4;"standard care or placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"mortality";"the probability of death";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"# patients  dying";"Bayesian Hierarchical Model";"Arm";"29";"0";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"Vague";"NA";"Unclear";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NR";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"205";"482362";"YES";"Strassman";2009;"Switzerland";"European Respiratory Journal";"Smoking cessation interventions in COPD: a network meta-analysis of randomised trials";7;"4";4;"usual care";"3 (non-pharmacological vs any)";"Yes";"Yes";"No - split and lump doses";"prolonged abstinence rate after 6 months with biochemical confirmation";"NR";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"# of  patients achieving abstinence";"Meta regression";"Arm";"5";"2";"1";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Both FE and RE";"sensitivity analysis";"Unclear";"NR";"NA";"Yes";"No";"NA";"Probability of being the best";"All";"Yes";"No";"NR";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"206";"482382";"YES";"Shams";2013;"Saudi Arabia";"J Gen Intern Med";"SSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials";9;"12";6;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"daily frequency of hot flashes";"When the mean response is not measured on the same scale, the standardized mean difference (SMD) was calculated allowing for pooling across trials on the same scale";"Effectiveness";"Beneficial";"Continuous";"Subjective";"mean difference";"difference in # hot flashes";"Bayesian Hierarchical Model";"Arm";"9";"0";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Both FE and RE";"The goodness of fit was checked using the incoherent value. When incoherent value of the fixed-effect model or random-effect model was obtained, the model with the lower value was used. When residual deviance was similar between the two models, a random-effect model was used.";"Unclear";"NR";"NA";"Unclear";"Yes";"Begg-Mazumdar rank correlation; Egger’s linear regression";"Probability of being the best";"Subset";"No";"No";"NR";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"207";"482415";"YES";"Dranitsaris";2014;"Canada";"Journal of Evaluation in Clinical Practice";"Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost";21;"10";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"allergic rhinitis (AR) symptom scores";"NR";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"standardized mean difference";"calculated from the ratio of the treatment effect (mean difference in treatment group minus difference in placebo group) to the pooled standard deviation of these differences";"Meta regression; Bucher method";"Study";"19";"1";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"Binary outcomes (e.g. drug discontinuation rates) were combined using a random effects model in cases of significant heterogeneity";"Unclear";"NA";"NR";"Yes";"Yes";"Egger's test";"NA";"Subset";"No";"No";"NR";"Paladin Labs Inc.";"Industry-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"208";"482416";"YES";"Huai";2015;"China";"Gastroenterology Research and Practice";"Submucosal Injection Solution for Endoscopic Resection in Gastrointestinal Tract: A Traditional and Network Meta-Analysis";8;"NR";7;"normal saline";"2 (pharmacological vs placebo)";"No";"Unclear";"Unclear";"complete resection rate";"defined as absence of neoplastic tissue in the edge of the cut lesion";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"NR";"Adjusted indirect comparison (Bucher)";"Arm";"11";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Fixed-effect";"Heterogeneity test and inverted funnel plot demonstrated that there were little heterogeneity and publication bias, and all the results were pooled in the fixed effect models";"NA";"NA";"NR";"NA";"Yes";"Funnel plot";"NA";"Subset";"No";"No";"NR";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"209";"482440";"YES";"Roskell";2014;"UK";"Current Medical Research & Opinion";"Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine";16;"NR";5;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"response to treatment";"ADHD-RS response was defined as the proportion of responders with at least a 25% reduction in score";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk ratio";"treatment response can be measured as either ADHD-RS or CGI-1";"Meta regression";"Arm";"15";"1";"0";"0";"0";"Full Network";"2";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"accounted for the between-trial treatment differences";"common within-network";"normal distribution (mean zero and unknown variance";"NR";"Yes";"No";"NA";"NA";"All";"No";"Yes";"imputations where appropriate";"Shire";"Industry-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"211";"482450";"YES";"Cui";2014;"China";"OrthOpedics";"A Systematic Review and Adjusted Indirect Comparison of Oral Anticoagulants";11;"13";4;"enoxoparin";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - lump doses";"venous thromboembolism (VTE)";"occurrence of proximal or distal deep venous thrombosis";"Effectiveness";"Harmful";"Binary";"Objective";"relative risk";"# patients with VTEs";"Adjusted indirect comparison (Bucher)";"Arm";"11";"0";"0";"0";"0";"Tree Network";"Unclear";"NR";"Unclear";"Unclear";"Mean patient age, average body weight, and proportion of females were similar and comparable across 3 sets of trials";"Both FE and RE";"sensitivity analysis";"Unclear";"NA";"NR";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"No";"NR";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"212";"482451";"YES";"Faggion";2014;"Germany";"Journal of Clinical Periodontology";"A systematic review and Bayesian network meta-analysis of randomized clinical trials on non-surgical treatments for peri-implantitis";11;"8";8;"subgingival scaling/debridement";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"Probing pocket depth (PPD)";"NR";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"difference in reduction in PPD";"Bayesian Hierarchical Model";"Arm";"11";"0";"0";"0";"0";"Full Network";"1";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"Non-informative priors";"NA";"Unclear";"Yes";"‘comparison-adjusted’ funnel plot";"Probability of being the best";"All";"No";"Yes";"corresponding authors of original studies were con- tacted by email for clarifications of dubious data and requests of unpub- lished data";"one author was supported by: National Science Council in Taiwan (Grant No. NSC 101-2314-B-002-197-MY2); All other authors were funded by their institutions for the purpose of this study";"Publicly-sponsored";NA;NA;NA;NA;"long";0;1;"""Non-numeric value for argument 'n'.""";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"213";"482465";"YES";"Snedecor";2014;"USA";"International Journal of Clinical Practice";"Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions";15;"28";21;"placebo";"2 (pharmacological vs placebo)";"Yes";"Yes";"No - lump doses";"pain reduction for PHN";"measured on an 11-point numeric rating scale (NRS) or 100m visual analog scale (VAS)";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk ratio";"proportion of patients achieving clinically significat reduction in pain score (>30%)";"Bayesian Hierarchical Model";"Arm";"19";"7";"2";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"Visual inspection of these latter data suggested heterogeneity could be because of variation in study durations and mean patient age";"Fixed-effect";"Random effects meta-analyses were not considered as there were too few studies";"NA";"NA";"NA";"NA";"Yes";"Funnel plot";"NA";"Subset";"No";"Yes";"All studies reporting imputation for missing data used the method of last observation carried forward.";"Pfizer";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"214";"482472";"YES";"Bow";2015;"Canada";"BMC Infectious Diseases";"Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients";5;"NR";4;"fluconazole";"1 (pharmacological vs pharmacological)";"No";"Unclear";"Unclear";"incidence of IFI/invasive aspergillosis/invasive candidiasis";"Incidence of proven/ probable IFI overall";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"# pts with IFI";"Bayesian Hierarchical Model";"Arm";"5";"0";"0";"0";"0";"Full Network";"1";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"assumed that the included trials are similar enough";"Random effects";"to account for potential between-trial heterogeneity";"common within-network";"non-informative prior with sensitivity analyses using moderately informative priors";"NA";"Unclear";"No";"NA";"Probability lower; Probability lowest risk";"Subset";"No";"No";"NR";"Pfizer";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"215";"482475";"YES";"Gray";2012;"UK";"obesity reviews";"A systematic review and mixed treatment comparison of pharmacological interventions for the treatment
of obesity";28;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"weight change";"change from baseline at 3 months";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"difference in weight (kg) at 3 months";"Bayesian Hierarchical Model";"Arm";"24";"3";"1";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"studies were expected to be heterogeneous";"Unclear";"Vague prior";"NA";"Yes";"Yes";"Funnel plot";"Probability of being the best";"Subset";"No";"Yes";"Where data were incomplete, the corresponding author of the study was contacted. If outcome data were missing, they were derived from related statistics where feasible.Where standard deviations for means were not reported, these were esti- mated from ranges, P-values or 95% confidence intervals as appropriate (25). Where data on baseline and follow-up weight/BMI were reported, the mean change was calculated and the standard deviation was imputed";"NIHR Health Technology Assessment grant.";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"216";"482476";"YES";"Dumville";2012;"UK";"Diabetologia";"Systematic review and mixed treatment comparison: dressings to heal diabetic foot ulcers";15;"9";9;"basic wound contact materials";"3 (non-pharmacological vs any)";"No";"No";"NA";"healing of diabetic foot ulcers";"number of ulcers completely healed within a specific time period";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"number of ulcers completely healed within a specific time period";"Bayesian Hierarchical Model";"Arm";"14";"1";"0";"0";"0";"Full Network";"Unclear";"Back-calculation; Inconsistency model";"Yes";"Yes";"NR";"Both FE and RE";"model fit assessed using the posterior mean of the residual deviance and the deviance information criterion (DIC).";"Unclear";"NR";"NA";"Unclear";"No";"NA";"SUCRA; Probability of being the best";"All";"No";"Yes";"attempted to contact researchers to obtain any required additional information not contained in the trial reports.";"National Institute for Health Research (NIHR)";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"217";"482477";"YES";"Orme";2014;"UK";"Diabetology & Metabolic Syndrome";"A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy";5;"7";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"change in HbA1c";"glycemic control";"Effectiveness";"Beneficial";"Continuous";"Objective";"mean difference";"mean change in HbA1c from baseline,";"Bayesian Hierarchical Model; Bucher method";"Arm";"5";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"All studies were comparable in terms of baseline characteristics";"Both FE and RE";"DIC, residual deviance, due to the limited number of studies involved in this analysis, fixed-effect models were preferred in all instances.";"Unclear";"uniform (uninformative) prior";"Mantel-Haenszel or inverse variance";"Yes";"No";"NA";"NA";"All";"No";"No";"NR";"Bristol-Myers Squibb Rueil-Malmaison";"Industry-sponsored";NA;NA;NA;NA;"long";0;1;"Identical treatments for the following studies:\n  'NA'";NA;NA;NA;NA;NA;"(one study contains multiple arms with the same intervention)";NA;NA;NA;NA;NA;NA;NA;NA
"221";"482519";"YES";"Moja";2015;"Italy";"Alimentary Pharmacology and Therapeutics";"Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn’s disease";11;"NR";7;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split and lump doses in ranges";"induction of remission";"at the last time-point assessment in the trial";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"# pts achieving remission";"Bayesian Hierarchical Model";"Arm";"7";"3";"1";"0";"0";"Full Network";"Unclear";"Inconsistency factors (model fit)";"Yes";"Yes";"NR";"Random effects";"We adopted the random-effects rather than the fixed-effects model as the most appropriate
and conservative approach to account for between-trial variability.";"common within-network";"Vague normal priors were placed on the study effects and a non-informative half-normal prior was placed on the common variance";"NA";"Unclear";"No";"NA";"SUCRA; Probability of being the best";"Subset";"No";"Yes";"All drop-outs were treated as treatment failures";"Centro Ricerca e Cura delle Malattie Infiammatorie Croniche Intestinali, IRCCS Istituto Clinico Humanitas; and the Fondazione Italiana per la Ricerca Sulle Malattie Apparato Digerente (FIRMAD)";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"223";"482521";"YES";"Stidham";2014;"USA";"Alimentary Pharmacology and Therapeutics";"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease";6;"4";4;"Placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"Induction  of remission";"Efficacy of treatment";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk ratio";"Defined as attainment of a CDAI score of less than 150 within 12 weeks of initiation of
treatment; (ii) Induction";"Bayesian Hierarchical Model";"Arm";"6";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"Analysis of comparable anti-TNF clinical trials";"Random effects";"No";"NR";"Non-informative uniform prior";"NA";"Yes";"Yes";"Harbord's test";"Probability of being the best";"Subset";"No";"No";"NA";"Crohn’s and Colitis Foundation of America; Veterans Affairs HSR&D Career Development Awards; American Cancer Society, Bankhead-Coley Team Science Program, Sylvester Comprehensive Cancer Center, Olympus America";"Industry and Publicly sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"224";"482522";"YES";"Stidham";2014;"USA";"Alimentary Pharmacology and Therapeutics";"Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of
ulcerative colitis";6;"NR";4;"Placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"Unclear";"Induction  of remission";"the efficacy of anti-TNF agents in UC.";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk ratio";"Remission – defined by the Mayo Score13
or Ulcerative Colitis Symptom Score13 within 8 weeks of
the initiation of the treatment; (ii)";"Bayesian Hierarchical Model";"Arm";"6";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"Non-informative uniform prior";"NA";"Yes";"Yes";"Harbord's test";"NA";"Subset";"No";"No";"NA";"Crohn’s and Colitis Foundation of America (Stidham), Veterans Affairs HSR&D Career Development Awards (Waljee, Saini).";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"225";"482527";"YES";"Edwards";2009;"UK";"Alimentary Pharmacology and Therapeutics";"Systematic review: standard- and double-dose proton pump
inhibitors for the healing of severe erosive oesophagitis – a
mixed treatment comparison of randomized controlled trials";12;"5";5;"omeprazole 20 mg";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split dose";"endoscopic healing rate at 4 weeks
";"Healing after the initiation of PPI treatment in patients with
severe erosive oesophagitis at 4  weeks.";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"severe erosive oesophagitis was defined as
grades C and D in the LA classification system15 or
comparable grades in other erosive oesophagitis classification
systems";"Bayesian Hierarchical Model";"Arm";"12";"0";"0";"0";"0";"Full Network";"3";"Lu and Ades";"Yes";"Yes";"NR";"Both FE and RE";"model fit";"Unclear";"Not reported";"NA";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"AstraZeneca";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"226";"482576";"YES";"Maxwell";2015;"Canada";"Cochrane Database of Systematic Reviews";"TNF-alpha inhibitors for ankylosing spondylitis (Review)";11;"10";5;"Placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"ASAS 40";"The Assessment of Spondylo-Arthritis international society";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"Risk ratio";"The criteria for an ASAS40 response is: at least a 40% improvement
with a minimum of 20 units (0 to 100 scale) improvement
compared with baseline in at least three of four domains (spinal
pain, function (BASFI), inflammation asmeasured by themean of
intensity and duration ofmorning stiffness in the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI), and patient global
assessment), and with no worsening in the fourth domain.";"Bayesian Hierarchical Model";"Arm";"18";"0";"0";"0";"0";"Full Network";"1";"Loop-specific";"Yes";"Yes";"We compared distribution of mean age, disease duration, baseline BASDAI and BASFI for trials of adalimumab versus placebo to etanercept versus placebo to golimumab versus placebo and to infliximab versus placebo. The results for themodifiers are similar and overlap across comparisons.";"Both FE and RE";"assessed the deviance information criterion and com- pared the residual deviance to the number of unconstrained data points to assess model fit and determine the choice of model";"common within-loop";"vague priors, such as N(0, 1002), for basic parameters of the treatment effects in the model and considered informative priors for the variance parameter in the random-effects model";"NA";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"Yes";"When the median change from baseline and interquartile range (IQR) change
from baseline were reported, we assumed the median change to be the mean change and calculated the standard deviation as the IQR at baseline divided
by 1.35 and this standard deviation (SD) assumed for the end of study score, as per the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Where no SD at end of study was reported or the variance for
the change from baseline was provided in the study report as the
standard error of the change, the baseline SD was assumed for the
end of study SD (Braun 2011; van der Heijde 2006a).";"National Institute for Health Research (NIHR) Cochrane Incentive Award";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"230";"482630";"YES";"Dong";2015;"China";"Medicine";"Treatments for Shoulder Impingement Syndrome A PRISMA Systematic Review and Network Meta-Analysis";26;"17";17;"EXE";"3 (non-pharmacological vs any)";"Yes";"Unclear";"NA";"pain score change associated with nonoperative treatments";"NR";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"visual analog scale (VAS) pain score, the numerical rating scale (NRS) pain score";"Bayesian Hierarchical Model";"Arm";"24";"2";"0";"0";"0";"Full Network";"3";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"No";"common within-loop";"Not reported";"NA";"Yes";"No";"NA";"SUCRA";"All";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"231";"482725";"YES";"Ashby";2014;"UK";"Health Technology Assessment";"VenUS IV (Venous leg Ulcer Study IV) – compression
hosiery compared with compression bandaging in
the treatment of venous leg ulcers: a randomised
controlled trial, mixed-treatment comparison
and decision-analytic model";16;"9";9;"4LB";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"time to complete healing of venous leg ulcers";"NR";"Effectiveness";"Beneficial";"Survival";"Semi-objective";"hazard ratio";"Not reported";"Bayesian Hierarchical Model";"Arm";"14";"2";"0";"0";"0";"Full Network";"1";"Back-calculation";"Yes";"Yes";"NR";"Both FE and RE";"also considered the use of a random-effects model. We found no significant gains in quality of fit, and thus adopted the more parsimonious fixed-effects approach throughout.";"Unclear";"vague or non-informative";"NA";"Yes";"No";"NA";"Probability of being the best";"All";"Yes";"Yes";"multiple imputations";"the National Institute for Health Research (NIHR) Health Technology
Assessment programme";"Publicly-sponsored";NA;NA;NA;NA;"long";0;1;"object 'metaNetw' not found";NA;NA;NA;"(For one study r=17,6 and 18,24)";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"232";"482734";"YES";"Furukawa";2014;"Japan";"Acta Psychiatrica Scandinavica";"Waiting list may be a nocebo condition in
psychotherapy trials: a contribution from
network meta-analysis";49;"4";4;"Unclear";"3 (non-pharmacological vs any)";"No";"No";"NA";"response to treatment";"the number of patients who responded to depression treatment";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"Hamilton Rating Scale for Depression (HAMD), Beck Depression Inventory (BDI)
 or any other validated depression scale at the
end of the acute phase treatment.";"Bayesian Hierarchical Model";"Arm";"47";"2";"0";"0";"0";"Full Network";"2";"Bucher method; Comparison of model fit and parsimony";"Yes";"Yes";"The baseline characteristics of included studies were similarly distributed across the comparisons";"Random effects";"Given the potentialMclinical heterogeneity of the populations studied as well as the CBT approaches used in the studies, we used the random-effects model in all analyses.";"Unclear";"Not reported";"NA";"Yes";"Yes";"Funnel plot; Egger's test";"NR";"All";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"233";"482745";"YES";"Leaviss";2014;"UK";"Health Technology Assessment";"What is the clinical effectiveness and
cost-effectiveness of cytisine compared with
varenicline for smoking cessation? A systematic
review and economic evaluation";16;"8";8;"Placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split dose";"Continuous abstinence at a minimum follow-up of 6 months.";"the study’s strictest reported
definition of abstinence, at a minimum of 6 months’ follow-up,";"Effectiveness";"Beneficial";"Survival";"Semi-objective";"hazard ratio";"Use of a range of outcome measurements to evaluate abstinence in different studies; The Russell Standard";"Bayesian Hierarchical Model";"Arm";"11";"4";"1";"1";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Random effects";"To allow for heterogeneity between studies";"comparison-specific";"weak prior distribution";"NA";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"the National Institute for Health Research (NIHR) Health Technology
Assessment programme";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"235";"482760";"YES";"Naudet";2013;"France";"BMC Medicine";"Which placebo to cure depression? A thought-provoking network meta-analysis";29;"5";5;"Unclear";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"response to treatment";"the proportion of patients who had a reduction of at least 50% from the baseline score on the Hamilton Depression
Rating Scale (HDRS) or the Montgomery-Åsberg Depression Rating Scale (MADRS)";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"Not reported";"Unclear";"Study";"25";"4";"0";"0";"0";"Full Network";"1";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Both FE and RE";"final models were selected by comparing a model fit criterion AIC";"Unclear";"Not reported";"NA";"Unclear";"Yes";"Funnel plot; Egger's test";"NR";"All";"No";"No";"NA";"Institut National de la Santé et de la Recherche Médicale (INSERM).";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"237";"501192";"YES";"Abdullah";2008;"USA";"Ann Allergy Asthma Immunol.";"Relative oral corticosteroid–sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis";18;"16";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy";"OCS Elimination in chronic asthma";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"rate of Complete Elimination of Oral Corticosteroid";"Adjusted indirect comparison (Bucher)";"Arm";"18";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"Yes";"Fail-safe number (Nfs); Tolerance level";"NA";"All";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"238";"501194";"YES";"V. S. Akshintala";2013;"USA";"Alimentary Pharmacology and Therapeutics";"Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis";99;"NR";17;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Efficacy of pharmacological agents for the prevention of post-ERCP pancreatitis";"incidence of  post-ERCP pancreatitis (PEP)";"Effectiveness";"Harmful";"Binary";"semi-objective";"odds ratio";"incidences of post-ERCP pancreatitis";"Bayesian Hierarchical Model";"Arm";"91";"8";"0";"0";"0";"Full Network";"Unclear";"Design by treatment";"Yes";"Yes";"None";"Random effects";"No";"NR";"Heterogeneity was quantified by including a random intercept for study within the Bayesian NMA model.";"NA";"Yes";"No";"NA";"Probability of being the best (rankograms)";"All";"No";"No";"None";"None";"Non-sponsored";"0.59";"0.56000000000000005";"0.82";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"239";"501195";"YES";"Anothaisintawee";2011;"Thailand";"JAMA";"Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome A Systematic Review and Network Meta-analysis.";11;"NR";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"pain score in chronic prostatitis";"pain and voiding questionnaires";"Effectiveness";"Harmful";"Continuous";"Subjective";"standardized mean difference";"The following
tools were used in these assessments: (1)
The National Institutes of Health Chronic
Prostatitis Symptom Index (NIH-CPSI)
consists of 3 domains (ie, pain, voiding,
and quality of life). The total scores range
from 0 to 43.18 (2) The International
Prostate Symptom Score (IPSS) questionnaire19
consists of 3 domains (ie,pain, voiding, and quality of life), with
combined scores ranging from 0 to 51.
(3) The Prostatitis Symptom Score Index
(PSSI) measures only pain scores,
with a total score of 0 to 12. (4) Other
pain and voiding questionnaires20 consist
of 7 and 5 items, respectively, with
each item graded as 0 to 3.";"Meta regression";"Arm";"10";"1";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Both FE and RE";"If there was evidence of heterogeneity, a random-effects model was used for pooling. Otherwise, a fixed-effects model was applied";"Unclear";"NA";"NR";"Yes";"Yes";"Funnel plot; Egger's test";"NA";"All";"No";"No";"NA";"the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, the Canada Institute for Health Research, and the Canada Research Chair Program.";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"240";"501196";"YES";"Ara";2012;"UK";"HTA";"What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review";26;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"clinical effectiveness  of three pharmacological interventions in obese patients";"Weight change from baseline (kg) in 3 months";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"mean change in weight from baseline";"Bayesian Hierarchical Model";"Arm";"22";"3";"1";"0";"0";"Full Network";"8";"Informal comparison of NMA results with pairwise meta-analysis results";"NA";"Yes";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Unclear";"Yes";"contour enhanced funnel plots";"Probability of being the best";"All";"No";"Yes";"Where possible, data from intention-to-treat analyses were extracted.; Where data were incomplete the corresponding author of the study was contacted.";"National Institute for Health Research Health Technology Assessment programme";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"241";"501197";"YES";"Ara";2009;"UK";"HTA";"Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.";11;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"Adverse event (treatment related) leading to drug Discontinuation, no. of patients";"Adverse event
(treatment related)
leading to drug
discontinuation,";"Safety";"Harmful";"Binary";"Objective";"risk ratio";"NR";"Bayesian Hierarchical Model";"Arm";"10";"0";"1";"0";"0";"Full Network";"5";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"HTA programme";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"243";"501199";"YES";"Abdullah Assiri";2013;"USA/Saudi Arabia";"Clinical Therapeutics";"Mixed Treatment Comparison Meta-Analysis of Aspirin,Warfarin, and New Anticoagulants for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation";17;"NR";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"Yes";"Compare available antiplatelet agents, warfarin and new anticoagulants in patients with atrial fibrillation (AF)";"All Stroke";"Safety";"Harmful";"Rate";"Objective";"Rate Ratio";"number of strokes";"Bayesian Hierarchical Model";"Arm";"15";"2";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"patient characteristics of the included trial populations are similar";"Random effects";"No";"Connected treatment networks were evaluated to identify heterogeneity and consistency within closed loop evidence structures. MTC methods were used to preserve the benefit ofwithin-trial randomization and to allow combinations of direct and indirect evidence under the premise of comparable patient characteristics between studies and similar heterogeneity between individual studies in the comparison.";"NR";"NA";"Unclear";"No";"NA";"NR";"All";"No";"No";"Not mentioned";"Not mentioned";"Funding source not reported";"no data available";"no data available";"no data available";NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"244";"501200";"YES";"Baker";2012;"USA";"Dermatol Ther";"Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses";15;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"impact of biologics on health outcomes";"physician’s global assessment (PGA) - clearing of psoriatic plaques from the skin, with higher scores denoting more severe disease";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"There is no standard PGA, and different
versions include six- or seven-point scales,
which measure the severity of psoriasis. Terms
such as ‘‘clear’’ or ‘‘excellent’’ (scores of 0 or 1)
are used to define the clearing of psoriatic
plaques from the skin, with higher scores
denoting more severe disease.";"Bayesian Hierarchical Model";"Study";"31";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"Yes";"Funnel plot; Egger's test";"NA";"All";"No";"No";"NA";"Pfizer Inc.";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"245";"501201";"YES";"Baker";2009;"USA";"Pharmacotherapy";"Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.";38;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"exacerbation episodes in Chronic Obstructive Pulmonary Disease (COPD>=1)";"episodes in Chronic Obstructive Pulmonary Disease (COPD>=1)";"Effectiveness";"Harmful";"Binary";"Subjective";"odds ratio";"more than one episode of COPD exacerbation";"Bayesian Hierarchical Model";"Arm";"29";"3";"6";"0";"0";"Full Network";"12";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Yes";"No";"NA";"NA";"All";"No";"Yes";"previous articles were reviewed to supplement missing data where applicable";"NA";"Funding source not reported";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"247";"501204";"YES";"Bally";2012;"Canada";"International  Journal  of  Antimicrobial  Agents";"A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection";24;"7";7;"control / vancomycin";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"efficacy";"clinical success at test of cure in the modified intention-to-treat population (MITT)";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"clinical success at test of cure in the following intention-totreat
(ITT) populations: the modified ITT (MITT) population; and the
MITT population with MRSA at baseline (MRSA m-MITT).";"Bayesian Hierarchical Model";"Arm";"24";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"The trials were also fairly homogeneous with respect to
patient demographics and duration of antibiotic treatment";"Fixed-effect";"we described the covariate–treatment interaction by a common distribution (fixed effect). By doing so we are assuming that diabetes or the presence of VAP will modify treatment effect in a similar fashion across all antibiotics. Although few details were available to confirm how the definition of VAP varied between studies, we believe this assumption is reasonable from a clinical standpoint.";"NA";"prior distributions for the between-study standard deviation of the ORs";"NR";"NA";"Yes";"Funnel plot; search of clinical trial registries";"Probability of being the best";"Subset";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"249";"501206";"YES";"Bangalore";2010;"USA";"Lancet";"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.";49;"NR";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"association between antihypertensive drugs and cancer risk";"cancer risk";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"cancer risk and cancerrelated
mortality.";"Bayesian Hierarchical Model";"Arm";"45";"4";"1";"0";"0";"Full Network";"18";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Both FE and RE";"sensitivity analysis";"Unclear";"vague prior";"NR";"Yes";"Yes";"Funnel plot; Begg's test; Egger's test";"Probability of being the best";"All";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"250";"501207";"YES";"Bansback";2009;"Canada";"Dermatology";"Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.";22;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"efficacy";"PASI 75 response score for the treatment of psoriasis";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"PASI score is a measure of body surface area involvement (on a scale from 0 to 6 for the
lower extremities, the trunk, the upper extremities, and the head
and neck) and psoriasis severity (on a scale from 0 to 4 for each of
3 parameters: erythema/redness, scaling and thickness) [9]. PASI
50, PASI 75 and PASI 90 responses are defined as a ~50%, ;?!75%
and ~90% reduction from baseline PASI, respectively.";"Bayesian Hierarchical Model";"Arm";"21";"1";"0";"0";"0";"Full Network";"2";"NR";"Unclear";"Unclear";"NR";"Random effects";"random effect models (rather than fixed effect models) were used throughout explicitly to take account of between-study heterogeneity.";"Unclear";"NR";"NR";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"Abbott Laboratories";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"252";"501209";"YES";"Lori";2012;"USA";"Cardiovasc Drugs Ther";"Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation";20;"22";11;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"relative efficacy of existing cardioversion approaches";"cardioversion within 2 h of treatment initiation (rapid cardioversion) among patients with short-duration AF";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"NR";"Bayesian Hierarchical Model";"Arm";"16";"6";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Both FE and RE";"Results are presented from the random-effect models (after confirming similar results between the two), the more conservative approach, only";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"United BioSource Inc., received funding support by Merck and Company, Inc";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"254";"501211";"YES";"Berner";2006;"Germany";"Int J Impotence Research";"Effectiveness of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administeringthe International Index of Erectile Function in broad-spectrum populations.";14;"NR";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"Unclear";"efficacy of PDE-5-inhibitors for erectile dysfunction";"IIEF score";"Effectiveness";"Beneficial";"Continuous";"Subjective";"mean difference";"Erectile dysfunction domain of the  IIEF score";"Adjusted indirect comparison (Bucher)";"Study";"14";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Fixed-effect";"As the stringent inclusion criteria probably led to reduced clinical heterogeneity, we also assumed a low statistical heterogeneity in primary study findings.
We, therefore, used a fixed-effect model for pooling the data.";"NA";"NR";"NR";"NA";"Yes";"Funnel plot";"NA";"Subset";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Frequentist";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"255";"501212";"YES";"G. Biondi-Zoccai";2013;"Italy";"HSR proceedings in intensive care and cardiovascular anesthesia";"Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses.";6;"13";5;"Warfarin";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split doses";"Comparative effectiveness of novel oral anticoagulants for atrial fibrillation";"long term stroke/systemic embolism";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"number of events of long term stroke/systematic embolism";"Bayesian Hierarchical Model";"Arm";"6";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"enrolment criteria were sufficiently homogeneous (i.e. all studies included patients in whom warfarin was considered beneficial) to ensure that the key assumption of network meta-analysis (namely the focus on a common patient
subset treated with the same comparator) hold true";"Both FE and RE";"Deviance and deviance information criterion (DIC) were used to appraise model fit in comparison to a random-effect model";"Unclear";"NR";"NA";"Unclear";"Yes";"Funnel plot";"NA";"All";"No";"No";"Incomplete outcome
data addressed in some trials";"None";"Non-sponsored";"no data available";"no data available";"no data available";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"256";"501213";"YES";"Blanchard";2011;"France";"JCE";"Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer";119;"6";6;"locoregional treatment";"3 (non-pharmacological vs any)";"No";"No";"NA";"Different treatments have been investigated in head and neck cancers (HNCs)";"overall survival";"Effectiveness";"Harmful";"Survival";"Objective";"hazard ratio";"mortality";"Bayesian Hierarchical Model";"Arm";"119";"0";"0";"0";"0";"Full Network";"4";"Loop-specific";"Yes";"Yes";"NR";"Both FE and RE";"model fit";"Unclear";"flat priors";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"Association pour la Recherche sur le Cancer, Ligue Nationale Contre le
Cancer, Programme Hospitalier de Recherche Clinique (no. IDF 95009 and 98083), and Sanofi-Aventis";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"257";"501214";"YES";"Bodalia";2013;"UK";"British Journal of Clinical Pharmacology";"Comparative Efficacy and Tolerability of Antiepileptic Drugs for Refractory Focal Epilepsy";41;"21";11;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Efficacy of antiepileptic drugs";"response rate";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"50% reduction in seizure rate from baseline";"Bayesian Hierarchical Model";"Arm";"40";"1";"0";"0";"0";"Full Network";"Unclear";"Bucher method";"Yes";"Yes";"None";"Random effects";"The model included random effects at the level of trials which allowed the estimation of the variance of treatment effects between trials";"Unclear";"NR";"NA";"Yes";"Yes";"Funnel plot; L' Abbe plot";"Probability of being the best";"All";"No";"No";"None";"None";"Non-sponsored";"0.52";"0.08";"0.56000000000000005";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"258";"501215";"YES";"Bottomley";2011;"UK";"CMRO";"The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence.";10;"NR";7;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"No";"efficacy of topical therapies for scalp psoriasis in adults";"IGA response after 4 weeks";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"percentage of IGA responder/non-responder";"Meta regression; Bucher method";"Arm";"8";"1";"1";"0";"0";"Full Network";"4";"Loop-specific";"Yes";"Yes";"similar patients were evaluated in studies";"Unclear";"No";"Unclear";"NA";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"LEO Pharma A/S";"Industry-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"259";"501216";"YES";"Sarah R. Braun";2013;"Austria";"Plos one";"Comparing bona fide psychotherapies of depression in adults with two meta-analytical approaches";45;"19";19;"Cognitive behavioural therapy";"3 (non-pharmacological vs any)";"Yes";"Unclear";"NA";"Efficacy in terms bona fide phychotherapies of depression";"bona fide phychotherapies of depression in patient's self ratings";"Effectiveness";"Beneficial";"Continuous";"Subjective";"standardized mean difference";"mean difference in patient's self-ratings";"Bayesian Hierarchical Model";"Study";"38";"7";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"NA";"Yes";"Trials must be comparable in terms of patient samples, outcome measures and other relevant characteristics. To account for similarity, study sample was restricted to studies in which therapies focused on the treatment of depressive disorders and only adult patient samples were included";"Random effects";"No";"NR";"NR";"NA";"Yes";"Yes";"Funnel plot; Trim and fill method";"Probability of being the best";"Subset";"No";"No";"Not mentioned";"None";"Non-sponsored";"0.27";"0.63";"0.73";NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"260";"501217";"YES";"Brown";2006;"UK";"HTA";"A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.";38;"6";6;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"effectiveness for the prevention of NSAID induced GI toxicity";"serious GI complications";"Safety";"Harmful";"Binary";"Semi-objective";"risk ratio";"defined as a GI perforation, bleed (including melaena) or obstruction.";"Adjusted indirect comparison (Bucher)";"Arm";"36";"2";"0";"0";"0";"Full Network";"6";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot; Begg's test; Egger's test";"NA";"Subset";"No";"No";"NA";"the HTA Programme";"Publicly-sponsored";NA;NA;NA;"Unclear";"long";0;1;"After removing comparisons with missing treatment effects or standard errors,\n  study '4' has a wrong number of comparisons. Please check data and\n  consider to remove study from network meta-analysis.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"261";"501219";"YES";"Buscemi";2007;"Canada";"Society of General Internal Medicine";"The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs";54;"4";4;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"efficacy of treatments for chronic insomnia in adults";"sleep onset latency - sleep diary";"Effectiveness";"Harmful";"Continuous";"Subjective";"mean difference";"(amount of
time between lying down to sleep and the onset of sleep);";"Adjusted indirect comparison (Bucher)";"Study";"46";"8";"0";"0";"0";"Full Network";"2";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot; Begg's test; Egger's test; Trim and fill method";"NA";"All";"No";"No";"NA";"Agency for Healthcare Research and Quality";"Publicly-sponsored";NA;NA;NA;"Unclear";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"262";"501220";"YES";"Jacopo Buti";2013;"Italy";"Journal of Clinical Periodontology";"Bayesian network meta-analysis of root coverage procedures: ranking efficacy and identification of best treatment.";26;"7";7;"coronally advanced flap";"1 (pharmacological vs pharmacological)";"No";"Unclear";"NA";"Efficacy for coronally advanced flap (CAF)";"Recession Reduction";"Effectiveness";"Beneficial";"Continuous";"semi-objective";"mean difference";"change in gingival recession expressed as RecRed (mm) at follow-up visit";"Bayesian Hierarchical Model";"Study";"26";"0";"0";"0";"0";"Full Network";"2";"Lumley model; Lu and Ades";"Yes";"Yes";"Not mentioned";"Both FE and RE";"in cases with only two studies fixed-effects model was preferred due to the little information on the heterogeneity variance";"Unclear";"Inverse Gamma distributions IG(10  3; 10  3) for τ2 and τ2w";"NA";"Yes";"No";"NA";"Probability of being the best; Posterior median rank";"All";"No";"No";"In case of missing data or lack of answer by the authors after two contact attempts, RCTs were considered not eligible for inclusion";"Not mentioned";"Non-sponsored";"0.65";"0.49";"0.82";NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"264";"501223";"YES";"Carroll C";2013;"UK";"Health Technology Assessment";"Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation";23;"4";4;"Stripping";"3 (non-pharmacological vs any)";"Yes";"Unclear";"NA";"Efficacy of minimally invasive to manage varicose veins";"recurrence of varicose veins";"Effectiveness";"Harmful";"Survival";"Objective";"hazard ratio";"Venous Clinical Severity Score (VCSS)";"Meta regression";"Arm";"17";"0";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Random effects";"to allow for heterogeneity in treatment effects across studies";"Unclear";"uniform prior";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"None";"National Institute for Health Research (NIHR)";"Publicly-sponsored";"no";"no";"no";NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"265";"501224";"YES";"Lana A Castellucci";2013;"Canada";"BMJ";"Efficacy and safety outcomes of oral anticoagulants
and antiplatelet drugs in the secondary prevention of
venous thromboembolism: systematic review and
network meta-analysis";11;"11";9;"placebo/observation";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"Efficacy of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism";"recurent VTE";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"number of reccurent VTE";"Bayesian Hierarchical Model";"Arm";"10";"1";"0";"0";"0";"Full Network";"3";"Comparison of model fit and parsimony";"NA";"Yes";"We assessed available study and patient characteristics to ensure similarity";"Both FE and RE";"model fit";"Unclear";"informative priors for heterogeneity variances";"NA";"Yes";"No";"NA";"SUCRA; Probability of being the best";"All";"No";"No";"Incomplete Outcome Data Addressed";"None";"Non-sponsored";"0.05";"0.37";"0.4";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"266";"501225";"YES";"Helene Cawston";2013;"France";"European Spine Journal";"Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials inchronic low back pain.";15;"18";6;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"Efficacy of duloxetine against alternative oral therapies";"Pain intensity";"Effectiveness";"Harmful";"Continuous";"Objective";"standardized mean difference";"change pain intensity from baseline";"Bayesian Hierarchical Model";"Arm";"15";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"None";"Both FE and RE";"The random effects model provided a better fit (DIC)";"Unclear";"uniform prior distribution (Uniform [0, 2]) was applied to the between-study variance parameter in the base-case analysis. A uniform distribution (Uniform [0, 2]) for the prior between-study standard deviation and a gamma distribution (Gamma [0.01, 100]) for the prior precision were tested in sensitivity analysis.";"NA";"Yes";"No";"NA";"NA";"Subset";"No";"No";"None";"Eli Lilly and Company";"Industry-sponsored";"0.68";"no";"0.68";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"267";"501226";"YES";"Chang";2012;"Taiwan";"Archives of Physical Medicine and Rehabilitation";"Comparative Effectiveness of Focused Shock Wave Therapy of Different Intensity Levels and Radial Shock Wave Therapy for Treating Plantar Fasciitis: a Systematic Review and Network Meta- analysis";12;"5";5;"placebo";"3 (non-pharmacological vs any)";"No";"Yes";"No - split doses";"effectiveness of focused shock wave (FSW) therapy of different intensity levels and a new alternative, radial shock wave (RSW) for managing plantar fasciitis";"success rates of treatment";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"pain reduction magnitudes";"Bayesian Hierarchical Model";"Arm";"12";"0";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"NR";"NA";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"National Science Council, International Joint Grant from the Royal Society, National Science Council";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"268";"501227";"YES";"Saurav Chatterjee";2013;"USA/Italy";"BMJ";"Benefits of β blockers in patients with heart failure and
reduced ejection fraction: network meta-analysis";21;"NR";8;"placebo /standard treatment";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"relative mortality benefit of β blockers in patients with heart failure as 20-35%";"All cause death";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"number of deaths";"Bayesian Hierarchical Model";"Arm";"21";"0";"0";"0";"0";"Full Network";"2";"Comparison of model fit and parsimony";"Yes";"Yes";"Not mentioned";"Random effects";"We used a random effects rather than a fixed effects model as this is probably the most appropriate and conservative analysis to account for variance within and between studies";"Unclear";"vague prior?";"NA";"Yes";"Yes";"Funnel plot; Harbord's test; Trim and fill method";"NA";"All";"No";"No";"Not mentioned";"None";"Non-sponsored";"0";"0.56000000000000005";"0.56000000000000005";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"269";"501228";"YES";"Chen";2012;"UK";"HTA";"Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis";46;"19";19;"other";"3 (non-pharmacological vs any)";"No";"No";"NA";"smoking cessation";"Point prevalence abstinence measured at longest follow-up";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"risk ratio";"point prevalence abstinence and/or prolonged
abstinence";"Bayesian Hierarchical Model";"Arm";"45";"1";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Both FE and RE";"In a few cases the pooled results from the fixed-effects model suggested a larger intervention effect than results from the random-effects model. The random-effects model remains the more appropriate method, given the aforementioned heterogeneity between studies.";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot; Egger's test";"NA";"Subset";"No";"No";"NA";"National Institute for Health Research Health Technology Assessment programme";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"270";"501229";"YES";"Chilton M";2013;"UK";"Diabetes, Obesity and Metabolism";"The effect of antiobesity drugs on waist circumference: a mixed treatment comparison";11;"NR";6;"placebo or standard care";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"Efficacy of orlistat and lorcaserin in the treatment of overweight and obesity";"Loss of weight";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"change in weight circumference at 3 months";"Bayesian Hierarchical Model";"Arm";"10";"1";"0";"0";"0";"Full Network";"1";"Comparison of model fit and parsimony";"Yes";"Yes";"Included studies had similar characteristics";"Random effects";"Because a large amount of heterogeneity between studies was expected as this was present in the original meta-analysis.";"Unclear";"vague prior?";"NA";"Yes";"Yes";"Contour enhanced funnel plots; Egger's test";"NA";"All";"No";"No";"If any data were missing, the corresponding author was contacted
";"NIHR Health Technology Assessment";"Publicly-sponsored";"0.99";"0.6";"0.99";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"272";"501231";"YES";"Cipriani";2011;"Italy";"Lancet";"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis";62;"NR";14;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy";"Mean change scores on the Young Mania Rating Scale (YMRS)";"Effectiveness";"Harmful";"Continuous";"Subjective";"standardized mean difference";"NR";"Bayesian Hierarchical Model";"Arm";"45";"17";"0";"0";"0";"Full Network";"33";"Loop-specific; Inconsistency model";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Yes";"No";"NA";"Probability of being the best; rankograms";"All";"No";"Yes";"imputation";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"273";"501232";"YES";"Cipriani";2009;"Italy";"Lancet";"Comparative e?   cacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis";111;"12";12;"-";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"efficacy";"the proportion of patients who responded to the allocated treatment";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"reduction of at least 50% from the baseline score on the
Hamilton depression rating scale (HDRS) or
Montgomery–Åsberg depression rating scale (MADRS),
or who scored much improved or very much improved
on the clinical global impression (CGI) at 8 weeks";"Bayesian Hierarchical Model";"Arm";"109";"2";"0";"0";"0";"Full Network";"70";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"to incorporate the assumption that different studies assessed different, yet related, treatment effects";"Unclear";"NR";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"Yes";"imputation";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"276";"501235";"YES";"Cooper";2011;"UK";"Epidemiol Rev";"Network Meta-analysis to Evaluate the Effectiveness of Interventions to Increase the Uptake of Smoke Alarms";20;"7";7;"control - usual care";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"possession of a functioning alarm";"household’s possession of a functioning smoke alarm (yes/no)-number of smoke alarms";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"possession of a functioning smoke alarm";"Bayesian Hierarchical Model";"Arm";"20";"0";"0";"0";"0";"Full Network";"4";"Node-splitting";"Yes";"Yes";"NR";"Random effects";"No";"Unclear";"using the between study standard deviation parameter.";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"National Institute for Health Research (NIHR) Programme Grants for Applied Research";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"277";"501236";"YES";"Cooper";2006;"UK";"Arch Intern Med";"Mixed comparison of stroke prevention treatments in individuals with noNRheumatic atrial fibrillation.";19;"9";9;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split and lump doses";"Stroke prevention in patients with atrial fibrillation";"Ischemic strokes";"Effectiveness";"Harmful";"Rate";"Objective";"Rate Ratio";"rate of stroke and the rate of
major or fatal bleeding episodes per 1000 person-years";"Bayesian Hierarchical Model";"Arm";"13";"5";"1";"0";"0";"Full Network";"11";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"The assumptions of a mixed- treatment comparison analysis are that (1) study-specific treat- ment effects are drawn from a common population (exchange- able) and (2) heterogeneity is constant between the different comparisons.";"NR";"NR";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"No";"NA";"Medical Research Council Training Fellowship in Health Services Research";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"278";"501237";"YES";"Shannon Cope";2013;"UK";"Respiratory Research";"Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analyses";17;"10";10;"placebo or monotherapy";"2 (pharmacological vs placebo)";"No";"No";"NA";"Efficacy of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD)";"Trough forced expiratory volume at 6 months";"Effectiveness";"Beneficial";"Continuous";"semi-objective";"mean difference";"change in baseline for trough forced expiratory volume in 1 second";"Bayesian Hierarchical Model";"Study";"10";"6";"1";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"
Meta-regression or by excluding specific studies that differed in terms of the characteristics identified";"Both FE and RE";"The two models were compared by the goodness-of-fit to the data (DIC),Fixed effect model was better";"Unclear";"non-informative prior";"NA";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"None";"Novartis";"Industry-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"279";"501239";"YES";"Cope";2011;"USA";"Int J Chron Obstruct Pulmon Dis";"Comparative efficacy of indacaterol 150 mg and 300 mg versus fixed-dose combinations of formoterol 􀀋 budesonide or salmeterol 􀀋 fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis";15;"7";7;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"efficacy";"trough FEV1 (reported predose values) at 12 weeks";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"trough FEV1
(reported predose values) at 12 weeks and 6 months,";"Bayesian Hierarchical Model";"Study";"10";"5";"0";"0";"0";"Full Network";"2";"Informal comparison of NMA results with previously published results";"Yes";"Yes";"NR";"Both FE and RE";"Model fit";"Unclear";"Non-informative Prior";"NR";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"Novartis Pharma AG";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"280";"501240";"YES";"Cope";2012;"US";"BMC";"Efficacy of once-daily indacaterol 75 mug relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis";22;"7";7;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"efficacy";"forced expiratory volume in 1 s (FEV1) at 24 hrs post-dose";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"FEV1 at 24 hrs post-dose (‘trough’; mean of the values
assessed at 23 h 10 min and 23 h 45 min following the previous morning dose),";"Bayesian Hierarchical Model";"Study";"18";"2";"1";"0";"0";"Full Network";"6";"Lumley model";"Yes";"Yes";"NR";"Both FE and RE";"The fixed and random effects models had similar results as indicated by the DIC. The DIC for the random effects model using an uninformed prior has a slightly higher DIC than the fixed effect model. Based on this it can be argued that the fixed effect models are appropriate, especially given that model diagnostics suggest the random effects model using an uninformative prior did not converge.";"Unclear";"Non-informative Prior";"NR";"Yes";"No";"NA";"Probability of being the best";"Subset";"Yes";"No";"NA";"Novartis Pharmaceuticals";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"283";"501243";"YES";"Daniels";2012;"UK";"BMJ";"Second generation endometrial ablation techniques for heavy menstrual bleeding: network meta-analysis";18;"7";7;"other - first generation hysteroscopic devices";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"relative effectiveness of second generation techniques in the treatment of heavy menstrual bleeding";"event rates for heavy bleeding at 12 months";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"rate of
amenorrhoea (converted from a pictorial bleeding assessment
score of zero when these data existed, otherwise as reported),
rate of heavy bleeding (likewise converted from a pictorial
bleeding assessment score of >10024 when data existed,
otherwise as reported), and";"Meta regression";"Arm";"18";"0";"0";"0";"0";"Full Network";"Unclear";"Lumley model";"Yes";"Yes";"NR";"Both FE and RE";"model fit";"Unclear";"NR";"NR";"Yes";"No";"NA";"NA";"All";"Yes";"No";"NA";"National Institute for Health Research (NIHR) Health Technology Assessment project; University of Birmingham Clinical Trials Unit, which is funded by an infrastructure grant from the NIHR.";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"284";"501244";"YES";"Del Santo";2011;"Italy";"Eur J Clin Pharmacol";"Treatments for relapsing–remitting multiple sclerosis: summarising current information by network meta-analysis";10;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"comparative effectiveness for relapsing–remitting multiple sclerosis (RRMS)";"relapse-free rate at 12 months";"Effectiveness";"Beneficial";"Survival";"Semi-objective";"hazard ratio";"terms of freedom from relapse at the 12-month follow-up
assessments";"Adjusted indirect comparison (Bucher)";"Arm";"10";"0";"0";"0";"0";"Full Network";"8";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NA";"NR";"Unclear";"No";"NA";"NA";"All";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Frequentist";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"289";"501250";"YES";"Ariel Dogliotti";2013;"Argentina";"Heart";"Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients";20;"8";8;"placebo/control";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"Efficacy of different classes of antithrombotic drugs";"reduction the incidence of stroke";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"number of strokes";"Bayesian Hierarchical Model";"Arm";"16";"4";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"None";"Random effects";"No";"NR";"NR";"NA";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"None";"NA";"Non-sponsored";"0.73";"0.33";"0.82";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"290";"501251";"YES";"Dong YH";2013;"Taiwan";"Thorax";"Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison 
meta-analysis of randomised controlled trials";41;"NR";6;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"No";"Risk of mortality for inhaled medications in patients with chronic obstructive pulmonary disease (COPD)";"Overall death";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"number of deaths";"Bayesian Hierarchical Model";"Arm";"27";"6";"7";"0";"1";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"Similarity in demographic characteristics across trials with meta-regression";"Both FE and RE";"Given the challenge of the homogeneity assumption in the MTC analysis, both fixed effect and random effects models were applied. To address the possible difference of demographic characteristics across trials, we performed meta-regression to adjust for variables of age, proportion of male, percentage of current smoker, study duration, FEV1, and percentage of subjects with concomitant use of LABA or ICS";"Unclear";"NR";"NA";"Yes";"Yes";"Funnel plot; Begg's test; Egger's test";"Probability of being the best";"All";"No";"No";"Not mentioned";"Taiwan Department of Health";"Publicly-sponsored";"no data available";"no data available";"no data available";NA;"long";0;1;"After removing comparisons with missing treatment effects or standard errors,\n  study '33' has a wrong number of comparisons. Please check data and\n  consider to remove study from network meta-analysis.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"291";"501252";"YES";"Christopher Dooley";2013;"USA";"Current Medical Research and Opinion";"Comparison of the efficacy and safety of low molecular weight heparins for venous thromboembolism prophylaxis in medically ill patients";14;"28";7;"placebo/control";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Efficacy of low molecular weight heparins for venous thromboembolism prophylaxis in hospitalized medically ill patients";"mortality";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"mortality during hospitalization up to one year";"Bayesian Hierarchical Model";"Arm";"14";"0";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"None";"Random effects";"No";"NR";"NR";"NA";"Unclear";"No";"NA";"NA";"All";"No";"No";"None";"None";"Non-sponsored";"0";"0.05";"0.05";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"292";"501253";"YES";"Dunkley";2012;"UK";"Diabetes, Obesity and Metabolism";"Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis";13;"11";11;"control / no treatment";"3 (non-pharmacological vs any)";"Yes";"Yes";"No - split doses";"reversal of metabolic syndrome";"proportion reversed";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"syndrome according to a recognized
definition; have a minimum follow-up of 24 weeks and have an
outcome relating to reversal of metabolic syndrome, incidence
of type 2 diabetes or cardiovascular events/mortality.";"Bayesian Hierarchical Model";"Arm";"6";"3";"4";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"the use of random-effect models enabled heterogeneity to be accounted for in the analysis";"Unclear";"NR";"NA";"Yes";"Yes";"Funnel plot; Peter's test";"Probability of being the best";"Subset";"No";"No";"NA";"NR";"Funding source not reported";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"294";"501255";"YES";"Edwards";2009;"UK";"CMRO";"Carbapenems versus other beta-lactamsin the treatment of hospitalized patients with infection: a mixed treatment comparison";30;"NR";4;"Imipenem/Cilastatin";"1 (pharmacological vs pharmacological)";"No";"Unclear";"No";"effectiveness of beta-lactams for the treatment of hospitalized patients with infection";"clinical response";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"Cure (coismplete remission of the signs and symptoms of infection without the addition of other antibiotics or reccurrence of symptom)";"Bayesian Hierarchical Model";"Arm";"39";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"selected based on lowest DIC";"Unclear";"NR";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"AstraZeneca UK Ltd; the UK Department of Health; the UK Medical Research Council";"Industry and Publicly sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"295";"501256";"YES";"Eisenberg";2008;"Canada";"CMAJ";"Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials";61;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"most rigorous criterion of abstinence in smoking cessation";"continuous abstinence at 12 months";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"as either continuous abstinence from cigarette
smoking or point prevalence of abstinence";"Bayesian Hierarchical Model";"Arm";"59";"3";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"CIHR";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"296";"501257";"YES";"Elliott";2007;"USA";"Lancet";"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.";22;"6";6;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"effect of antihypertensives on incidence diabetes mellitus";"proportion of patients who developed diabetes";"Safety";"Harmful";"Binary";"Semi-objective";"odds ratio";"new-onset
diabetes";"Meta regression";"Arm";"18";"4";"0";"0";"0";"Full Network";"16";"Lumley model";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"National Institutes of Health";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"298";"501261";"YES";"Filippini G";2013;"Italy";"The cochrane library";"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis (Review)";21;"23";10;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"the relative effectiveness of immunomodulators and immunosuppressants in patients with MS";"Recurrence of relapses";"Effectiveness";"Harmful";"Binary";"semi-objective";"odds ratio";"proportion of participants who experienced new relapses over 12 months
";"Bayesian Hierarchical Model; Bucher method";"Arm";"21";"0";"0";"0";"0";"Full Network";"4";"Loop-specific; Comparison of model fit and parsimony; Lu and Ades";"Yes";"Yes";"adjust for potential effect modifiers using network meta-regression";"Random effects";"No";"Unclear";"NR";"NA";"Yes";"Yes";"‘comparison-adjusted’ funnel plot";"SUCRA";"All";"No";"No";"Incomplete outcome data in included studies";"Ministero della Salute - Direzione Generale della Ricerca Scientifica e Tecnologica; Fondazione Istituto Neurologico Carlo Besta - Milan, Italy";"Publicly-sponsored";"0.74";"0.09";"0.92";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"299";"501263";"YES";"Fox";2012;"Canada";"BMJ";"Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials";9;"5";5;"control / traditional
treatment
with
vitamin
K
antagonists";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"acute venous thromboembolism";"recurrent acute venous thromboembolism, as defined by the study protocol";"Effectiveness";"Harmful";"Binary";"Subjective";"risk ratio";"acute symptomatic venous thromboembolism (that is, deep vein
thrombosis or pulmonary embolism, or both) objectively
diagnosed with standard imaging techniques;";"Adjusted indirect comparison (Bucher)";"Arm";"9";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"theDerSimonian and Laird random-effects method";"NR";"Unclear";"Yes";"Funnel plot";"NA";"Subset";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"303";"501267";"YES";"Fretheim";2012;"Norway";"BMC";"Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis";26;"9";9;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"incidence of cardiovascular disease outcomes";"total mortality";"Effectiveness";"Harmful";"Binary";"Subjective";"risk ratio";"mortality";"Bayesian Hierarchical Model";"Arm";"22";"3";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR";"Random effects";"No";"NR";"Non-informative Prior (vague)";"NR";"Unclear";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"Norwegian Directorate for Health";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"304";"501268";"YES";"Gafter-Gvili";2005;"Israel";"Annals of Internal Medicine";"Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients.";37;"NR";5;"placebo/no treatment";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"antibiotic prophylaxis in neutroneutropenic patients";"all-cause mortality";"Effectiveness";"Harmful";"Binary";"objective";"risk ratio";"mortality";"NR";"Arm";"33";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"We used a fixed-effect model by using the Mantel–Haenszel method for dichotomous data for pooling trial results throughout the review unless statistically significant heterogeneity was found, in which case, we chose a random-effects model by using the DerSimonian and Laird method.";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot; Begg's test";"NA";"Subset";"No";"No";"NA";"Rabin Medical Center, European Commission fifth framework International Society Technologies";"Publicly-sponsored";NA;NA;NA;"NR";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"305";"501269";"YES";"Joshua J Gagne";2013;"USA";"BMJ";"Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison";9;"7";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Efficacy of antiplatelet agents";"cardiovascular death in smokers";"Effectiveness";"Harmful";"Binary";"objective";"risk ratio";"25% reduction in a composite outcome comprising cardiovascular death";"Adjusted indirect comparison (Bucher)";"Study";"9";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"The indirect comparison methods require that the included trials be similar with respect to potential modifiers of treatment effect";"Fixed-effect";"No";"NA";"NR";"NR";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"No";"None";"Brigham and Women’s Hospital and Harvard Medical School";"Publicly-sponsored";"0";"no";"no";NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"307";"501272";"YES";"Gartlehner";2011;"Austria";"Annals of Internal Medicine";"Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis";64;"14";14;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"efficacy and effectiveness of second-generation anti- depressants for treatment of MDD";"response rates";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"weighted mean
difference of changes on the Hamilton Rating Scale for
Depression (HAM-D) or the Montgomery-Asberg Depression
Rating Scale (MADRS).";"Bayesian Hierarchical Model";"Arm";"52";"12";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with previously published results";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Unclear";"Yes";"Funnel plot; Begg's test";"NA";"All";"No";"No";"NA";"Agency for Healthcare Research and Quality";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"308";"501273";"YES";"Golfinopoulos";2009;"Belgium";"Cancer Treatment Reviews";"Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis";8;"5";5;"-";"1 (pharmacological vs pharmacological)";"No";"Unclear";"NA";"Diverse chemotherapy regimens for cancer";"death";"Effectiveness";"Harmful";"Time to event";"Objective";"hazard ratio";"mortality";"Bayesian Hierarchical Model";"Study";"10";"0";"0";"0";"0";"Full Network";"11";"NR";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"309";"501274";"YES";"Golfinopoulos";2007;"Greece";"Lancet";"Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis";35;"11";11;"-";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"Survival with treatment regimens for advanced colorectal cancer";"death";"Effectiveness";"Harmful";"Time to event";"Objective";"hazard ratio";"mortality";"Bayesian Hierarchical Model";"Study";"29";"6";"0";"0";"0";"Full Network";"9";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"No";"Unclear";"NR";"NR";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"312";"501277";"YES";"Goudswaard";2009;"Netherlands";"CDSR";"Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.";13;"4";4;"Insulin once daily";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split doses";"insulin therapies in patients with type 2 diabetes";"HbAIc change";"Effectiveness";"Harmful";"Continuous";"Objective";"mean difference";"change in HbAIc from baseline [%]";"NR";"Arm";"12";"1";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Unclear";"Yes";"Funnel plot";"NA";"Subset";"No";"No";"NA";"Novo Nordisk";"Industry-sponsored";NA;NA;NA;"NR";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"314";"501281";"YES";"A.K. Gupta";2013;"Canada";"British Journal of Dermatology";"Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants ofeight interventions for actinic keratosis: a follow-up on a Cochrane review.";35;"NR";9;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"The relative efficacy of eight treatments in nonimmunosuppressed participants for actinic keratosis";"participant complete clearance";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"number of patients with no lesions";"Bayesian Hierarchical Model";"Arm";"32";"3";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"The participant characteristics were generally similar between all the interventions";"Random effects";"No";"NR";"NR";"NA";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"No";"None";"None";"Non-sponsored";"0.85";"7.0000000000000007E-2";"0.86";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"315";"501282";"YES";"Guyot";2011;"Netherlands";"Arthritis Research & Therapy";"Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis";16;"24";9;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"No";"efficacy";"Health Assessment Questionnaire change from baseline (HAQ CFB)";"Effectiveness";"Harmful";"Continuous";"Subjective";"mean difference";"mean difference in HAQ at 24 weeks:";"Bayesian Hierarchical Model";"Arm";"16";"0";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"most studies were generally comparable in design, although
differences were identified regarding patients not responding to treatment";"Both FE and RE";"depending on the heterogeneity as assessed by the goodness-of-fit test based on the residual deviance [19], either a fixed effect or a random effects model was chosen.";"Unclear";"Non-informative Prior";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"imputation";"Bristol-Myers Squibb";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"316";"501283";"YES";"Haas";2012;"USA";"BMJ";"Tocolytic therapy for preterm delivery: systematic review and network meta-analysis";55;"NR";17;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy";"delivery successfully delayed for 48 hours";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"delivery successfully delayed for 48 hours";"Bayesian Hierarchical Model";"Arm";"2";"53";"0";"0";"0";"Full Network";"29";"Comparison of model fit and parsimony";"Yes";"Yes";"characteristics of the trials and participants were similar enough
to be combined in the network meta-analysis";"Both FE and RE";"In the case of two or fewer trials we carried out a fixed effect meta-analysis.";"Unclear";"NR";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"NIH-NICHD and the Indiana University-Purdue University-Indianapolis Signature Center grant to the Indiana University Center for Pharmacogenetics and Therapeutics Research in Maternal and Child Health (PREGMED)";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"320";"501287";"YES";"Hartling";2011;"Canada";"BMJ";"Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis";14;"6";6;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"efficacy and safety of bronchodilators and steroids";"admission rates from emergency department  at day 1";"Effectiveness";"Harmful";"Binary";"Semi-objective";"risk ratio";"outcome selected by the clinician authors a priori based on clinical
relevance, were rate of admissions at day 1 and day
7 for outpatient studies and length of stay in hospital for
inpatient studies.";"Bayesian Hierarchical Model";"Arm";"14";"0";"0";"1";"0";"Full Network";"15 - verify with analysis";"Back-calculation";"Yes";"Yes";"NR";"Random effects";"No";"NR";"non-informative prior distributions";"NR";"Yes";"No";"NA";"Probability of being the best";"Subset";"Yes";"No";"NA";"the Canadian Institutes of Health Research knowledge synthesis grant programme.";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"326";"501293";"YES";"Hofmeyr";2009;"South Africa";"Bull World Health Organ";"Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects.";24;"4";4;"placebo/other uterotonics";"2 (pharmacological vs placebo)";"No";"No";"NA";"effectiveness for the prevention of postpartum haemorrhage";"blood loss ? 1000 ml";"Effectiveness";"Harmful";"Binary";"Objective";"risk ratio";"risk of postpartum haemorrhage (blood loss more than 1000 ml)";"Adjusted indirect comparison (Bucher)";"Arm";"18";"1";"0";"0";"0";"Full Network";"1";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Both FE and RE";"We used fixed effects meta-analysis for combining data in the absence of significant heterogeneity.";"Unclear";"NR";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"United States Agency for International Development";"Publicly-sponsored";NA;NA;NA;"Unclear";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"329";"501297";"YES";"Hutton";2012;"Canada";"BMJ";"Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies";82;"4";4;"no treatment";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"relative risks of death between antifibrinolytics and no treatment";"mortality";"Safety";"Harmful";"Binary";"Objective";"odds ratio";"mortality";"Bayesian Hierarchical Model";"Arm";"71";"11";"0";"0";"0";"Full Network";"4";"Node-splitting";"Yes";"Yes";"NR";"Random effects";"No";"Unclear";"NR";"NR";"Yes";"No";"NA";"average rank; Probability of being the best";"Subset";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"330";"501298";"YES";"Ibrahim";2011;"UK";"JHS";"Surgical Versus Nonsurgical Treatment of Acute Minimally Displaced and Undisplaced Scaphoid Waist Fractures: Pairwise and Network Meta-Analyses of Randomized Controlled Trials";9;"5";5;"control / non surgiacal treatment";"3 (non-pharmacological vs any)";"No";"No";"NA";"effectiveness of surgical treatment for minimally displaced and undisplaced scaphoid waist fractures";"rate of fracture union in patients undergoing surgery versus those undergoing nonsurgical treatment";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"number of fracture unions in";"Bayesian Hierarchical Model";"Arm";"9";"0";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with previously published results";"Yes";"Yes";"NR";"Fixed-effect";"No";"NA";"NR";"NR";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"331";"501299";"YES";"Imamura";2010;"UK";"HTA";"Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence.";37;"NR";13;"no treatment";"2 (pharmacological vs placebo)";"No";"Unclear";"No";"effectiveness of non-surgical treatments for women with stress urinary incontinence";"cure";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"Cure of incontinence (defined as the involuntary leakage of urine,2,3 and this can
be subcategorised qualitatively according to the
patient’s description)";"Bayesian Hierarchical Model";"Arm";"31";"5";"2";"0";"0";"Full Network";"26";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"vague prior";"NR";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"Unclear";"HTA programme";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"332";"501300";"YES";"Jansen";2006;"Netherlands";"CMRO";"Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons.";12;"4";4;"no self monitoring";"3 (non-pharmacological vs any)";"No";"No";"NA";"relative efficacy";"change in HbA1c level from baseline";"Effectiveness";"Harmful";"Continuous";"Objective";"mean difference";"change in HbA1c level from baseline";"Bayesian Hierarchical Model";"Arm";"11";"1";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Random effects";"Based on clinical heterogeneity, as observed from the data-extraction, it was decided to use a random-effects model instead of a fixed effects-model";"Unclear";"Non informative prior";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"Roche Diagnostics";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"333";"501302";"YES";"Jansen";2010;"USA";"Semin Arthritis Rheumatol";"The Effcacy of Bisphosphonates in the Prevention of Vertebral, Hip, and Nonvertebral-Nonhip Fractures in Osteoporosis: A Network Meta-Analysis.";8;"9";6;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy of bisphosphonates";"prevention of vertebral fractures";"Effectiveness";"Harmful";"Binary";"Semi-objective";"risk ratio";"Number of vertebral fractures (morphometric)";"Bayesian Hierarchical Model";"Arm";"8";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"the included studies were similar with regard to average age and bone mineral density";"Both FE and RE";"Assessment of residual deviance showed no appreciable difference between random and fixed effects assumptions, and a fixed effects model was considered appropriate.";"Unclear";"Non-informative Prior";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"Novartis Pharmaceuticals";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"336";"501305";"YES";"Nasreen Khan";2013;"USA";"Current Medical Research & Opinion";"The efficacy and tolerability of perampanel and
other recently approved anti-epileptic drugs for
the treatment of refractory partial onset seizure:
a systematic review and Bayesian network
meta-analysis";12;"13";5;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Efficacy of anti-epileptic drugs";"responder rate";"Effectiveness";"Beneficial";"Binary";"semi-objective";"odds ratio";">=50% reduction in seizure frequency from baseline measured over the maintenance period";"Bayesian Hierarchical Model";"Arm";"12";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"All the studies were similar in design and quality";"Both FE and RE";"Choice between fixed- and random-effect models was assessed using the deviance information criterion (DIC) and total residual deviance to detect which model was considered a better fit";"Unclear";"NR";"NA";"Yes";"No";"NA";"NR";"All";"No";"No";"Not mentioned";"Eisai Inc";"Industry-sponsored";"0.8";"no";"0.8";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"337";"501307";"YES";"Krogh";2012;"Denmark";"The American Journal of Sports Medicine";"Comparative Effectiveness of Injection Therapies in Lateral Epicondylitis";17;"9";9;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"change in pain intensity";"Composite patient-reported outcomes";"Effectiveness";"Harmful";"Continuous";"Subjective";"standardized mean difference";"mean change in pain intensity from baseline";"Multivariate meta regression";"Arm";"15";"2";"0";"0";"0";"Full Network";"2";"NR";"Unclear";"Unclear";"None";"Both FE and RE";"consistent with our protocol, we used random-effects meta-analysis as a default option and considered the fixed-effect analysis for sensitivity analytic purposes.";"Unclear";"NR";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"Oak foundation, The Danish Rheumatism Association, Research Foundation at Region Hospital Silkeborg and Copenhagen University Hospital, Frederiksberg";"Publicly-sponsored";"no data available";"no data available";"no data available";"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"338";"501308";"YES";"Kyrgiou";2006;"Greece";"J National Cancer Institute";"Survival Benefi ts With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments";60;"9";9;"-";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"Chemotherapy regimens for ovarian cancer";"median survival";"Effectiveness";"Harmful";"Survival";"objective";"hazard ratio";"mortality";"Bayesian Hierarchical Model";"Study";"53";"5";"2";"0";"0";"Full Network";"Unclear";"Lumley model";"NA";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"339";"501309";"YES";"Lam";2007;"UK";"BMJ";"Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials.";12;"7";7;"medical therapy";"3 (non-pharmacological vs any)";"No";"No";"NA";"Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction";"all-cause mortality";"Effectiveness";"Harmful";"Binary";"objective";"odds ratio";"mortality";"Bayesian Hierarchical Model";"Arm";"9";"2";"0";"0";"0";"Full Network";"3";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"Yes";"Funnel plot";"Probability of being the best";"Subset";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"341";"501311";"YES";"Lang";2012;"UK";"CMRO";"Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis";15;"4";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"efficacy";"MACE (major adverse cardiac event) 30 days; 14 trials";"Effectiveness";"Harmful";"Binary";"Semi-objective";"risk ratio";"major adverse cardiac events
(MACE), which included cardiac death, non-fatal myocardial
infarction (MI), revascularization, or other composite
endpoint as defined by the authors.";"Bayesian Hierarchical Model";"Arm";"9";"5";"1";"0";"0";"Tree network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"NA";"No";"NR";"Random effects";"to acknowledge the potential for unobserved differences between trials";"Unclear";"Non-informative Prior";"NR";"Unclear";"No";"NA";"NA";"All";"No";"No";"NA";"Iroko Cardio International Sarl, Geneve, Switzerland";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"342";"501312";"YES";"Lapitan";2009;"Philippines";"CDSR";"Open retropubic colposuspension for urinary incontinence in women.";22;"9";9;"conservative interventions";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"Open retropubic colposuspension for urinary incontinence in women";"number not cured within first year";"Effectiveness";"Harmful";"Binary";"Subjective";"risk ratio";"Number not cured within first year (subjective)";"Adjusted indirect comparison (Bucher)";"Arm";"19";"2";"1";"0";"0";"Full Network";"5";"NR";"Unclear";"Unclear";"NR";"Both FE and RE";"fixed effects approach to the analysis was undertaken unless there was evidence of heterogeneity across studies.";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"National Health Service Executive Research and Development Programme, UK.";"Publicly-sponsored";NA;NA;NA;"Unclear";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"343";"501313";"YES";"Launois";2011;"France";"The Journal of Rheumatology";"Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis";19;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"clinical efficacy of anticytokine agents for the treatment of rheumatoid arthritis (RA)";"The American College of Rheumatology (ACR) response criteria; ACR20 (minimal therapeutic response) as the primary outcome";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"Number achieving ACR 20";"Bayesian Hierarchical Model";"Arm";"19";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"The multiple-treatment random-effects model integrates, on the one hand, the information resulting from direct and/or indirect comparisons between treatments and on the other hand, the heterogeneity existing between the trials, in a randomeffects model that takes into account the variability of the measured effect between trials (between-trial variability may be caused by some unmeasured characteristics such as heterogeneity of patient populations or of methods of care)";"Unclear";"noninformative uniform (0, 10) prior distributions";"NR";"Unclear";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"UCB Pharma";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"346";"501316";"YES";"Wei-Chih Liao";2013;"Taiwan";"Lancet Oncology";"Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis";9;"13";6;"Observation";"3 (non-pharmacological vs any)";"No";"Unclear";"NA";"Efficacy of adjuvant treatments for patients suffering from pancreatic adenocarcinoma";"overall death after tumor resection";"Effectiveness";"Harmful";"Survival";"objective";"hazard ratio";"number of deaths";"Bayesian Hierarchical Model";"Arm";"8";"0";"1";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"Meta-regression";"Random effects";"To account for heterogeneity between studies, we used random-eff ects models";"Unclear";"NR";"NA";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"When hazards ratios were not reported they were estimated from summary statistics with the method described by Tierney. If the report did not provide enough information for estimating HRs median survival durations were employed";"None";"Non-sponsored";"no";"no";"no";NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"347";"501317";"YES";"Lin";2012;"Taiwan";"J Clinical Periodology";"In-office treatment for dentin hypersensitivity: a systematic review and network meta-analysis";41;"6";6;"placebo";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"effectiveness in resolving dentin hypersensitivity among different in-office desensitizing treatments";"visual analogue scales (VAS) or verbal rating scales (VRS) for pain assessment of DH";"Effectiveness";"Harmful";"Continuous";"Subjective";"mean difference";"Change in pain from baseline";"Bayesian Hierarchical Model";"Arm";"29";"10";"1";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"Non-informative Prior";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"348";"501318";"YES";"Lin VW";2012;"USA";"Arch Dermatol";"Comparison of Ustekinumab With Other Biological
Agents for the Treatment of Moderate to Severe
Plaque Psoriasis A Bayesian Network Meta-analysis";17;"15";7;"Placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split dose and sensitivity analyses";"PASI 50";"achieving PASI 50 Reported between 10 and 16 weeks";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"50% Reductions in the Psoriasis Area and Severity Index (PASI)";"Bayesian Hierarchical Model";"Arm";"15";"2";"0";"0";"0";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"The patient characteristics across
trials (such as age, disease duration, BSA involvement,
and baseline PASI) were similar.";"Both FE and RE";"In the end, we used the previously described deviance information criteria to assess the model fit between the fixed-effects and random-effects models and determined that the random-effects model achieved the best fit.";"comparison-specific";"noninformative
normal distribution";"NA";"Yes";"No";"NA";"NR";"All";"No";"No";"NA";"University of Washington, Agency for Healthcare Research and Quality";"Publicly-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"349";"501319";"YES";"Littlewood";2012;"Netherlands";"Journal of Cystic Fibrosis";"A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis";11;"6";6;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"efficacies of antibiotics";"Percent change from baseline in forced expiratory volume (FEV1)% predicted in cystic fibrosis patients";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"Mean Change in FEV1";"Bayesian Hierarchical Model";"Arm";"11";"0";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Both FE and RE";"The choice between a fixed or random effects model for reported outcomes was based on model fit criteria (Deviance Information Criteria (DIC)";"Unclear";"Non-informative Prior";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"imputation";"Novartis Pharma AG";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"350";"501320";"YES";"Jinling Liu";2013;"China";"Plos one";"Comparative efficacy and Accebtability of Antidepressants in Parkinson's Disease: A Network Meta-Analysis";11;"NR";6;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"Efficacy of antidepressants used in patients suffering from Parkinson's disease";"response rate";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"50% reduction reduction of the baseline score on the scales for depressioin assessment";"Bayesian Hierarchical Model";"Study";"8";"3";"0";"0";"0";"Full Network";"Unclear";"Loop-specific";"Yes";"Yes";"None";"Both FE and RE";"If heterogeneity was moderate or great";"Unclear";"NR";"NA";"Unclear";"No";"NA";"NA";"All";"No";"No";"None";"None";"Non-sponsored";"0.41";"0.24";"0.55000000000000004";NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"351";"501321";"YES";"Liu";2012;"Taiwan";"Diabetes, Obesity and Metabolism";"Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis";39;"9";9;"placebo";"3 (non-pharmacological vs any)";"No";"NR";"NA";"effectiveness";"decrease in glycated haemoglobin A1c";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"Change in A1C levels";"Bayesian Hierarchical Model";"Arm";"39";"0";"0";"0";"0";"Full Network";"8 -  verify with analysis";"Informal comparison of NMA results with previously published results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"352";"501324";"YES";"Macfayden";2009;"UK";"CDSR";"Topical antibiotics without steroids for chronically discharging ears with underlying eardrum perforations.";13;"4";4;"no treatment";"2 (pharmacological vs placebo)";"No";"No";"NA";"Treatment failure";"persistent discharge";"Effectiveness";"Harmful";"Binary";"Semi-objective";"risk ratio";"Existence of persistent discharge at 1 week";"NR";"Arm";"10";"3";"1";"0";"0";"Full Network";"2";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"All";"No";"No";"NA";"Cochrane Ear, Nose and Throat Disorders Group, UK; Department for International Development, UK.";"Publicly-sponsored";NA;NA;NA;"NR";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"353";"501325";"YES";"Mak";2012;"Singapore";"BMJ";"Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials";26;"8";5;"control / conventional treatment (warfarin or enoxaparin or placebo)";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"Acute coronary events comprising either MI or ACS";"based on individual reports";"Safety";"Harmful";"Binary";"Subjective";"odds ratio";"MI or ACS (unstable angina, MI or
cardiac death), based on individual reports.";"NR";"Arm";"28";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"For studies using dissimilar agents in the control group, the random-effects
model was applied instead";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot; Egger's test";"NA";"Subset";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Unclear";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"354";"501326";"YES";"Makani";2011;"USA";"Amer. J Medicine";"Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema.";25;"NR";4;"CCB";"1 (pharmacological vs pharmacological)";"No";"Unclear";"No";"efficacy of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema";"incidence";"Effectiveness";"Harmful";"Binary";"Subjective";"risk ratio";"incidence of peripheral edema";"NR";"Arm";"25";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"if I2 was greater than 25% or heterogeneity P value was less than .05.";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot; Begg's test; Egger's test";"NA";"All";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"NR";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"357";"501330";"YES";"Mason";2004;"UK";"BMC";"Topical NSAIDs for acute pain: a meta-analysis.";29;"7";7;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"efficacy of topical NSAIDs for acute pain";"50% or more reduction";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"clinical success, representing
approximately a 50% reduction in pain [1]. This
was either the number of patients with a ""good"" or ""excellent""
global assessment of treatment, or ""none"" or ""slight""
pain on rest or movement (or comparable wording)
measured on a categorical scale.";"NR";"Arm";"29";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Fixed-effect";"No";"NA";"NR";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"Pain Research funds, Oxford Pain Relief Trust";"Publicly-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"358";"501332";"YES";"Maund";2011;"UK";"British Journal of Anaesthesia";"Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review";59;"4";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"morphine-related outcomes";"cumulative morphine consumption in the first 24 h post- surgery";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"cumulative morphine consumption in the first 24 h postsurgery,";"Bayesian Hierarchical Model";"Arm";"55";"4";"0";"0";"0";"Full Network";"2";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"Non-informative Prior";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"the NIHR Health Technology
Assessment programme";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;1;"""Non-numeric value for argument 'sd'.""";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"359";"501333";"YES";"Mauri";2008;"Greece";"J National Cancer Institute";"Multiple-Treatments Meta-analysis of Chemotherapy  and Targeted Therapies in Advanced Breast Cancer";128;"NR";22;"-";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split and lump doses";"Chemotherapy 
and Targeted Therapies in Advanced Breast Cancer";"mortality";"Effectiveness";"Harmful";"Survival";"objective";"hazard ratio";"mortality";"Bayesian Hierarchical Model";"Study";"110";"18";"0";"0";"0";"Full Network";"Unclear";"Loop-specific";"NA";"No";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"No";"NR";"NA";"Subset";"No";"No";"No";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"360";"501334";"YES";"McDaid";2010;"UK";"HTA";"Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review.";56;"NR";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy of non-opioid analgesics";"reduction in 24-hour morphine consumption";"Effectiveness";"Harmful";"Continuous";"Objective";"mean difference";"24-hour morphine
consumption (mg)";"Bayesian Hierarchical Model";"Arm";"52";"4";"0";"0";"0";"Full Network";"2";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"vague prior";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"imputation";"the HTA programme";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;1;"""Identical treatments for the following studies:\n  '14' - '24' - '34' - '4' - '44' - 'NA' - 'NA' - 'NA' - 'NA";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"(some studies contain multiple arms with the same intervention)";NA;NA;NA
"362";"501336";"YES";"McLeod";2007;"UK";"HTA";"Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.";8;"4";4;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"effectiveness of drugs for the treatment of ankylosing spondylitis";"ASAS 20 at 12 weeks";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"20 % improvement in the  Assessment
in Ankylosing Spondylitis (ASAS) at 12 weeks";"Adjusted indirect comparison (Bucher)";"Arm";"8";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"Where quantitative heterogeneity was indicated, analysis using a random-effects model was conducted for comparison with results of fixed effect-based analysis and is discussed within the appropriate section of the results.";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"All";"No";"No";"imputation";"NHS R&D HTA programme";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"363";"501337";"YES";"Meader";2010;"UK";"Drug and Alcohol Dependence";"A comparison of methadone, buprenorphine and alpha2 adrenergic agonists for opioid detoxification: A mixed treatment comparison meta-analysis";20;"4";4;"other / opioids";"1 (pharmacological vs pharmacological)";"No";"Unclear";"NA";"Completion of treatment";"being retained in treatment up to the final day of its planned duration, ingestion of the final dose of study medication, or reaching the point of zero dose of study medica- tion";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"as being
retained in treatment up to the final day of its planned duration, ingestion of the
final dose of study medication, or reaching the point of zero dose of study medication.";"Bayesian Hierarchical Model";"Arm";"19";"1";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"364";"501338";"YES";"Stuart Mealing";2013;"UK";"Experimental Hematology & Oncology";"The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis";7;"6";5;"Imatinib 400mg";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split doses";"Efficacy of Dasatinib, Nilotinib and Imatinib in patients suffering from chronic myeloid leukemia";"complete cytogenetic response";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"complete cytogenetic response in six months";"Bayesian Hierarchical Model";"Arm";"6";"1";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"assumed commonality of treatment effect modifiers across all included studies";"Fixed-effect";"No";"NA";"NR";"NA";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"None";"Bristol-Myers Scuibb Ltd";"Industry-sponsored";"0.47";NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"365";"501339";"YES";"Mhaskar";2012;"USA";"CDSR";"Bisphosphonates in multiple myeloma: a network meta- analysis (Review)";12;"6";7;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"Overall survival (OS)";"OS and progression-free survival (PFS)";"Effectiveness";"Beneficial";"Survival";"Subjective";"hazard ratio";"Mortality";"Bayesian Hierarchical Model; Bucher method";"Arm";"12";"1";"1";"0";"0";"Full Network";"Unclear";"Loop-specific";"Yes";"Yes";"NR";"Both FE and RE";"No";"NR";"vague prior distribution";"NR";"Yes";"Yes";"Funnel plot; Begg's test; Egger's test";"Probability of being the best";"Subset";"No";"No";"NA";"Center for Evidence-based Medicine,The University of South Florida, USA; Department of Internal Medicine, University of Bonn, Germany; Leukämie-Initiative Bonn e.v., Germany; Cochrane Haematological Malignancies Group (CHMG), Germany.";"Publicly-sponsored";NA;NA;NA;"bayesian & frequentist";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"366";"501340";"YES";"Middleton";2010;"UK";"BMJ";"Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review andmeta-analysis of data from individual patients";20;"4";4;"-";"3 (non-pharmacological vs any)";"Yes";"No";"NA";"efficacy as second line treatment for heavy menstrual bleeding";"dissatisfaction at 12 months";"Effectiveness";"Harmful";"Binary";"Subjective";"odds ratio";"Number of participants with dissatisfaction";"Meta regression";"Arm";"20";"0";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Fixed-effect";"No";"NA";"NA";"NR";"Yes";"No";"NA";"NA";"Subset";"Yes";"No";"Unclear";"NIHR";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"369";"501343";"YES";"Mills";2009;"Canada";"Ann Clin Microbiology & Antimicrobials";"Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis.";14;"5";5;"Amphotericin B Deoxycholate";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"effectiveness of antifungal treatment for invasive Candida infections";"all cause mortality";"Effectiveness";"Harmful";"Binary";"objective";"risk ratio";"mortality";"Bayesian Hierarchical Model";"Arm";"11";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Fixed-effect";"No";"NA";"NR";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"Pfizer Ltd";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"370";"501344";"YES";"Mills";2009;"Canada";"BMC";"Metastatic renal cell cancer treatments: An indirect comparison meta-analysis.";5;"4";4;"Interferon-a";"1 (pharmacological vs pharmacological)";"No";"No";"NA";"relative effectiveness of new therapies for metastatic renal cell cancer";"progression free survival";"Effectiveness";"Harmful";"Survival";"objective";"hazard ratio";"mortality";"Adjusted indirect comparison (Bucher)";"Study";"7";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"similar comparators
across similar patient groups";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"Pfizer Ltd";"Industry-sponsored";NA;NA;NA;"Frequentist";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"371";"501345";"YES";"Mills";2008;"Canada";"J Amer College of Cardiology";"Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.";19;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"effectiveness of statins in CVD";"cardiovascular disease mortality";"Effectiveness";"Harmful";"Binary";"objective";"risk ratio";"mortality";"Bayesian Hierarchical Model";"Arm";"19";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"Yes";"Funnel plot";"Probability of being the best";"All";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"372";"501346";"YES";"Mills";2011;"Canada";"QJM";"Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials.";58;"33";7;"control";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy of statins for cardiovascular disease";"all cause mortality";"Effectiveness";"Harmful";"Binary";"objective";"risk ratio";"mortality";"Bayesian Hierarchical Model";"Arm";"58";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"374";"501348";"YES";"Mills";2010;"Canada";"Harm Reduction Journal";"Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis.";89;"4";4;"control";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"Smoking Abstinence";"Smoking Abstinence at approximately 4 weeks post-target quit date (TQD)";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"Number with at least 4 weeks duration with biochemical confirmation
of smoking";"Adjusted indirect comparison (Bucher)";"Arm";"86";"3";"0";"0";"0";"Full Network";"2";"Loop-specific";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"NA";"NR";"Yes";"Yes";"Funnel plot; Egger's test";"NA";"Subset";"No";"No";"NA";"Pfizer Ltd";"Industry-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"375";"501350";"YES";"Murad";2012;"USA";"J Clin Endocrinol Metab.";"Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis";40;"NR";11;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"risk  of fractures";"reduction in the risk of hip fracture";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"Numer with hip fracture";"Bayesian Hierarchical Model";"Arm";"37";"1";"2";"0";"0";"Full Network";"Unclear";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"No";"NR";"Non-informative Prior";"NR";"Yes";"Yes";"Funnel plot; Egger's test";"Probability of being the best";"All";"No";"No";"NA";"The Endocrine Society";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"376";"501351";"YES";"Huseyin Naci";2013;"UK";"Circulation: Cardiovascular Quality and Outcomes";"Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials";135;"26";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"Harms of individual statins";"discontinuations because of adverse events";"Safety";"Harmful";"Binary";"semi-objective";"odds ratio";"number of participants who discontinued the study medication due to adverse events";"Bayesian Hierarchical Model";"Arm";"89";"10";"10";"4";"1";"Full Network";"Unclear";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"we assumed that the distribution of relative treatment effect modifiers (eg, baseline cholesterol levels) was balanced across different treatment comparisons";"Random effects";"random-effects model took into account potential heterogeneity by assuming that each treatment was drawn from the same distribution, whose mean and variance were estimated from the data";"Unclear";"NR";"NA";"Yes";"Yes";"contour enhanced funnel plots";"SUCRA; Probability of being the best";"All";"No";"No";"Incomplete outcome data";"Not mentioned";"Funding source not reported";"no data available";"no data available";"no data available";NA;"long";0;1;"""After removing comparisons with missing treatment effects or standard errors,\n  study '98' has a wrong number of comparisons. Please check data and\n  consider to remove study from network meta-analysis.""";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"379";"501354";"YES";"Nelson";2006;"USA";"JAMA";"Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis.";26;"NR";6;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"Unclear";"efficacy of nonhormonal therapies for menopausal hot flashes";"benefits";"Effectiveness";"Harmful";"Continuous";"Subjective";"mean difference";"Reduced in the frequency of hot flashes";"NR";"Study";"24";"1";"1";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"because there was evidence of heterogeneity between trials based on the  2 test for heterogeneity at a significance level of P=.10 and the I2 statistic, percentage of total variation across studies due to heterogeneity rather than chance, of more than 25%";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot; Egger's linear regression method";"NA";"Subset";"No";"No";"NA";"The National Institutes of Health (NIH) Office of Medical Applications of Research; the Portland Veterans Affairs Medical Center Women’s Health Fellowship.";"Publicly-sponsored";NA;NA;NA;"Unclear";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"380";"501355";"YES";"Nixon";2007;"UK";"Rheumatology";"The efficacy of inhibiting tumour necrosis factor a and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons";11;"9";9;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"ACR20 at 6 months for Rheumatoid arthritis";"reduction by 20% or more in the number of tender and swollen joints plus 20% improvement in at least three of the following five measures: pain, patient global assessment, physician global assessment, self-assessed physical disability (measured";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"Number of those achieving ACR20 at 6 months";"Adjusted indirect comparison (Bucher)";"Arm";"10";"1";"0";"0";"0";"Full Network";"2";"NR";"Unclear";"Unclear";"No (Baseline characteristics differ substantially)";"Both FE and RE";"The effect sizes, adjusted for study-level characteristics, will not be identical, as the regression will not completely explain the heterogeneity, and so a random-effects distribution is placed on the adjusted effects sizes. Validation model used FE";"The study-level covariables, mean disease duration and mean disability index at baseline, explain 67% and 91% of the between-study heterogeneity in the ACR20 and ACR50 log odds response rates, respectively";"NR";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"Wyeth, Interleukin Genetics Inc.; Abbott Laboratories; the British Society of Rheumatology; the US Agency for Healthcare Research and Quality; AstraZeneca";"Industry and Publicly sponsored";NA;NA;NA;"Unclear";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"383";"501358";"YES";"Padwal";2011;"Canada";"Obes Rev";"Bariatric surgery: a systematic review and network meta-analysis of randomized trialsobr_";15;"9";9;"standard care";"3 (non-pharmacological vs any)";"Yes";"NA";"NA";"comparison of bariatric surgeries and standard care";"differences in BMI levels from baseline";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"Per cent excess
weight loss was converted to change in BMI by defining
excess as a BMI >25 kg m-2 at 1 year";"Bayesian Hierarchical Model";"Arm";"15";"0";"0";"0";"0";"Full Network";"Unclear";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"Due to the differences expected between trials, we decided a priori to combine results using a random effects model";"Unclear";"Non-informative Prior";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"imputation";"the Canadian Agency for Drugs and Technology in Health; the Alberta Heritage Foundation for Medical Research;  the Canadian Institutes of Health Research";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"386";"501361";"YES";"Carlo Palmieri";2013;"UK";"Clinical Cancer Research";"Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis";7;"6";6;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"Efficacy of zoledronic acid, clodronate, pamidronate and ibandronate (i.v. and oral)";"skeletal-related events (SRE) secondary to metastatic breast";"Effectiveness";"Harmful";"Rate";"Semi-objective";"Relative rate";"mainly skeletal related events per patient per year,secondary number of patients affected by skeletal related events per period";"Bayesian Hierarchical Model";"Arm";"7";"0";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"breast cancer studies were comparable in terms of patient populations and skeletal endpoints";"Fixed-effect";"No";"NA";"NR";"NA";"Unclear";"No";"NA";"Probability of being the best";"Subset";"No";"No";"None";"Novartis UK Limited";"Industry-sponsored";"no";"no";"no";NA;"long";0;1;"object 'metaNetw' not found";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"387";"501363";"YES";"Petros Pechlivanoglou";2013;"Canada";"Journal of Antimicrobial Chemotherapy";"Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review";25;"NR";9;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"Efficacy of antifungal prophylaxis strategies";"risk of proven or probable invasive fungal infections (IFIs)";"Effectiveness";"Harmful";"Rate";"objective";"Relative risk";"total number of proven or probable invasive fungal infections";"Bayesian Hierarchical Model";"Arm";"24";"0";"1";"0";"0";"Full Network";"Unclear";"Loop-specific";"Yes";"Yes";"None";"Both FE and RE";"DIC was compared between the two models - Random effects had better goodness-of-fit";"Unclear";"NR";"NA";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"Cross-sectional imputation method";"Merck & Co";"Industry-sponsored";"no";"no";"no";NA;"long";0;1;"object 'metaNetw' not found";NA;NA;NA;NA;"(one study contains multiple arms with the same intervention)";NA;NA;NA;NA;NA;NA;NA;NA;NA
"388";"501364";"YES";"Peterson";2008;"USA";"Psychopharmacology";"Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis.";17;"25";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy";"clinical response for adults with attention-deficit hyperactivity disorder";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"Numbers with clinical response";"Meta regression";"Study";"17";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"We used a random effects model to combine the data to account for variation among studies. When there is no variation among studies, the random effects model yields the same results as a fixed effects model";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot; Egger's linear regression method";"NA";"Subset";"No";"No";"NA";"Drug Effectiveness Review Project";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"389";"501365";"YES";"Phung";2011;"USA";"Chest";"Dosing frequency of unfractionated heparin thromboprophylaxis: A meta-analysis.";13;"4";4;"control/placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"Efficacy of thromboprophylaxis strategies";"risk of deep venous thrombosis";"Effectiveness";"Harmful";"Binary";"Semi-objective";"risk ratio";"Number of participants with  deep venous thrombosis";"Bayesian Hierarchical Model";"Arm";"12";"0";"0";"0";"0";"Full Network";"2";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"NA";"All";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"390";"501366";"YES";"Phung";2010;"USA";"JAMA";"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.";20;"NR";7;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"No";"comparative efficacy";"change in HbA1c level from baseline";"Effectiveness";"Harmful";"Continuous";"Objective";"mean difference";"Average change in the  HbA1c level";"Bayesian Hierarchical Model";"Arm";"18";"2";"0";"0";"0";"Full Network";"4";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"Yes";"Funnel plot; Egger's test";"NA";"Subset";"No";"No";"NA";"Hartford Hospital Research Foundation,
Hartford, Connecticut.";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"391";"501367";"YES";"Phung";2011;"USA";"Diabetic Medicine";"Oral anti-diabetic drugs for the prevention of Type 2 diabetes.";20;"NR";6;"control/placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"Efficacy of oral anti-diabetic drugs for the prevention of Type 2 diabetes";"number of patients developing new-onset diabetes";"Effectiveness";"Harmful";"Binary";"Semi-objective";"risk ratio";"# of patients developing new-onset diabetes";"Bayesian Hierarchical Model";"Arm";"16";"1";"0";"0";"0";"Full Network";"1";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"Yes";"Egger’s weighted regression statistic";"NA";"All";"No";"No";"NA";"Takeda Pharmaceuticals North America Inc.";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"392";"501368";"YES";"Picard";2000;"France";"Anesth Analg";"Prevention of pain on injection with propofol: a quantitative systematic review.";43;"17";8;"no treatment";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"analgecic efficacy of proplylactic interventions for the prevention of pain on injection with propofol";"no pain";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"Number with complete absence of pain (dichotomous data)";"NR";"Arm";"28";"12";"3";"0";"0";"Full Network";"33";"NR";"Unclear";"Unclear";"NR";"Fixed-effect";"No";"NA";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"Swiss National Science Foundation";"Publicly-sponsored";NA;NA;NA;"Unclear";"long";0;1;"""After removing comparisons with missing treatment effects or standard errors,\n  study '2' has a wrong number of comparisons.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Please check data and\n  consider to remove study from network meta-analysis"
"394";"501370";"YES";"Playford";2009;"Australia";"CDSR";"Antifungal agents for preventing fungal infections in solid organ transplant recipients.";10;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"Antifungal agents for preventing fungal infections in solid organ transplant recipients";"mortality";"Effectiveness";"Harmful";"Binary";"objective";"risk ratio";"mortality";"NR";"Arm";"10";"0";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"NR";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"395";"501371";"YES";"Playford";2006;"Australia";"Eur J Clin Microbiol Infect Dis";"Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients.";7;"4";4;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"antifungal agents for preventing fungal infections in liver transplanet recipients";"total mortality";"Effectiveness";"Harmful";"Binary";"objective";"risk ratio";"mortality";"NR";"Arm";"9";"1";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"Treatment effects across trials were combined using a randomeffects model and compared with a fixed-effect model in a sensitivity analysis.";"Unclear";"NR";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Unclear";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"396";"501372";"YES";"Pollock";2009;"UK";"CDSR";"Physiotherapy treatment approaches for the recovery of postural control and lower limb function following stroke.";9;"5";5;"no treatment/placebo";"3 (non-pharmacological vs any)";"Yes";"NA";"NA";"recovery of postural control and lower limb function in patients with stroke";"global dependency scale";"Effectiveness";"Beneficial";"Continuous";"Subjective";"standardized mean difference";"Average change in the Barthel Index for measurement of the  global dependency scale";"NR";"Arm";"8";"1";"0";"0";"0";"Full Network";"2";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"Chest Heart and Stroke, The Big Lottery, UK";"Publicly-sponsored";NA;NA;NA;"NR";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"397";"501373";"YES";"Psaty";2003;"USA";"JAMA";"Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis.";28;"NR";7;"placebo/untreated/usual care";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"Antihypertensive Therapy-Coronary heart disease (CHD) including fatal and nonfatal events";"Cardiovascular disease events included CHD, stroke, CHF, and other cardiovascular disease mortality";"Effectiveness";"Harmful";"Binary";"Objective";"risk ratio";"Number of Cardiovascular disease events";"Meta regression";"Arm";"24";"4";"0";"0";"0";"Full Network";"10";"Lumley model";"Yes";"Yes";"comparative trials address the question
of which first-line treatment regimen is
optimal";"Random effects";"No";"Unclear";"NR";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"National Heart, Lung, and Blood Institute, National Institute on Aging, Patient Care and Outcomes Research Program of the American Heart Association, AHA Pharmaceutical Roundtable Outcomes Research Program";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"398";"501374";"YES";"Puhan";2009;"Switzerland";"BMC";"Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis.";34;"22";5;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"exacerbation in patients with chronic obstructive pulmonary disease";"event based (physician or emergency room visit, hospital admission) or symptom based (increase of dysp- nea, sputum, or cough; for example according to Anthonisen et al )";"Effectiveness";"Harmful";"Binary";"Subjective";"odds ratio";"Number with exacerbation";"Meta regression";"Arm";"27";"1";"6";"0";"0";"Full Network";"7";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"Swiss National Science Foundation, The Helmut Horten Foundation";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"400";"501376";"YES";"Ramsberg";2012;"Sweden";"Plos One";"Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta- Analysis and Cost-Effectiveness Model";87;"17";17;"control";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy of different antidepressants";"remission rates defined as a Hamilton Depression Rating Scale (HAMD)-score <= 7";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"Number with remission";"Bayesian Hierarchical Model";"Arm";"87";"0";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR";"Both FE and RE";"the outcome, i.e. probability of remission, was modelled on the log-odds scale with additive fixed effects for each treatment. A random-baseline model was employed to account for heterogeneity between trials.";"A random-baseline model was employed to account for heterogeneity between trials";"Non-informative Prior";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"401";"501377";"YES";"Reich";2011;"Germany";"British Journal of Dermatology";"Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta- analysis of randomised controlled trials";20;"15";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"Yes";"effectiveness of all biologic agents indicated in the treatment of moderate to severe psoriasis";"PASI 50, 75 and 90 response rates (PASI 90 - primary)";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"Number achieving PASI 50";"Bayesian Hierarchical Model";"Arm";"13";"7";"0";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"vague prior";"NR";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"Johnson and Johnson Pharmaceutical Services";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"402";"501378";"YES";"Rheims";2011;"France";"Epilepsia";"Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review andmeta-analysis.";58;"63";20;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy of antiepileptic drugs in adult refractory partial epilepsy";"Mean responder rate";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"responder rate (proportion of
patients with 50% or greater reduction in seizure frequency
during the treatment period as compared to baseline).";"NR";"Study";"58";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"similar baseline patients’ characteristics between trials";"Fixed-effect";"In the absence of a clear explanation for heterogeneity, fixed-effect models for relative risk were planned";"NA";"NR";"NR";"NA";"Yes";"Funnel plot";"NA";"Subset";"No";"Yes";"completer-based analylsis vs. LOCF?";"NA";"Funding source not reported";NA;NA;NA;"NR";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"403";"501379";"YES";"Ribeiro";2011;"Brazil";"International Journal of Cardiology";"Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients";39;"10";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split and lump doses";"cardiovascular prevention";"reduction of cardiovascular events";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"number of cardiovascular events";"Bayesian Hierarchical Model";"Arm";"37";"2";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR";"Both FE and RE";"MTC analyses were performed using both fixed (FE) and random effect (RE) models. Although the number of parameters in the RE models was higher than in the FE models, the posterior means of the residual deviance were always much lower, resulting in a lower DIC. The results shown are from RE models, with homogeneous between-trial variability. The goodness- of-fit of all MTC models was generally good, considering the residual deviance criteria.";"To analyze the data in this study, we used the MTC random effect model with homogeneous between-trial variability";"NR";"NR";"Yes";"No";"NA";"NA";"Subset";"No";"No";"NA";"MCT/CNPq and Brazilian Ministry of
Health";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;1;"""After removing comparisons with missing treatment effects or standard errors,\n  study '14' has a wrong number of comparisons. Please check data and\n  consider to remove study from network meta-analysis.""";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"405";"501381";"YES";"Roskell (1)";2010;"UK";"Pain Practice";"A meta-analysis of pain response in the treatment of fibromyalgia.";12;"10";10;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"efficacy for the treatment of fibromyalgia";"30% improvement in pain response";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"number with 30% improvement in pain response";"Bayesian Hierarchical Model";"Arm";"15";"1";"1";"0";"0";"Full Network";"6";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Both FE and RE";"No";"NR";"NR";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"Eli Lilly and Company";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"406";"501382";"YES";"Roskell (2)";2010;"UK";"Thromb Haemost";"Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate";17;"11";11;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"efficacy of treatments for stroke prevention in atrial fibrillation";"ischemic stroke";"Effectiveness";"Harmful";"Binary";"Semi-objective";"risk ratio";"number of  ischemic stroke";"Meta regression";"Arm";"6";"6";"0";"0";"0";"Full Network";"3";"NR";"Unclear";"Unclear";"NR";"Both FE and RE";"Only random effects estimates were presented here because, in most cases, the fixed and random effects estimates were nearly identical.";"Unclear";"NA";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"Boehringer Ingelheim International GmbH (BI)";"Industry-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"407";"501383";"YES";"Roskell";2012;"UK";"CMRO";"Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod";14;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"relative effects of treatment in relapsing–remitting multiple sclerosis (RRMS)";"annualized relapse rate (ARR), defined as total number of relapses divided by the total person-time at risk for relapse";"Effectiveness";"Harmful";"Rate";"Subjective";"Rate Ratio";"annualized relapse rate";"Meta regression";"Arm";"12";"2";"0";"0";"0";"Full Network";"6 -  verify with analysis";"Informal comparison of NMA results with previously published results";"Unclear";"Unclear";"The distributions of the
patient and trial characteristics were reasonably similar
across the treatments";"Random effects";"to account for the response variables of patients within a given trial being correlated";"Unclear";"NR";"NR";"Yes";"No";"NA";"NA";"Subset";"NO";"No";"NA";"Novartis Pharmaceuticals US";"Industry-sponsored";NA;NA;NA;"Frequentist";"long";0;1;"""object 'metaNetw' not found""";NA;NA;NA;"(in some studies r bigger than n)";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"408";"501384";"YES";"Inajara Rotta";2013;"Brazil";"Jama Dermatology";"Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments.";60;"NR";15;"Placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"Efficacy of topical antifungals used in dermatophytosis treatment";"mycologic cure at the end of treatment";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"number of cures obtained up to 7 days after therapy conclusion
";"Bayesian Hierarchical Model";"Arm";"58";"2";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR

";"Both FE and RE";"The goodness-of-fit of the models was measured through residual deviance and deviance information criteria,RE models had better fitting

";"Unclear";"NR";"NA";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"None";"Pharmaceutical Sciences Postgraduate Program, Federal University of Parana, Brazil";"Publicly-sponsored";"no data available";"no data available";"no data available";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"410";"501387";"YES";"Salliot";2010;"Canada";"Ann Rheum Dis";"Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-ana";15;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"ACR50 response rates at week 24 in patients with rheumatoid arthritis despite methotrexate";"at least 50% improvement according to the American College of Rheumatology criteria in the number of swollen and ten- der joints, and in three of the following five parameters: phy- sician global assessment of disease, patient global assessment";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"number achieving ACR50";"Adjusted indirect comparison (Bucher)";"Arm";"14";"1";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"The main patient characteristics were similar across trials";"Unclear";"No";"Unclear";"NA";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"411";"501388";"YES";"E.J. Samarasekera";2013;"UK";"British Journal of Dermatology";"Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses.";34;"14";14;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"Efficacy of topical treatments in chronic plaque psoriasis";"Clear or nearly clear status for trunk and limbs on either the Investigator's Assessment of Overall Global Improvement (IAGI) or dynamic Physician's Global Assessment (PGA)";"Effectiveness";"Beneficial";"Binary";"Semi-objective";"odds ratio";"Proportion of patients who had clear or nearly clear status";"Bayesian Hierarchical Model; Bucher method";"Arm";"29";"3";"2";"0";"0";"Full Network";"Unclear";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"No";"Unclear";"NR";"NA";"Yes";"No";"NA";"Rankograms";"All";"No";"No";"the majority of the trials focused on achievement of remission, with very limited data on key outcomes of relevance to psoriasis such as relapse rates


";"National Institute for Health and Clinical Excellence, and National Institute for Health Research";"Industry-sponsored";"0.72";"0.47";"0.85";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"413";"501390";"YES";"Sciarretta";2010;"Italy";"Arch Intern Med";"Antihypertensive Treatment and Development of Heart Failure in Hypertension A Bayesian Network Meta-analysis of Studies in Patients With Hypertension and High Cardiovascular Risk";26;"NR";8;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"antihypertensive treatments for the prevention of heart failure";"incidence of heart failure";"Effectiveness";"Harmful";"Binary";"Semi-objective";"odds ratio";"numer with heart failure";"Bayesian Hierarchical Model";"Arm";"24";"2";"0";"0";"0";"Full Network";"13";"Lu and Ades";"Yes";"Yes";"NR";"Random effects";"No";"NR";"Non-informative Prior";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"414";"501391";"YES";"Scott";2013;"UK";"Diabetes, Obesity and Metabolism";"A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily, or placebo";22;"6";6;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split doses";"relative efficacies of various injectable therapies for glycaemic control";"mean difference in HbA1c (%) vs. placebo";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"mean change in HbA1c from baseline";"Bayesian Hierarchical Model";"Arm";"18";"4";"0";"0";"0";"Full Network";"Unclear";"Node-splitting";"NA";"Yes";"Meta-regression";"Random effects";"No";"NR";"NR";"NR";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"No";"imputation";"Amylin Pharmaceuticals, Inc., and Eli Lilly and Company";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"415";"501392";"YES";"Ke-Qing Shi";2013;"China";"European Journal of Clinical Investigation";"Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis";51;"NR";12;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"the relative effectiveness of competing interventions for the prevention of rebleeding";"variceal rebleeding";"Effectiveness";"Harmful";"Binary";"Objective";"odds ratio";"number of patients that had a variceal rebleeding";"Bayesian Hierarchical Model";"Arm";"61";"2";"2";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"Most studies included in this study were very similar in terms of design and conduct";"Random effects";"No";"NR";"NR";"NA";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"Not mentioned";"the Scientific Research Foundation of Wenzhou, Zhejiang Province, China (H20090014, Y20090269), Health Bureau of Zhejiang Province (2010KYB070), Research Foundation of Education Bureau of Zhejiang Province (Y201009942) and Project of New Century 551 Talent Nurturing in Wenzhou, Natural Science Foundation of Shandong Province (ZR2010HQ040).";"Publicly-sponsored";"no data available";"no data available";"no data available";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"416";"501393";"YES";"Singh";2009;"USA";"CMAJ";"A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.";27;"7";7;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"efficacy of biologics for rheumatoid arthritis";"ACR50";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"number achieving ACR50";"Meta regression";"Arm";"27";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"Eligibility criteria and patient populations were
similar across reviews";"Random effects";"No";"NR";"NR";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"US National Institutes of Health Center for Clinical and Translational Science Award, Parker Institute, Oak Foundation, Australian National Health and Medical Research Council Practitioner Fellowship";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"418";"501395";"YES";"Soares-Weiser";2007;"UK";"HTA";"A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.";14;"8";8;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"pharmacological and/or psychosocial interventions for the prevention of relapse in people with bipolar disorder";"admission to hospital";"Effectiveness";"Harmful";"Binary";"Semi-objective";"odds ratio";"Number admitted to hospital";"Bayesian Hierarchical Model";"Arm";"10";"4";"0";"0";"0";"Full Network";"4";"NR";"Unclear";"Unclear";"NR";"Fixed-effect";"The assumption that the true treatment effect is common to all trials";"NA";"uninformative vague priors";"NR";"NA";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"HTA Programme";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"419";"501396";"YES";"Squires";2011;"UK";"HTA";"A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease";10;"7";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No";"clinical effectiveness";"maximal walking distance (MWD)";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"mean change in MWD from baseline";"Bayesian Hierarchical Model";"Arm";"7";"3";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Random effects";"used a random effects model (to allow for heterogeneity in treatment effect across studies)";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"All";"No";"No";"imputation";"The National Institute for Health Research Health Technology
Assessment programme";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;1;"Non-numeric value for argument 'sd'.";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"421";"501399";"YES";"Stowe";2010;"UK";"Movement Disorders";"Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.";29;"4";4;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"efficacy";"off-time reduction to levodopa therapy in Parkinson's Disease patients with motor complications";"Effectiveness";"Harmful";"Continuous";"Semi-objective";"mean difference";"Average off-time reduction";"Adjusted indirect comparison (Bucher)";"Arm";"28";"1";"0";"0";"0";"Full Network";"1";"Informal comparison of NMA results with previously published results";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NA";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"422";"501400";"YES";"Sultana";2008;"UK";"BMC";"Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.";11;"5";5;"Gemcitabine";"1 (pharmacological vs pharmacological)";"No";"Unclear";"No";"treatment of advanced pancreatic cancer";"overall survival";"Effectiveness";"Harmful";"Survival";"Objective";"hazard ratio";"mortality";"Adjusted indirect comparison (Bucher)";"Study";"11";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"comparability between trials dealing with antimicrobial prophylaxis in colorectal
cancer";"Random effects";"No";"NR";"NR";"NR";"Unclear";"No";"NA";"NA";"All";"No";"No";"NA";"Cancer Research UK";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"425";"501403";"YES";"Terasawa";2012;"Japan";"Cancer Treatment Reviews";"Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: A multiple-treatment meta-analysis";25;"10";10;"other";"1 (pharmacological vs pharmacological)";"No";"NR";"NA";"comparative effectiveness and safety of all clinically relevant treatments for CLL";"overall survival";"Effectiveness";"Beneficial";"Survival";"Objective";"hazard ratio";"mortality";"Bayesian Hierarchical Model";"Arm";"21";"4";"0";"0";"0";"Full Network";"4";"Loop-specific";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Yes";"No";"NA";"Probability of being the best; SUCRA";"All";"No";"No";"NA";"United States Agency for Healthcare Research and Quality";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"426";"501404";"YES";"Thijs";2008;"Belgium";"European Heart";"Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.";23;"5";5;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"efficacy of antiplatelet";"prevention of serious vascular events after transient ischaemic attack or stroke";"Safety";"Harmful";"Binary";"Semi-objective";"odds ratio";"number of serious vascular events";"Meta regression";"Arm";"20";"3";"0";"0";"0";"Full Network";"3";"Lumley model";"Yes";"Yes";"NR";"Random effects";"Heterogeneity of the treatment effects can be captured by extending this model with a random trial effect, its variance reflecting the between-trial variance.";"Unclear";"DerSimonian and Laird approach";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"the Fund for Scientific Research Flanders";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"429";"501407";"YES";"Trikalinos";2009;"USA";"Lancet";"Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis.";61;"4";4;"medical therapy";"3 (non-pharmacological vs any)";"No";"NA";"NA";"Coronary artery disease";"death";"Effectiveness";"Harmful";"Binary";"Objective";"risk ratio";"mortality";"Meta regression";"Arm";"62";"0";"0";"0";"0";"Full Network";"1";"Lumley model";"Yes";"Yes";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"430";"501408";"YES";"Tropeano";2010;"France";"Fundamental & Clin Pharmacology";"Do all antihypertensive drugs improve carotid intima-media thickness? A network meta-analysis of randomized controlled trials.";28;"NR";6;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"No";"decrease of carotid intima-media thickness (CIMT)";"CIMT measurement by ultrasonography";"Effectiveness";"Harmful";"Continuous";"Semi-objective";"mean difference";"average decrease in carotid intima-media thickness";"Meta regression";"Arm";"28";"0";"0";"0";"0";"Full Network";"11";"Lumley model";"Yes";"Yes";"NR";"Both FE and RE";"to take incoherence and heterogeneity into account, a linear mixed model with a random effect. SGA used fixed";"To take incoherence and hetero- geneity into account, a linear mixed model with a random effect specific to each pair of comparisons wasused, with the reciprocals of the standard errors as weights. Because the mixed model was used for exploratory analyses, its results were not corrected for multiple comparisons";"NA";"NR";"Yes";"Yes";"Funnel plot";"NA";"All";"No";"No";"NA";"NA";"Funding source not reported";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"431";"501409";"YES";"Tu";2012;"UK";"Journal of Clinical Periontology";"A bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies";50;"8";8;"placebo";"3 (non-pharmacological vs any)";"No";"NA";"NA";"treatment effects of GTR, EMD for periodontal infrabony lesions";"probing pocket depth (PPD) reduction";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"Average probing pocket depth (PPD) reduction";"Bayesian Hierarchical Model";"Arm";"42";"6";"2";"0";"0";"Full Network";"Unclear";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"No";"NR";"Non-informative Prior";"NR";"No";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"United Kingdom government’s Higher Education Funding Council for England (HEFCE). The last author is partially funded by a postdoctoral fellowship from the Medical Faculty of the University of Heidelberg.";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"432";"501410";"YES";"Tu";2010;"UK";"J Clin Periodontol";"Do bone grafts or barrier membranes provide additional treatment effects for infrabony lesions treated with enamel matrix derivatives? A network meta-analysis of randomized-controlled trials.";27;"21";6;"EMD+Bone Grafts";"3 (non-pharmacological vs any)";"Yes";"Yes";"No - lump doses";"treatment effects of enamel matrix derivatives with other regenerative materials for infrabony lesions";"probing pocket depth reduction";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"mean difference";"Average change in probing pocket depth";"Bayesian Hierarchical Model";"Study";"27";"1";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Both FE and RE";"When studies reported treatment outcomes at different follow-ups after surgery, the length of follow-up was modelled as both random and fixed effects.
Study design (parallel groups versus split mouth) was also modelled as both random and fixed effects to account for the heterogeneity in treatment effects.";"Unclear";"NR";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"imputation";"The United Kingdom government’s Higher Education Funding Council for England (HEFCE) and UK Medical Research Council";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"434";"501412";"YES";"Uthman";2010;"UK";"CMRO";"Comparative effectiveness and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis.";14;"6";6;"placebo";"2 (pharmacological vs placebo)";"No";"No";"NA";"efficacy for treating anxiety disorders in children and adolescents";"improvement";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"Treatment response was defined in this review as a score
of 1 (very much improved) or 2 (much improved) on the Clinical Global
Impressions scale (CGI-I)";"Bayesian Hierarchical Model";"Arm";"16";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Unclear";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"436";"501414";"YES";"Van de Bruel";2010;"belgium";"Br J Ophthalmol";"The protective effect of ophthalmic viscoelastic devices on endothelial cell loss during cataract surgery: a meta-analysis using mixed treatment comparisons";21;"6";6;"other / ophthalmic viscoelastic devices";"3 (non-pharmacological vs any)";"No";"NA";"NA";"protective effect of ophthalmic viscoelastic devices";"loss in endothelial cell density 3 months after surgery";"Effectiveness";"Harmful";"Continuous";"Semi-objective";"mean difference";"absolute
number of cells/mm2 lost 3 months after the cataract procedure,
compared with the baseline density.";"Bayesian Hierarchical Model";"Arm";"16";"3";"2";"0";"0";"Full Network";"4";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Both FE and RE";"Because some comparisons showed heterogeneity in the study results, random effects models were preferred to the fixed effect model. The choice between fixed effects and random effects model was based on a goodness-of-fit statistic (deviance information criterion (DIC)";"Unclear";"NR";"NR";"Yes";"No";"NA";"Probability of being the best";"Subset";"No";"No";"imputation";"NA";"Non-sponsored";NA;NA;NA;"Bayesian";"long";0;1;"object 'n' not found";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"437";"501416";"YES";"van der Valk";2009;"Netherlands";"JCE";"A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure.";24;"9";9;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"effectiveness of drugs in patients with primary open-angle glaucoma or ocular hypertension";"lowering intraocular pressure at though";"Effectiveness";"Harmful";"Continuous";"Semi-objective";"mean difference";"The relative change in IOP from baseline";"Meta regression";"Arm";"19";"5";"0";"0";"0";"Full Network";"10";"Lumley model";"Yes";"Yes";"NR";"Random effects";"This model incorporates heterogeneity between multiple trials of the same pair of treatments and, in addition, adds a random effect for each treatment pair";"This model incorporates heterogeneity between multiple trials of the same pair of treatments and, in addition, adds a random effect for each treatment pair. Let Yijk be the re- ported treatment effect comparing treatments i and j in trial k and s2ijk be the reported variance of Yijk. The model is Yijk 5 mi 􏰔 mj þ eijk þ xij, where mi represents the effect of treatment i; eijk | N(0, a(b þ sijk)2) is a residual incorporat- ing sampling error with heterogeneity specified by parame- ters a and b, and xij | N(0, u2) is an inconsistency effect specific to a pair of treatments, rather than a trial.";"NR";"NR";"Unclear";"No";"NA";"Subset";"None";"No";"No";"NA";"NA";"Non-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"438";"501418";"YES";"Vejakama";2011;"Thailand";"Diabetologia";"Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis";9;"38";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No (unclear)";"renal outcomes";"end-stage renal disease (ESRD)- a requirement for renal replacement therapy or dialysis";"Safety";"Harmful";"Binary";"Semi-objective";"risk ratio";"number of ESRD  defined as a requirement for renal
replacement therapy or dialysis";"Meta regression";"Arm";"8";"1";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Both FE and RE";"RE if heterogeneity was present";"Unclear";"NR";"NR";"Yes";"Yes";"Funnel plot; Harbord's test; Trim and fill method";"NA";"Subset";"No";"No";"NA";"Multi-Sectoral Network for Non-Communicable Disease Control
(NCD network) of Thailand";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"439";"501419";"YES";"Vieira";2011;"USA";"HIV Clinical Trials";"Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.";7;"6";6;"other / first-line treatments for HIV-infected adults (EFV as reference treatment)";"1 (pharmacological vs pharmacological)";"No";"Yes";"No - split doses";"virological suppression";"proportion of patients with virological response (primary - 48 wks)";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"proportion of patients with virological response at 48 wks measured by
HIV-1 RNA level";"Bayesian Hierarchical Model";"Arm";"7";"0";"0";"0";"0";"Full Network";"1";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Both FE and RE";"The fixed effects model resulted in the lowest DIC and, as such, was con- sidered appropriate for the synthesis of the avail- able evidence.";"Unclear";"Non-informative Prior";"NR";"Unclear";"No";"NA";"Probability of being the best; SUCRA";"All";"No";"No";"NA";"Merck and Company, Inc";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"440";"501420";"YES";"Virgili";2011;"Italy";"Current Drug Targets";"Pharmacological treatments for neovascular age-related macular degeneration: can mixed treatment comparison meta-analysis be useful?";10;"7";5;"control";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy of treatments for neovascular age-related macular degeneration";"visual acuity loss";"Effectiveness";"Harmful";"Binary";"Subjective";"odds ratio";"The number of patients with visual loss or visual gain of 3 or more lines of visual
acuity (15 ETDRS letters) at 1 year.";"Bayesian Hierarchical Model; Meta regression";"Arm";"10";"0";"0";"0";"0";"Full Network";"1";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"No";"NA";"NA";"All";"No";"Yes";"LOCF?";"NA";"Funding source not reported";NA;NA;NA;"Frequentist, Bayesian";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"442";"501423";"YES";"Wandel";2010;"Switzerland";"BMJ";"Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis.";10;"8";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"absolute pain intensity in patients with osteoarthritis of hip or knee";"pain scores";"Effectiveness";"Harmful";"Continuous";"Subjective";"standardized mean difference";"Change in pain scores";"Bayesian Hierarchical Model";"Arm";"9";"0";"1";"0";"0";"Full Network";"3";"Loop-specific";"Yes";"Yes";"NR";"Random effects";"No";"NR";"gamma, uniform";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"Swiss National Science Foundation’s National Research Program";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"443";"501424";"YES";"Wang";2010;"China";"J Hospital Infection";"Effectiveness of different central venous catheters for catheter-related infections: a network meta-analysis.";43;"9";9;"standard catheter";"3 (non-pharmacological vs any)";"No";"NA";"NA";"effectiveness of venous catheters for catheter-related infections";"colonisation";"Effectiveness";"Harmful";"Binary";"Semi-objective";"odds ratio";"Catheter colonisation: a quantitative culture tip yielding more
than 1000 colony-forming units (cfu)/mL or a semiquantitative
culture tip yielding >15 cfu/mL.";"Bayesian Hierarchical Model";"Arm";"41";"2";"0";"0";"0";"Full Network";"4";"Informal comparison of NMA results with pairwise meta-analysis results";"Yes";"Yes";"NR";"Both FE and RE";"We explored both fixed effects model and random effects model and selected the model by the deviance information criterion";"Unclear";"NR";"NR";"Yes";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"Scientific Research Fund of Zhejiang Provincial Education Department  and Health Bureau of Zhejiang Province";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"444";"501425";"YES";"Welton";2009;"UK";"Amer J Epidemiology";"Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease.";35;"16";16;"control (usual)";"3 (non-pharmacological vs any)";"No";"NA";"NA";"Psychological Interventions in Coronary Heart Disease";"Total mortality";"Effectiveness";"Harmful";"Binary";"objective";"odds ratio";"mortality";"Bayesian Hierarchical Model";"Arm";"31";"4";"0";"0";"0";"Full Network";"4";"NR";"Unclear";"Unclear";"NR";"Random effects";"heterogeneity can be incorporated by using random effects models";"Unclear";"flat priors";"NR";"Unclear";"No";"NA";"Probability of being the best";"Subset";"No";"No";"NA";"Medical Research Council Health Services Research Collaboration";"Publicly-sponsored";NA;NA;NA;"Bayesian";"long";0;1;"""After removing comparisons with missing treatment effects or standard errors,\n  study '19' has a wrong number of comparisons. Please check data and\n  consider to remove study from network meta-analysis.""";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"445";"501426";"YES";"Wilhelmus";2000;"USA";"Trans Am Ophthalmol Soc.";"The treatment of herpes simplex virus epithelial keratitis";60;"24";24;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"efficacy for dendritic or geographic HSV epithelial keratitis";"proportions healed";"Effectiveness";"Beneficial";"Binary";"Subjective";"odds ratio";"the proportions healed at 7 or 14 days after trial entry.";"Adjusted indirect comparison (Bucher)";"Study";"55";"3";"2";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Both FE and RE";"pooled odds ratios using randoom-effects miiodels are reported elsewhere in this report if significant heterogeneity was found";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"Subset";"No";"No";"NA";"the National Eye Institute; the Research to Prevent Blindness, Inc; the Sid Richardson Foundation";"Publicly-sponsored";NA;NA;NA;"Unclear";"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"446";"501427";"YES";"Wolff";2012;"UK";"CMRO";"Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain";7;"27";4;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"efficacy and safety of buprenorphine patch versus fentanyl patch in patients with chronic moderate to severe pain";"Any measurement of pain, including pain intensity, pain relief";"Effectiveness";"Beneficial";"Continuous";"Subjective";"odds ratio";"Change in pain intensity in any measurement of pain, including pain intensity, pain relief,";"NR";"Arm";"7";"1";"0";"0";"0";"Full Network";"1";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Unclear";"No";"NA";"NA";"All";"No";"No";"NA";"Grunenthal GmbH";"Industry-sponsored";NA;NA;NA;NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"447";"501429";"YES";"Wong";2011;"China";"Journal of Dental Research";"Cochrane Reviews on the Benefits/Risks of Fluoride Toothpastes";74;"17";7;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - split and lump doses";"increment in the permanent or primary dentition";"percentage prevalence of fluorosis in the permanent dentition";"Effectiveness";"Beneficial";"Continuous";"Semi-objective";"risk ratio";"The prevented fraction (PF) was the primary estimate of effect.
The PF is expressed as the mean increment in the control group
minus the mean increment in the intervention group divided by
the mean increment in the control group, i.e., the caries increment
in the treatment group expressed as a percentage of the
control group.";"Adjusted indirect comparison (Bucher)";"Arm";"64";"7";"3";"0";"0";"Full Network";"Unclear";"NR";"Unclear";"Unclear";"NR";"Random effects";"No";"NR";"NR";"NR";"Yes";"No";"NA";"NA";"All";"No";"No";"NA";"the Department of Health Cochrane Review Incentive Scheme 2008, UK; the National Institute for Health Research (NIHR), UK; and The University of Hong Kong";"Publicly-sponsored";NA;NA;NA;"Frequentist";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"448";"501430";"YES";"Woo";2010;"Canada";"Gastroenterology";"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.";19;"15";10;"placebo";"2 (pharmacological vs placebo)";"No";"Yes";"No - lump doses";"relative efficacy of nucleostides in the treatment of chronic hepatidis B";"HBV DNA levels";"Effectiveness";"Beneficial";"Binary";"Objective";"odds ratio";"rates of virologic and biochemical response (HBV DNA)";"Bayesian Hierarchical Model";"Arm";"16";"3";"0";"0";"0";"Full Network";"3";"NR";"Unclear";"Unclear";"NR";"Random effects";"any variation in treatment effect owing to the threshold became part of the random between-study variance";"Unclear";"normal, uniform";"NR";"No";"No";"NA";"Probability of being the best";"All";"No";"No";"NA";"Gilead Sciences, Inc.";"Industry-sponsored";NA;NA;NA;"Bayesian";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"449";"501431";"YES";"Hon-Yen Wu";2013;"Taiwan";"BMJ";"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis";62;"NR";11;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"Efficacy of different classes of renin-angiotensin system blockers";"all cause mortality";"Effectiveness";"Harmful";"Binary";"objective";"odds ratio";"incidence of all cause death";"Bayesian Hierarchical Model";"Arm";"50";"11";"1";"0";"0";"Full Network";"Unclear";"Node-splitting";"Yes";"Yes";"NR";"Random effects";"No";"NR";"NR";"NA";"Unclear";"Yes";"Egger's test; Begg's test";"Probability of being the best";"Subset";"No";"No";"None";"None";"Non-sponsored";"0.81";"0";"0.81";NA;"long";0;1;"""After removing comparisons with missing treatment effects or standard errors,\n  the following studies have a wrong number of comparisons: '18', '31'\n  Please check data and consider to remove studies from network meta-analysis.""";NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"451";"501434";"YES";"Yu";2006;"Canada";"Can J Anesth";"The effects of volatile anesthetics on cardiac ischemic complications and mortality in CABG: a meta-analysis.";14;"6";6;"control";"2 (pharmacological vs placebo)";"No";"No";"NA";"effectiveness of inhaled anesthetics in reducing post-operative myocardial infractions after cardiac surgery";"acute myocardial infarction (AMI)";"Effectiveness";"Harmful";"Binary";"Semi-objective";"odds ratio";"Number of AMI";"NR";"Arm";"11";"2";"1";"0";"0";"Full Network";"5";"NR";"Unclear";"Unclear";"NR";"Unclear";"No";"Unclear";"NR";"NR";"Unclear";"Yes";"Funnel plot";"NA";"Subset";"No";"No";"NA";"R. Fraser Elliot endowment";"Publicly-sponsored";NA;NA;NA;"Unclear";"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"452";"501435";"YES";"JinQiu Yuan";2013;"China";"European Urology";"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis";69;"NR";7;"placebo";"2 (pharmacological vs placebo)";"No";"Unclear";"NA";"Efficacy of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction";"Oral Phosphodiesterase type 5 inhibitors (PDE5-Is)";"Effectiveness";"Beneficial";"Binary";"Subjective";"risk ratio";"Global Assessment Questionnaire question 1";"Bayesian Hierarchical Model; Bucher method";"Arm";"69";"0";"0";"0";"0";"Full Network";"Unclear";"Loop-specific";"NA";"Yes";"meta-regression";"Both FE and RE";"DIC was compared between the two models - Random effects had better goodness-of-fit and more conservative estimated effects";"Unclear";"NR";"NA";"Yes";"Yes";"Funnel plot";"Mean Rank";"All";"No";"No";"The authors of original studies were consulted for missing information where necessary";"Health and Medical Research Fund from the Food and Health Bureau of Hong Kong";"Publicly-sponsored";"0.47";"0";"0.39";NA;"long";1;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
"456";"Fountolakis 2013";"YES";"Fontoulakis";2013;"Greece";"Annals of General Psychiatry";"No role for initial severity on the efficacy of antidepressants: results of a
multi-meta-analysis";35;"NR";5;"Placebo";"2 (pharmacological vs placebo)";"Unclear";"Unclear";"Unclear";"response to treatment";"NR";"Effectiveness";"Beneficial";"Continuous";"Unclear";"mean difference (RMD); standardised mean difference (SMD)";"NR";"Bayesian Hierarchical Model";"Arm";"35";"0";"0";"0";"0";"Tree Network";"NA";"NA";"NA";"NA";"NR";"Random effects";"No";"NR";"12 different prior distributions ranged from 0 to 0.04";"NA";"Yes";"Yes";"Funnel plot";"SUCRA; Probability of being the best";"Subset";"No";"No";"NA";"None";"Non-sponsored";NA;NA;NA;NA;"long";0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA
